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METHODS FOR INTEGRATIVE ANALYSIS OF GENOMIC DATA
Paul T. Manser, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
In recent years, the development of new genomic technologies has allowed
for the investigation of many regulatory epigenetic marks besides expression levels,
on a genome-wide scale. As the price for these technologies continues to decrease,
study sizes will not only increase, but several different assays are beginning to be
used for the same samples. It is therefore desirable to develop statistical methods to
integrate multiple data types that can handle the increased computational burden of
incorporating large data sets. Furthermore, it is important to develop sound quality
control and normalization methods as technical errors can compound when integrating
multiple genomic assays.
DNA methylation is a commonly studied epigenetic mark, and the Infinium
HumanMethylation450 BeadChip has become a popular microarray that provides
genome-wide coverage and is affordable enough to scale to larger study sizes. It
employs a complex array design that has complicated efforts to develop
normalization methods. We propose a novel normalization method that uses a set of
stable methylation sites from housekeeping genes as empirical controls to fit a local
regression hypersurface to signal intensities. We demonstrate that our method
performs favorably compared to other popular methods for the array. We also
discuss an approach to estimating cell-type admixtures, which is a frequent
biological confound in these studies.
For data integration we propose a gene-centric procedure that uses canonical cor-
relation and subsequent permutation testing to examine correlation or other measures
of association and co-localization of epigenetic marks on the genome. Specifically, a
likelihood ratio test for general association between data modalities is performed af-
ter an initial dimension reduction step. Canonical scores are then regressed against
covariates of interest using linear mixed effects models. Lastly, permutation testing
is performed on weighted correlation matrices to test for co-localization of relation-
ships to physical locations in the genome. We demonstrate these methods on a set
of developmental brain samples from the BrainSpan consortium and find substantial
relationships between DNA methylation, gene expression, and alternative promoter
usage primarily in genes related to axon guidance. We perform a second integrative
analysis on another set of brain samples from the Stanley Medical Research Institute.
CHAPTER 1
INTRODUCTION
1.1 Overview of necessary molecular biology
1.1.1 The central dogma of molecular biology
The central dogma of molecular biology states that information in an organism
is stored in DNA as nucleic acid sequences, but is functional in the form of protein
polypeptides. Information in DNA propagates by transcription into RNA which is
then translated into these proteins (Krebs, Goldstein, and Kilpatrick 2013, Ch. 1.8).
Discoveries in the field of epigenetics have found that information is not only stored
within DNA sequences, but also on DNA in its surrounding protein structures. In
fact, a single gene may be transcribed several different ways, with modification of
epigenetic factors playing a role in the process.
The transcription of DNA into RNA begins with the binding of a collection
of proteins known as the transcription apparatus to an area at the beginning of a
gene called the promoter. Proteins called transcription factors bind in this promoter
region and potentially in associated distal regions called enhancers to initiate gene
transcription. An enzyme called RNA polymerase, which actually synthesizes the
resulting RNA is also part of this transcription complex. Once the transcription
apparatus and transcription factors have assembled, transcription starts at the 5′
end of the gene moving towards the 3′ end. As RNA polymerase moves along the
gene, it creates a single-stranded RNA molecule with bases complementary to the
DNA sequence being transcribed, with exception of thymine being replaced by uracil.
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When the polymerase reaches the end of the gene, it falls off and the RNA transcript
is released (Krebs, Goldstein, and Kilpatrick 2013, Ch. 20).
Before the RNA leaves the nucleus, it undergoes several processing steps. First,
a guanine base is added to the 5′ end of the RNA (commonly referred to as the
5′ cap) which usually occurs soon after transcription initiation. The 5′ cap serves
to protect the RNA from degradation by certain kinds of exonucleases. Once the
gene has finished transcription, another polymerase called poly(A) polymerase adds
a stretch of roughly 200 adenosine bases to the end of the RNA to create what is
commonly referred to as the poly(A) tail. The poly(A) tail serves to insulate the
coding sequence of the RNA, provide stability, and again protect it from degradation.
A specific protein binds to this poly(A) tail to help further protect from degradation as
well as facilitate RNA translation into protein (Krebs, Goldstein, and Kilpatrick 2013,
Ch. 21). The poly(A) tail is also commonly used for identifying and isolating RNA
before performing microarray and next generation sequencing (NGS) experiments.
Once RNA passes out of the nucleus into the cytoplasm, a free-floating ribosome
attaches itself to the RNA molecule to begin the process of translation. Once a
ribosome has initiated translation, the RNA is translated into protein one codon at
a time. Codons are three-base sequences of DNA that correspond to a specific amino
acid which are the building blocks of proteins. Since there are four bases, there are
43 = 64 possibile codons. However, there are only 20 main amino acids used to build
proteins, so several 3 base sequences can code for the same amino acid, with usually
the third base being allowed to vary. Other codons indicate the start and stop sites
for ribosomes to translate the protein. Once translation finishes, the ribosome falls off
the protein, which then may require further processing and folding before becoming
fully functional (Krebs, Goldstein, and Kilpatrick 2013, Ch. 25).
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1.1.2 Introduction of epigenetics
Although DNA is popularly portrayed as existing as a lone, elegant double helix,
it is in fact rarely found in this form in living cells. Instead, it is tightly packed and
wound around DNA-binding proteins that give it support and structure. Histones,
one major category of DNA-binding proteins, combine to form nucleosomes which
function as the basic unit of DNA packaging. Modifications of these histones can
locally control how DNA is packaged which determines how accessible DNA is to
transcription factors and other proteins floating around in the nucleus required for
transcription (Krebs, Goldstein, and Kilpatrick 2013, Ch. 29).
Another epigenetic factor affecting DNA accessibility is DNA methylation. In
mammals, DNA methylation generally consists of the addition of a methyl group
to a cytosine base. DNA methylation often occurs in CpG sites which are 2 base
palindromes that are read as CG in either direction on the DNA, with both cytosines
usually being methylated. Non-palindromic strand-specific DNA methylation can also
occur in brain tissue (Lister et al. 2013). The addition of a methyl group acts as a
bump on DNA that can hinder the binding of transcription factors and other proteins,
although certain proteins such as MECP2 bind specifically to methylated DNA, but
enhance its repressive effect. Cancer studies have shown that methylation of promoter
regions of genes has a silencing effect on gene expression (Baylin et al. 2001; Warden
et al. 2013), while more recent studies suggest that DNA methylation in gene bodies
and other regions may play a more subtle role in gene regulation (Maunakea et al.
2013).
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1.1.3 The role of epigenetics in modifying transcription
While there are currently believed to be roughly twenty thousand genes in the
human genome, initial estimates were much higher. This overestimate was partly due
to a phenomenon known as alternative splicing which allows a single gene to code
for multiple RNAs. While an RNA is being transcribed, it can be cut apart and
put back together into multiple different configurations by a complex of RNA and
proteins called the spliceosome. These different isoforms of RNA can then go on to
code different functional protein forms.
A typical gene consists of two major types of regions: introns and exons. While a
gene exists on a single stretch of DNA, generally not all of it is ultimately translated
into protein. First, DNA is transcribed into a premature RNA, which includes both
introns and exons. Once the genic DNA sequence is transcribed, the spliceosome
removes introns from the transcript, leaving only the exons in the final transcript.
Alternative splicing occurs when these introns and exons are excluded or included
in the final RNA transcript in different combinations. Sometimes introns may not
be excised, and can be included in the final transcripts. Additionally, certain exons
may be removed, or some may be mutually exclusive. A simple metric for assessing
alternative splicing is to look at how often an exon is included in the total number of
transcripts for a gene. This can be thought of in general terms as an exon inclusion
ratio or percentage. Most exons should be included in close to 100% of the transcripts,
but some may be included in only 30%, or perhaps not at all in a certain tissue.
Genes can also have multiple transcription start sites, where start sites can begin
in the middle of the full gene and code for transcripts excluding multiple upstream
exons.
Recent studies have suggested a role for DNA methylation in the regulation of
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alternative splicing (Maunakea et al. 2013; Cingolani et al. 2013). Exons that are
spliced out generally seem to have a lower level of DNA methylation than similar
exons that are constitutively included (Maunakea et al. 2013). However, increased
DNA methylation in transcription factor binding sites proximal to exons can have the
reverse effect(Shukla et al. 2011). These findings are observational, and cannot es-
tablish a causal relationship between increases in exonic DNA methylation and exon
inclusion. However, a study in bees showed that experimentally induced changes
in DNMT3, an enzyme that catalyzes the addition of methyl groups to CpG sites,
was able to change patterns of alternative splicing (Cingolani et al. 2013). As ge-
nomic technologies become more affordable and reliable, integrative studies will be
able to establish relationships between gene expression, alternative splicing and DNA
methylation as well as other epigenetic marks.
1.2 Overview of the Infinium HumanMethylation450 BeadChip
1.2.1 Microarray design
The Infinium HumanMethylation450 BeadChip (also known as the Illumina 450k
array) is a bead-based microarray that can assess DNA methylation on a genome-
wide scale at over 480,000 CpG sites (Bibikova et al. 2011). The 450k array surpasses
its predecessor, the Illumina 27k array (Bing Fan 2010), by providing additional
coverage of CpG sites particularly in non-promoter regions and gene bodies. It is
able to accomplish this by employing a complex array design that uses multiple bead
types to reduce the amount of space needed on the array. The complex design along
with the popularity of the 450k array have made it a popular platform for statisticians
to develop normalization methods.
The Illumina 450k array uses a bisulfite treatment to assess methylation status.
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Treatment with bisulfite converts unmethylated cytosine to uracil, while methylated
cytosines remain unaffected. This treatment creates what might be considered a
pseudo-SNP (Single nucleotide polymorphism) with methylated loci having one al-
lele and unmethylated loci having another. After the bisulfite conversion, DNA is
amplified using the whole-genome amplification reaction, fragmented enzymatically,
precipitated, and suspended in a hybridization buffer (Bibikova et al. 2011). It is
then applied to the array and allowed to hybridize for twenty hours.
The microarray generates two signals for each methylation site: one for the
methylated state, and one for the unmethylated state. The Illumina 450k array is a
bead-based array, meaning that probes for specific DNA sequences are not directly
attached to the array, but rather are attached to beads which are washed over the
array and settle in wells. Beads are identified by a unique 23 base barcode “address”
sequence at the base of probes. The 450k array has two bead types that both share
this common mechanism of identification.
Type I beads are the older bead technology on the array, inherited from the
previous 27k array. They mostly target CpGs in promoter regions of genes (Bing Fan
2010). For a given CpG, there are actually two beads, one with a sequence specific
to the methylated state, and one specific to the unmethylated state. The CpG site of
interest occupies the last two bases at the tail of the probe sequence. After the DNA
is hybridized to the probe, a florescent base is added that is complementary to the
next base after the CpG site. If the hybridized sequence matches perfectly (has the
correct methylation state), then the florescent base is added on at the end, giving off
a burst of light. Each bead then gives off a signal giving a measure of each of the two
possible states.
Type II probes are a more recent technology, added specifically for the 450k
array. Their advantage over the type I beads is that they only require one bead type
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and therefore less space on the chip. The single probe type on the type II bead has a
non-specific sequence that will match either of the methylated states for the targeted
CpG. The last base of the probe targets the first half (the G base) of the CpG. Two
florescent bases are then added to the assay and will selectively hybridize to the end of
the probe depending on whether the cytosine has been bisulfite converted or not. In
order for the Type II probes to work, each of the two fluorescent bases must operate in
different color channels since they are competitively hybridizing to the same location.
This competitive hybridization seems to result in lower data quality relative to type
I probes.
Resulting output after scanning arrays and recording signal intensities are stored
in Intensity Data Files (.idat). These files contain all the signal information extracted
from the array including negative control probes as well as signal intensities from the
unused color channel of type I probes. Several normalization methods require .idat
files, but often only summary measures are available from online repositories such
as the Gene Expression Omnibus (GEO). However, other repositories such as The
Cancer Genome Atlas (TCGA) have .idat level data publicly available.
The 450k array is a cost effective approach for assaying DNA methylation, and
samples can be run in parallel in batches of twelve. Despite the increase in coverage
relative to the 27k array, the array still surveys only roughly one percent of the
CpGs in the human genome. Furthermore, coverage in gene bodies can be somewhat
sparse and varies from gene to gene which can narrow the scope of certain types of
analyses. Nevertheless, the 450k array provides a scalable solution to assaying DNA
methylation with relatively high coverage on a large number of samples.
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1.2.2 Summarization methods
1.2.2.1 β-values
The β-value is the standard summarization method for the 450k array. Subse-
quent methods for summarization either modify or aggregate β-values in some way.
β-values combine unmethylated and methylated signals into a single measure. Equa-
tion 1.1 gives the formula for β-values where M is the methylated signal intensity, U
is the unmethylated signal intensity, and  is a small offset parameter suggested by
Illumina which is set to 100 by default that stabilizes β-values when both M and U
are small.
β =
M
M + U + 
(1.1)
β-values can be interpreted as a measure of “proportion methylated.” A β-value
close to zero implies the locus is not methylated, while a β-value close to one implies
it is methylated. Intermediate β-values can mean several things. Some loci are
imprinted and are methylated only on one chromosome which will result in a β-value
near 0.5. Loci can be hemi-methylated where only one cytosine in a CpG site is
methylated which can also result in a β-value near 0.5. Lastly, only a subset of cells
in a sample may be methylated. If 30% of cells in a sample are methylated at a
given locus, then this will result in a β-value near 0.3. It is therefore important to
be careful when interpreting β-values, as they may be reflecting one or more of these
phenomena.
1.2.2.2 M-values
One potential disadvantage of β-values is that their range is bounded below by
zero and above by one. This boundedness can create data that violate the normality
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assumption for many common statistical methods such as simple linear models and
t-tests. β-values also have problems with heteroscedasticity for highly methylated or
unmethylated CpG sites (Du et al. 2010). In order to transform β-values to span the
real line, a logit transform using log2 is used to compute M-values (Equation 1.2).
The M-value method provides better performance in terms of Detection Rate (DR)
and True Positive Rate (TPR) for both highly methylated and unmethylated CpG
sites (Du et al. 2010). M-values however, are not as straightforward to interpret as
β-values.
M = log2
(
β
1− β
)
(1.2)
1.2.2.3 Bump Hunting
DNA methylation can be highly correlated within local regions (Zhang et al.
2013). Therefore, nearby probes may be redundant and it may make more sense to
aggregate them and fit region-level models when analyzing methylation data. Func-
tional biological mechanisms may also correspond to regional changes rather than
single CpG differences (e.g. promoter regions and CpG Islands). A bump hunt-
ing approach for performing aggregation and significance testing has recently been
suggested by Jaffe et al. 2012.
The approach is as follows:
1. M-values are regressed against covariates of interest for each probe.
2. Regression coefficients are then smoothed over genomic location using a loess
curve.
3. Predefined thresholds for effect sizes are then used to find contiguous regions
where smoothed coefficient estimates are above the specified threshold.
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4. The area under the loess curve for the contiguous region is then taken as a test
statistic.
5. Significance testing is then performed by comparing the area against a null
permutation distribution.
While the bump hunting method for summarization is specific to the subsequent
analysis, the idea of summarizing DNA methylation locally is important. Summariza-
tion not only reduces the number of eventual significance tests, but can also reduce
the correlation among these tests since correlated CpG sites are aggregated.
1.3 Overview of the Affymetrix Human Exon 1.0 ST Array
1.3.1 Microarray design
Traditionally, gene expression microarrays have targeted multiple parts of the 3′
tail end of an RNA transcript using sets of complementary probes (probesets) that are
then summarized into a single measure of expression. These 3′ regions of the gene are
believed to be included in all transcripts. While expression arrays give a measure of
overall gene abundance, they give no insight into the types of gene modifications, such
as alternative splicing or alternative transcription start sites, which may be occurring
upstream from the 3′ end. The Affymetrix Human Exon 1.0 ST Array contains
an increased number of probesets that target all putative exonic regions of a gene
(GeneChip Exon Array Design 2005). For the Affymetrix Exon Array, probesets for
exonic regions generally consist of a set of four probes, but longer exons or extended
3′ UTR regions may have multiple probesets. Unlike the Illumina 450k array, the
Affymetrix Exon array does not use beads, but rather has a static design with each
probe anchored to a fixed point on the chip with known X and Y coordinates in a
grid. This makes quality control and adjustment for spatial artifacts simpler than in
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the case of the 450k array.
After RNA is isolated from a sample and fragmented, it is then reverse-transcribed
into complementary DNA, or cDNA. After reverse transcription, the cDNA is am-
plified, labeled with a fluorescent dye, and hybridized to the microarray. If a cDNA
molecule binds to a probe, it fluoresces indicating the presence of that particular exon
in that sample. Signal intensities are captured with a camera, and quantified. Once
signal intensities are obtained, many methods exist for preprocessing, summarization,
and analysis.
1.3.2 Summarization methods
A unique issue to the Affymetrix Exon array is that in order to measure al-
ternative splicing it is necessary to obtain reliable measures of two different kinds
of information: The first is a measure of overall gene expression. The second is a
measure of exon-specific expression. Some models for assessing alternative splicing
treat aggregate gene expression as a model parameter that is estimated rather than
directly computing summary statistics for exon inclusion (Purdom et al. 2008; Cline
et al. 2005). If familiar statistical methods are to be directly applied, then a direct
measure of exon inclusion needs to be computed. This is commonly done by taking
the ratio of exon expression levels with the aggregate gene expression level. These
measures can then be interpreted as an approximate measure of how many gene tran-
scripts contain the given exon. Here we briefly review methods for summarization for
the Affymetrix Human Exon 1.0 ST Array.
1.3.2.1 RMA
Robust multi-chip average, or RMA, is a popular method for obtaining expres-
sion measures from gene expression microarrays (Irizarry et al. 2003). It performs
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background correction, normalization, and summarization. RMA first performs a
background correction using a normal-exponential deconvolution. The equation for
background correction is given in Equation 1.3. Signal intensities yijk for probe k
in probeset j on array i are modeled as a function of probe-specific signal psijk and
non-specific background bgijk .
yijk = psijk + bgijk (1.3)
Here ps is exponentially distributed, bg ∼ N(0, σ2) and ps ⊥ bg. Once back-
ground correction is performed, RMA then performs quantile normalization (Bolstad
et al. 2003). The steps for the quantile normalization algorithm are given below.
1. Let Yi be the vector of signal intensities for array i
2. Sort each vector Yi from largest to smallest to obtain Y
∗
i
3. Compute the mean sorted vector Y¯ ∗ =
∑I
i=1 Yi
I
4. Replace each value of Y ∗i with the corresponding mean value from Y¯
∗
5. Unsort each vector Yi, returning it to its original ordering
Once quantile normalization is performed, probe sets are summarized to obtain
a single measure of expression using an additive linear model given in Equation 1.4.
yijk = µj + Pjk +Mij + ijk (1.4)
Here µj denotes the overall mean for probeset j, Pjk is the probe-specific effect
for probe k, and Mij is the sample effect on the probe set. The expression summary
for a probe set j on array i is then given by µˆj + Mˆij. Tukey’s median polish is
then used to obtain estimates of the parameters. An implementation of RMA for the
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Affymetrix ST 1.0 Exon Array exists in the oligo package in R (Carvalho and Irizarry
2010a; Carvalho and Irizarry 2010b).
1.3.2.2 Splicing Index
The splicing index, or exon inclusion ratio, is a straightforward and simple
method for characterizing exon inclusion. Both the geneBASE and COSIE meth-
ods compute splicing indices using different approaches. It is a ratio of exon-specific
expression to aggregate gene expression. Ideally, a measure of exon inclusion would
take on a value between zero and one the way that a β-value does. However, since
dynamic ranges of different exon probesets can vary substantially for purely techni-
cal reasons, the splicing index often takes on values greater than one and cannot be
directly interpreted like a β-value. Instead, splicing indices are generally transformed
to the log2 scale. A general form for the splicing index is given in Equation 1.5.
Splicing Index = log2
(
exon expression
gene expression
)
(1.5)
1.3.2.3 geneBASE
geneBASE uses a data-driven approach to obtain an aggregate measure for gene
expression (Xing, Kapur, and Wong 2006). Rather than using the Affymetrix an-
notations for constitutive exons, geneBASE performs hierarchical clustering using a
correlation distance metric for each gene across a tissue panel. The set of probes
meeting a correlation threshold are declared as constitutive and are then summarized
using the RMA linear model to get an aggregate measure of gene expression. The
geneBASE paper demonstrates that Affymetrix annotations of constitutive exons are
often incorrect and that their method provides a better measure of aggregate gene
expression, which is important for obtaining accurate measures of exon inclusion.
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1.3.2.4 COSIE
COrrected Splicing Indices for Exon arrays, or COSIE, is a method that attempts
to correct for systematic biases in the detection of alternative splicing on the HT1
Exon Array (Gaidatzis et al. 2009). Since each exon is represented by a probeset that
covers a small genomic region, probe sequence content can vary substantially between
probesets for different exons on the same gene. Probe sequence content affects mRNA
binding efficiency to microarray probes and therefore signal intensity. Gaidatzis et al.
2009 show that by simply diluting an mRNA sample many statistically significant
changes in alternative splicing appear when comparing the diluted sample to the
original sample. This phenomenon is due to the different probesets decreasing in
signal intensity at differing non-linear rates. They were able to predict this effect
moderately well using a model using only features of sequence content.
COSIE takes a simple initial approach to compute splicing indices by taking
the standard RMA summary for each exon and dividing it by the mean of all exons
for that gene in that sample. After computing splicing indices, additional steps are
taken to remove the previously mentioned bias that occurs when gene expression
differs substantially between tissues.
In order to reduce potential biases resulting from differences in gene expression,
Gaidatzis et al. 2009 fit a non-linear regression model to splicing indices as a function
of aggregate gene expression across a tissue panel. Smooth systematic relationships
between alternative splicing and gene expression are then subtracted out leaving
residuals that should reflect only true changes in splicing. This observed bias in
splicing indices seems to occur to a substantial degree only when changes in aggregate
gene expression are on the order of multiple fold changes.
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1.3.3 Methods for the analysis of alternative splicing
1.3.3.1 MADS
Microarray analysis of differential splicing (MADS) is a suite of methods for
preprocessing, filtering, and performing inference on exon microarray data, with
geneBASE being an important component of the preprocessing methods (Kapur et al.
2007; Kapur et al. 2008; Xing et al. 2008). In addition to geneBASE summarization,
MADS uses a sophisticated background correction method as well as an algorithm to
detect potential cross-hybridizing probes. Once pre-processing has been performed,
the statistical methods used to detect differential splicing are relatively simple. Two-
sample t-tests are conducted on splicing indices computed for each probe, not probe-
set, in a gene and then p-values are combined using Fisher’s method to create a single
significance test for each gene.
1.3.3.2 ANOSVA
Analysis of Splice Variation (ANOSVA) uses a two-way ANOVA model for each
gene to model log intensities of each probe in a gene (Cline et al. 2005). The linear
model for the two-way ANOVA is given in Equation 1.6.
yijk = µ+ αi + βj + γij + eijk (1.6)
Here µ represents the baseline background intensity level for all probes, αi rep-
resents the differing probe affinities, βj represents the main effect for the covariate of
interest, and γij is a probe×effect interaction. ANOSVA assumes all effects are linear
and additive, which is rather unrealistic. Also, individual probe signal intensities can
be highly variable and have been shown to increase at different rates, even on the
log2 scale (Gaidatzis et al. 2009).
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1.3.3.3 FIRMA
Finding isoforms using robust multichip analysis, or FIRMA, is a method similar
to ANOSVA that does not estimate the interaction γij explicitly (Purdom et al.
2008). Instead, a main effects model is fit to log2 intensities for probe k of exon
i in experiment j: yijk. Equation 1.7 gives the main effects model where cj is the
experiment effect and pk is the probe effect. Residuals rijk are then computed from
using the parameter estimates.
yijk = cj + pk + eijk
rijk = yijk − (cˆj + pˆk) (1.7)
The residual describes the discrepancy between the expected probe intensity
under no alternative splicing and the observed probe intensity. A score statistic for
testing for alternative splicing is then given in Equation 1.8 where the standard error
s is calculated using the median absolute deviation (MAD) of the residuals (Lu,
Scho¨lkopf, and Zao 2011).
Fij = mediank∈exonj(rijk/s) (1.8)
1.4 Overview of RNA-Seq
1.4.1 Work flow
RNA-Seq (RNA-Sequencing) is a technology that uses next-generation sequenc-
ing to quantify the amount of RNA from a sample. Several of the preprocessing
steps are similar to those of microarrays: coding RNA is extracted from a sample
and reverse-transcribed into cDNA, amplified, and fragmented. However, once cDNA
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is fragmented it is sequenced rather than hybridized to a microarray. While several
protocols exist for next-generation sequencing, the end goal of all of methods is to
obtain the actual nucleotide base sequences for these cDNA fragments. Generally, the
whole fragments are not sequenced, but only the first 50 to 75 bases are sequenced
depending on the protocol. This is usually enough to uniquely identify a large frac-
tion of the cDNA fragments. Sequencing quality tends to decrease as more bases are
added.
Once reads are sequenced, they are mapped to a reference genome using an
alignment tool such as Bowtie (Langmead et al. 2009). From these reads, count data
can then be obtained for genomic intervals by counting the number of reads falling
in that interval. For RNA-Seq these intervals usually correspond to exons. Once raw
count data is obtained, several methods exist for summarization and analysis.
1.4.2 Methods for summarization and analysis
While RNA-Seq ultimately produces count data, it is often summarized using a
measure called “reads per kilobase per million,” or RPKM (Mortazavi et al. 2008).
RPKM scales read counts by the total number of reads in the sample as well as the
size of the interval since larger exons should have more reads for the same amount of
gene expression. Equation 1.9 gives the formula for RPKM.
RPKM =
(#mapped reads)/(length of transcript/1000)
total reads in sample/106
(1.9)
The square root transformation, which is the variance stabilizing transformation
for count data from a Poisson distribution, can be applied to RPKM which can
then be treated as continuous for genes or exons with enough counts. Robinson and
Oshlack 2010 showed that RPKM can be biased when a subset of genes are very
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highly expressed in one tissue, but not another. Nevertheless, RPKM has become the
standard way of summarizing RNA-Seq data.
Many statisticians have contended that since RNA-Seq data is in fact count
data, is should be treated as such when performing modeling and significance testing.
Therefore, methods using negative binomial generalized linear models have been de-
veloped to explicitly treat the data as counts (Robinson, McCarthy, and Smyth 2010;
Anders and Huber 2010).
1.5 Overview of MBD-Seq
MBD-Seq is a cost-effective method for assaying DNA methylation on a genome-
wide scale (Serre, Lee, and Ting 2010). MBD-Seq uses the methyl-CpG-binding do-
main (MBD) protein to extract regions of DNA containing methylated CpGs. Unlike
the Illumina 450k array, MBD-Seq only obtains signals from methylated CpG sites
and not unmethylated sites. After DNA fragments with methylated CpG sites are
extracted, next generation sequencing is applied to map them to a reference genome
as in RNA-Seq. MBD-Seq can be “tuned” to preferentially bind to areas with a given
CpG density by altering the salt concentration of the buffer solution.
MBD-Seq is not a widely used assay, so few published methods exist for normal-
ization and preprocessing (Chen et al. 2013a). For the purposes of analysis in later
chapters we simply bin the data in windows of fixed width and adapt the RPKM
measure from RNA-Seq.
1.6 Overview of genotyping arrays
Genotyping arrays are a type of microarray used to detect single nucleotide poly-
morphisms (SNPs) in DNA. A SNP is a variation in DNA sequence occurring at a
single base. Different variations of a SNP are commonly referred to as alleles. Most
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alleles have a common version called the major allele, and a less common version
called the minor allele. These different alleles can affect phenotypes such as eye color
or baldness or more complicated phenotypes such cancers or psychiatric disorders.
Alleles are also used in DNA fingerprinting in forensic science.
Genotyping arrays function similarly to the Illumina 450k array, and are in
essence a simpler version. For each SNP assayed by the array, a probe exists for
each possible allele and a signal intensity is obtained for each. While a continuous
measure is obtained for each allelle, it should hypothetically correspond to only one of
three possibilities: the absence of the minor allele, presence of the minor allele on one
chromosome, or the presence of the minor allele on both chromosomes. Therefore, the
output of genotyping arrays for a given SNP is generally coded as an integer value
0, 1, or 2 corresponding to the three outcomes mentioned previously. These inte-
ger values are usually treated as ordinal rather than nominal when fitting statistical
models.
1.7 Traditional approaches for integrative analysis
1.7.1 eQTL analysis
Quantitative trait loci (QTLs) are regions of DNA linked to genes associated
with a quantitative trait. Traditionally, quantitative traits have been considered to
be phenotypes such as height, blood pressure, or IQ that take on a continuous distri-
bution. These kinds of quantitative traits are often complex and can be influenced
by several genes. Studies of quantitative trait loci existed before the era of genome-
wide association studies (GWAS), but assayed much smaller sets of candidate alleles
(Plomin et al. 1994).
In the post-GWAS era, it is now possible to assess millions of SNPs simulta-
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neously for an individual. Additionally, genomic measures can now be considered
as quantitative traits. Expression quantitative trait loci (eQTLs) and methylation
quantiative trait loci (mQTLs) are two examples of these new genomic QTLs (Gibbs
et al. 2010). Studies of genomics QTLs involve integrating multiple types of genomic
data generated by different microarrays or sequencing methods. Integrating genomic
data presents several challenges, both statistical and bioinformatic.
There are various approaches to eQTL analysis. Most eQTL studies perform
separate testing for all possible transcript-SNP pairs using standard linear regression
or ANOVA models. For this reason, eQTL studies can be severely underpowered. A
procedure for controlling false-discovery rate, such as Benjamini and Hochberg 1995,
is then used to call significant eQTLs. eQTLs can be categorized into two major
types: cis-acting and trans-acting. Cis-acting eQTLs are located within, or very
close to the gene whose expression the are correlated with. Trans-acting eQTLs are
distal SNPs affecting expression that may even be on different chromosomes.
1.7.2 Gene expression and promoter methylation
Integrating gene expression and DNA methylation has established a relation-
ship between DNA methylation in promoter regions and gene expression in cancer
studies (Baylin et al. 2001). Unlike eQTL analyses, integrating DNA methylation is
more targeted and tests are conducted on a gene-by-gene basis rather than using all
pair-wise combinations of expression and methylation measures. Methylation may
be considered as a binary variable in some situations, but is generally treated as
continuous.
Therefore, the most straightforward approach to integration is to use a Pearson’s
correlation coefficient for methylation/expression pairs (Warden et al. 2013). How-
ever, recent studies have demonstrated a relationship between non-promoter methy-
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lation and exon inclusion (Maunakea et al. 2013). New microarray and sequencing
technologies now make exploration of these kinds of relationships in large studies pos-
sible. Since most genes have multiple exons and CpG sites, alternative splicing and
DNA methylation now both become multivariate continuous data and more sophis-
ticated techniques are needed for integration.
1.8 Summary
In this section we have introduced the necessary concepts and terminology to
motivate following chapters. Microarray design and summarization methods have
been introduced for the Illumina 450k array. In Chapter 2, a novel robust normal-
ization method for the 450k array will be introduced and compared to other popular
normalization methods on several criteria. In Chapter 3, a novel method for genomic
data integration will be introduced as a way to perform multivariate data analysis
when p > n with specific focus on integrating genic DNA methylation and exon inclu-
sion. This method will then be applied in Chapter 4 to a set of developmental brain
samples. In Chapter 5, a similar integrative analysis will be performed integrating
gene expression and DNA methylation using brain samples taken from schizophrenic,
bipolar, and neurotypical control patients.
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CHAPTER 2
NORMALIZATION AND QUALITY CONTROL FOR DNA
METHYLATION ARRAYS
2.1 Overview of normalization methods for 450k array
In recent years, the number of normalization methods for the Illumina 450k array
has grown rapidly, and now a multitude of normalization methods and accompanying
pipelines and R packages exist. Some of these methods normalize within arrays to
account for the complex array design, while others focus on normalization between
arrays to account for technical artifact and batch effects. Different normalization
methods also operate on different levels of data summarization. Some methods re-
quire the summary level β-values, while other require the signal intensities. Some
methods specifically require the raw signal .idat files which contain additional signal
information that is not used in the standard Illumina summarization.
These different levels of data summarization can be problematic when choosing
a normalization method. Most Gene Expression Omnibus (GEO) data sets provide
raw signal intensities along with summarized β-values, but do not provide .idat files.
This has reduced the pool of candidate data sets on which we are able to compare
between-array normalization methods in later sections.
In the following section we provide a brief overview of popular methods in the
literature. We give each method an intuitive conceptual introduction and highlight
their strengths and potential shortcomings. Some of these shortcomings, particu-
larly for quantile normalization, will be important later when motivating our new
normalization method.
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2.1.1 Within-array methods
As previously mentioned, there are two distinct bead types on the 450k array that
have substantially differing signal characteristics as well as distribution throughout
the genome. The type I beads are generally thought of as producing higher quality
signals and are therefore used as a reference, or gold standard, for normalizing the
type II beads in the following methods. Bibikova et al. 2011 observed that type II
beads have a more compressed dynamic range than the type I probes. Teschendorff
et al. 2012 showed that this compressed range in type II can result in a relative
enrichment of type I beads to type II in when performing significance testing and
sample clustering.
All three of the following methods attempt to make the data from type II beads
look more like that from the type I. This task is complicated by the fact that the
majority of type I beads have sequences lying in promoter regions, whereas type II
beads are distributed throughout locations in the gene, which results in the two bead
types having different overall signal distributions. Each of the following methods has
a different way of normalizing the type II relative to type I, while trying to address
the confounding issue of distribution of genomic location.
2.1.1.1 Peak-Based Correction (PBC)
Peak-based correction is a method that aligns the upper and lower peaks of type
II beads with those of type I (Dedeurwaerder et al. 2011). This is accomplished by
first computing summary β-values and transforming them into M-values using the
relation: M-value = log2(β-value/(1 − β-value)). Next, a kernel density estimator is
used to detect the upper and lower peaks for the type I and type II beads. Separate
scaling factors are then applied to the M-values above and below zero such that
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the type II peaks align with the type I peaks. These adjusted M-values are then
transformed back into β-values for further analysis. The main shortcoming of this
method is that it assumes a bi-modal methylation distribution with two distinct
peaks. In most healthy adult tissues this is usually true, but it may not be the case
for cancer samples or tissue that is a mixture of differentiated and non-differentiated
cells. Samples may have more than two modes, or have wider, less-distinct peaks that
may be difficult to align accurately.
2.1.1.2 Beta Mixture Quantile Normalization (BMIQ)
BMIQ performs a sophisticated quantile normalization procedure on the sum-
mary β-values by fitting a mixture of beta probability distributions (Teschendorff
et al. 2012). Like peak-based correction, BMIQ uses the type I beads as a reference
and normalizes the type II probes with respect to them. Rather than using a scal-
ing factor to align peaks, BMIQ performs a quantile normalization procedure using
the results of a three-state beta-mixture model that assigns CpGs as being either
unmethylated, hemi-methylated, or fully methylated. After the three-state model is
fit, each CpG is assigned to the most likely state. New values for the type II probes
are then determined by assigning them the beta-distribution quantile from the type I
density corresponding to their assignment probabilities determined from the original
type II density.
BMIQ explicitly assumes that methylation values take only three possibly true
underlying states. In the case of complex tissue where a β-value of 0.4 results from
only 40 percent of cells being methylated at a locus, this assumption is invalid. An-
other weakness of both PBC and BMIQ is that they operate on the level of the β-value
summary measure, and are unable to directly adjust signal intensities at a lower level
before summarization.
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2.1.1.3 Subset-quantile Within Array Normalization (SWAN)
SWAN performs a subset quantile normalization approach on signal intensities,
rather than β-values, to make type II signals look more like type I (Maksimovic,
Gordon, and Oshlack 2012). Since there are differing numbers of type I and type II
probes, an average quantile distribution is first determined using a randomly selected
subset of type II probes. This distribution is then quantile normalized to be identical
with the type I distribution, with remaining probes adjusted by linearly interpolating
the quantile distribution. This method is stratified by CpG content which is used as
a proxy for biologically similar genomic regions. In practice, the adjustments made
by SWAN are rather modest.
2.1.2 Between-array methods
The goal of between-array normalization is to remove artifact from signal inten-
sities while preserving the biological signal. Several between-array methods for the
450k array have been recently developed. The complicated array design has made
widely used general methods for microarray normalization, such as quantile normal-
ization, not easily adaptable. The following between-array methods each have their
own way of normalizing between arrays, while accounting for this complex design.
2.1.2.1 Subset Quantile Normalization (SQN)
Subset quantile normalization is an adaptation of the standard quantile normal-
ization as performed in RMA (Touleimat and Tost 2012; Irizarry et al. 2003). In some
ways, it is an extension of SWAN. The type I beads are used as anchors to create
an average quantile distribution for several biologically distinct strata taken from the
450k array annotation file. Then both type I and type II beads are normalized with re-
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spect to these average distributions using a standard quantile normalization approach
on both the red and green channels. Once the stratified quantile normalization has
been performed on the signals, normalized β-values are computed.
A criticism of SQN is that the fundamental assumption that all samples should
have the same overall distribution, even when stratified by genomic location, can be
invalid. It may be close to true for samples of healthy tissue, but it can fail for samples
with aberrant methylation, or a set of samples with substantially varying cell type
compositions. When this assumption fails, false apparent differences between groups
can be created that may even be reproducible. More attention will be given to this
phenomenon in following sections.
2.1.2.2 Normal-Exponential Using Out-of-Band Probes (Noob)
Noob is a background correction method that fits the standard normal-exponential
model used by RMA, where observed signals are modeled as a convolution of a nor-
mally distributed background and exponentially distributed true signal (Irizarry et
al. 2003). While a few hundred background probes exist for the 450k array to esti-
mate parameters for the background normal density, fitting of the normal-exponential
model is greatly enhanced by the use of “out-of-band probes” (Timothy J. Triche
et al. 2013). These out-of-band probes are actually the signal intensities from the
unused color channel of type I probes. Measures from the unused channels serve as
additional measures of non-specific background hybridization, effectively increasing
the number of background control probes from roughly 600 to 135,000. Noob requires
the .idat signal intensity files to perform normalization, which are often unavailable
as public data sets from websites such as GEO.
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2.1.2.3 Functional Normalization (Funnorm)
Functional normalization uses the same principle as SQN, by using a quantile-
based normalization approach stratified by genomic location (Fortin et al. 2014).
However, rather than applying quantile normalization, a quantile regression method
is used. First, principal component analysis is used to obtain summary measures
from background and out-of-band probes. Then, the distribution quantiles are re-
gressed against the first two principal components using a simple linear model. Since
these background and out-of-band probes should not contain biologically relevant in-
formation, model fits should only be removing variation due to artifact. Quantile
normalization can be seen as a special case of functional normalization that fits and
subtracts out a saturated ANOVA model. Functional normalization may suffer from
some of the same issues as subset quantile normalization, but they should be less
severe.
2.2 Analysis of complex tissue using the 450k array
2.2.1 Complex tissues are a mixture of cell types
The human body is composed of many types of tissues such as muscle, skin, liver,
and brain. Some of these tissues, such as skin and muscle, are composed mostly of
a single cell type with a common origin. Therefore, we can be relatively confident
that observed differences in these tissues are due to changes in methylation within
the single given cell type. Even if the observed change is slight, we can be some-
what confident that some proportion of the cells are likely having a real change in
methylation.
Other tissues such as brain, liver, and blood are made up of multiple different
cell types with distinct methylation profiles. The brain is composed of a mixture of
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Fig. 1. An idealized example of observed intermediate β-values. An observed methy-
lation profile of intermediate β-values M is a linear combination of β-value
methylation profiles from cell types A, B, and C which are either completely
methylated or unmethylated at each of five loci.
neurons, astrocytes, oligodendrocytes, and microglia. In blood, there are multiple
different types of immune cells. In complex tissue, changes in the proportions of
different cell types between samples can produce significant differences when no actual
differential methylation within cell types is occurring. In fact, a meta-analysis of
several studies using peripheral blood showed that the majority of age-related findings
were in fact due to differences in cell proportions (Jaffe and Irizarry 2014).
Figure 1 gives an idealized example of a complex tissue composed of three dif-
ferent cell types. The three pure cell methylation profiles, given in the middle, are
mixed in different proportions given on the left. The resulting β-values on the right
can then take on intermediate values. More importantly, both changes within cell
types as well as differences in cell proportions will produce slight changes in methy-
lation. Changes in cell proportions will however, produce many slight changes on
a global scale. Methods have been developed to estimate relative cell proportions
when isolated cell methylation profiles exist (Houseman et al. 2012). Isolated cell
type profiles have been obtained for both blood and brain for the 450k array using
FACS (Reinius et al. 2012; Kozlenkov et al. 2013).
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2.2.2 Addressing differences in cell type proportions
A method for estimating and adjusting for differences in cell type mixtures in
complex tissue using isolated methylation profiles has recently been developed (House-
man et al. 2012). While originally developed for the Illumina 27k array, it has been
adapted to the Illumina 450k array (Jaffe and Irizarry 2014). The method first ap-
plies a quadratic programming routine to obtain estimates of cell proportions that
are constrained to sum to 1. Once these estimates are obtained, a double-bootstrap
procedure is used to obtain standard errors for the estimates. Predicted methylation
values from the model can then be subtracted out from the original data to pro-
duce mixture-adjusted residuals. Other more sophisticated models for incorporating
estimated cell type proportions exist, but do not directly lend themselves to data
integration (Guintivano, Aryee, and Kaminsky 2013). Significant differences in these
residuals can then be attributed to real differences methylation, although we cannot
say for sure in which cell type. A brief development of the method follows below.
Let Y 0h be an m× 1 vector of methylation assay values from a purified cell type
with the qualitative characterization given by a d0 × 1 covariate vector wh which
is generally given as a set of indicator variables for cell type. Here, h ∈ {1, ..., n0}
where n0 is the number of specimens and m corresponds to the number of CpG sites
on the DNA methylation array. Then let Y 1i be an m × 1 vector of the same CpG
sites in the same order, but assayed from a sample that is a mixture of cells. Here
i ∈ {1, ..., , n1} where n1 is the number of target specimens. Let z1i be d1×1 covariate
vector representing phenotypic information. We can then posit the two following
linear models describing the purified cell types and mixed samples, respectively, in
Equation 2.1.
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Y 0h = B0w0h + e0h
Y 1i = B1z1i + e1i
(2.1)
We can then posit the following surrogacy relation between the two models in
Equation 2.2.
B1 = 1mγ
T
0 +B0Γ +U (2.2)
Here Γ is a d0 × d1 matrix summarizing associations between the rows of B0j
and B1i and U is a matrix of errors. Substituting Equation 2.2 into the second part
of Equation 2.1 yields the following in Equation 2.3.
Y 1i =
d0∑
l=0
b0l(γ
T
l z1i) + (1mγ
T
0 +U)z1i + e1i (2.3)
Estimation of B0 and B1 procedes by applying an appropriate linear or mixed
effects linear model. Estimates of γ0 and Γ are then obtained by projecting Bˆ1 onto
the column space of B˜0 = (1m, Bˆ0) using a constrained linear programming routine.
The mixture coefficients ω
(z)
l can then be recovered from Γ by ω
(z)
l = γ
T
l z1i. To
impart a biological interpretation, we can say that the observed methylation profiles
arise as a mixture of cell types whose isolated methylation profiles have coefficients
given by b0l in proportions given by ω
(z)
l and some residual mixture of unobserved
cell type proportions and true methylation differences ξ(z). Equation 2.4 gives the
relationship explicitly below.
E(Y 1i|z1i = z) = ξz +
d0∑
l=1
b0lω
(z)
l (2.4)
A straightforward method for downstream analysis is using the residuals ξz as a
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measure of remaining real methylation changes after accounting for differences in cell
proportions. Remaining significant findings in these residuals may then be attributed
to real methylation differences although the specific tissue or tissues where the changes
are occuring is not specified.
2.2.3 Complex tissue and microarray normalization
Complex tissues also pose a problem for many common normalization methods.
A common assumption of many normalization methods for genomic data is that the
majority of observations should be similar between samples. This assumption is nec-
essary in order to have additional points of reference for comparison between samples
aside from the background probes. Quantile normalization goes so far as to enforce
the empirical distributions of samples to be identical (Touleimat and Tost 2012; Bol-
stad et al. 2003). This assumption is often untrue, but is particularly problematic in
the case of complex tissues where differences in cell proportions can result in global
changes in the overall methylation distribution.
Quantile normalization of samples with different β-value distributions can lead to
reproducible false differences. Figure 2 shows density plots for average β-values from
69 technical replicates of a liver sample and 55 placenta (Aryee et al. 2014). After
quantile normalization, intermediate β-values in placenta must be increased and β-
values closer to one in liver must be decreased in order to match the two distributions.
This warping not only changes the resulting mean methylation profiles, but also their
relationship to each other. A CpG site that has a mean β-value = 0.5 in both tissues
may have a statistically significant mean difference after quantile normalization. If we
perform this analysis on independent subsets of the data, the same result will occur.
This phenomenon could cause two completely separate and independent microarray
studies using the same study design to replicate false discoveries!
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Fig. 2. Average methylation profiles for 69 technical replicates of liver and 55 technical
replicates of placenta
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In order to determine the extent to which quantile normalization warps mean
β-value distributions of these two tissue types, we plot mean differences after normal-
ization against each other. Ideally, a normalization method shouldn’t change the mean
profiles of technical replicates by much in any direction, but if it does it shouldn’t
do so in opposing directions in different tissues. Equation 2.5 gives the formula for
computing differences in mean β-values (∆ik) for technical replicates j ∈ {1, ..., J} of
tissue type k at probe i.
∆ik =
∑J
j=1 β
Norm
ijk −
∑J
j=1 β
Raw
ijk
J
(2.5)
Quantile normalization was applied to all samples in aggregate. While samples
can be normalized separately by tissue type, which will avoid the problem in this
scenario, this approach is not a cure-all and should ideally not be necessary. In the
case of confounding continuous covariates such as differing cell proportions over age,
a stratified normalization approach is not directly applicable.
Figure 3 plots changes in mean β-values in placenta after quantile normaliza-
tion against changes in mean β-values in liver after quantile normalization for CpGs
that were only significantly different between the two tissues after quantile normal-
ization. Significant differences were determined using a two-sample t-test on β-values
from each CpG site and controlling FDR=0.1 using the Benjamini-Hochberg method.
Points are colored by global average β-value before normalization in the left panel,
and by probe type in the right panel. Again, changes in mean methylation profiles
after normalization should be minimal. However, we observe changes in β-values that
can be almost as big as ∆ik = 0.3. Points that are far from the y = x line indicate
CpG sites where mean differences between the two tissues change, sometimes almost
as much as |∆i1−∆i2| = 0.2. We can see that type two probes are being adjust almost
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Fig. 3. Changes in average methylation profiles in liver and placenta after subset quan-
tile normalization. Points in the left panel are colored by mean β-value. Inter-
mediate beta values are more strongly affected. The number of points lying in
each quadrant are given. The right panel is colored by probe type on the array.
Many Type I probes and nearly all Type II probes are adjusted in opposing
directions, creating false differences that did not exist before normalization.
exclusively in opposing directions between the two tissues, creating substantial mean
differences that were not present before.
This is perhaps an extreme example of what can happen if distributional dif-
ferences are ignored during normalization. This warping effect can be particularly
problematic in methylation data where the data have a bi-modal distribution and
differences in heights of modes between samples can have global effects on interme-
diate methylation values. Ideally, a normalization method should be robust to these
kinds of distributional differences, whether they arise from differences in cell pro-
portions in complex tissues or some other mechanism. Our proposed normalization
method is designed with this exact goal of being robust to distributional differences.
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2.3 Normalization using local regression on empirical controls
We propose a normalization method “Flexible local Regression on Empirically Se-
lected COntrol probes,” or fresco, as a supervised model-based normalization method
for the Illumina 450k array. fresco was developed with the goal of creating a method
that is robust to samples with varying methylation profiles as in Figure 2. The method
uses a stable subset of CpGs, called empirical control probes, to fit a non-linear local
regression hyper-surface to model signal intensities as a function of known covariates.
fresco adjusts probe signal intensities, but does not require .idat files, so GEO data
sets providing raw signals can be used. Using raw signals allows for normalization of
red and green channels separately, which have been shown to have differing properties
(Bibikova et al. 2011). The method has proceeds in three steps which are detailed
below.
2.3.1 Selection and filtering of empirical controls
Empirically selected control probes are CpG sites taken from regions of the
genome that should generally be consistent between all samples. The concept of em-
pirical controls has been used by Gagnon-Bartsch and Speed 2011 for gene expression
microarrays, but using a different statistical model. Unlike negative control probes
on a microarray, the full set of empirical control probes employed by our method is
representative of the entire range of variation in signal intensities. This is accom-
plished by having three subsets of empirical controls: methylated, unmethylated, and
hemi-methylated.
It is has been generally observed that active genes have mostly unmethylated
promoters and mostly methylated gene bodies. The so-called housekeeping genes are
prime candidates for genes that should be active across all cell-types. Eisenberg and
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Levanon 2013 identified a list of 3804 housekeeping genes using RNA-seq. While RNA
gene expression patterns may be less consistent across samples due to a myriad of
other factors such as lncRNAs, RNA binding proteins, RNA degradation, or distal
enhancer activity, their methylation should be relatively more stable. From these
housekeeping genes we obtain a set of negative controls from promoters that have
beta values near zero, and a set of positive controls that have beta values near one.
In order to have a truly representative subset of empirical control CpGs, we still
need to have a set of CpGs that cover the intermediate range of methylation values. To
accomplish this we use the set of known imprinted genes whose promoters should be
methylated on one chromosome and unmethylated on the other, therefore producing
intermediate beta values (Jirtle 2012). Once the full set of empirical controls are
obtained, an additional quality control step is taken.
Once candidate empirical control probes are selected, a filtering and quality
control check is performed to ensure that they are indeed stable. First, we filter out
probes containing known SNPs within their target sequences as well as probes that
have been shown to cross-hybridize with sites on sex chromosomes which can lead to
false autosomal gender differences (Chen et al. 2013b). After this initial filtering, the
empirical control CpGs are then filtered for stability across a tissue panel composed
of healthy adult tissues: brain, blood, and liver (Reinius et al. 2012; Aryee et al.
2014). Probes with standard deviations falling below a cut-off of σ = 0.1 are then
included in the final set of empirical controls. Figure 4 illustrates the empirical control
filtering process. This same filtering step is available for new data sets as a part of
the normalization function.
Once we have selected the final set of empirical controls, we want to ensure
that they are indeed representative of the overall range of possible signal intensities.
Figure 5 shows the range of coverage for empirical control probes for both type I and
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Fig. 4. Filtering empirical controls across a tissue panel by standard deviation. The
left-most panel gives a heat map of β-values where each column is a CpG site,
and each row corresponds to a sample. CpGs are sorted according to average
methylation, with average methylation level given by the black line on a scale
from 0 to 1. The middle panel gives the density of standard deviations of
β-values and the threshold used to discard empirical controls. The right-most
panel is the same as the first panel with the more variable probes removed
type II probe signal intensities. For each set of probes log2(Unmethylated Signals)
are plotted against log2(Methylated Signals). Additionally, log2 signal intensities are
plotted against target GC content, a covariate of interest. Empirical control probes
are colored by their type: Methylated, Unmethylated, and Hemi-methylated.
2.3.2 Alignment and scaling
Although β-values taken from empirical control probes are filtered to be similar,
the distributions of signal intensities taken from these empirical controls can still differ
substantially. The variability in these signal intensities is likely largely a function
of technical artifact rather than true biological signal. Therefore, we perform our
normalization method on signal intensities from these sets of empirical control probes
and extend model fits to remaining probes.
After empirical control probes are selected, an initial alignment and scaling pro-
cedure is performed before fitting the local regression hyper-surface. Since the 450k
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Fig. 5. Empirical controls span the range of microarray signal intensities and CG con-
tent. Green, yellow, and red points correspond to unmethylated, hemi-methy-
lated, and methylated controls, respectively.
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array contains two bead types, all subsequent normalization steps are stratified by
type I and type II beads, essentially conducting two completely separate normalization
procedures in parallel with each other. For the alignment step, a kernel density esti-
mate is fit for the distribution of empirical control probes for each of the methylated
and unmethylated control probe signal densities. The lower peaks of the densities are
calculated by finding the max of each of the kernel densities and then subtracting it
out so that they all share a common lower peak at zero.
Once signal densities are aligned by their lower peaks, a linear scaling factor is
applied to minimize the difference between each sample’s empirical control density and
the average empirical control density. This is done by fitting an ordinary least squares
zero-intercept linear model for each sample: one for each of the type I channels, and
one for each of the type II channels. Equation 2.6 gives the formula for the linear
model.
For each sample j ∈ {1, ..., J} and for empirical control probes i ∈ {1, ..., I}, we
model each empirical control profile Yij as a function of the average empirical control
profile Yi· using a zero-intercept linear model. A scaling factor is then estimated for
the jth sample as 1/θj. Equation 2.6 gives the resulting linear model.
Yij = θjYi· + ij (2.6)
Once scaling factors are computed and applied, the average lower peak is added
back in. If there are any negative values after alignment and scaling they are set
to zero. Once alignment and scaling have been performed on the empirical control
probes, the same process is applied to remaining probes using the empirical control
model fits. Figure 6 gives an example of the alignment and scaling procedure for the
type II unmethylated channel.
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Fig. 6. Densities of signal intensities for unmethylated channel of type II probes before
and after initial alignment and scaling. The left panel gives densities of raw
signals. The right panel gives densities after samples are aligned by peaks and
a linear scaling factor is applied.
2.3.3 Flexible local regression on technical covariates
Once signals have been aligned and scaled, a final step is performed by fitting a
local polynomial regression hyper-surface to each sample to remove remaining techni-
cal artifacts. Local regression is a non-parametric regression technique that fits many
linear models to local subsets of data whose sizes are determined by a span parameter
λ (Cleveland, Grosse, and Shyu 1992). For each subset, observations are weighted by
their proximity to the center of the subset using a kernel function, and a weighted
linear model is fit. For the normalization method, surfaces are fit as a function of
technical covariates which are probe-specific covariates thought to be representative
of sources of technical bias. Local regression on technical covariates provides a general
framework that can be adapted to other microarray or sequencing technologies. The
loss function for weighted local polynomial regression for a single subset of data is
given below in Equation 2.7.
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n∑
i=1
(Yi − βxi − γx2i )2ω(ti) (2.7)
We use a span of 15% and the tricube kernel given by Equation 2.9 when fitting
the weighted local regression hyper-surface. Choice of span generally does not seem to
make a large difference, but 15% seems appropriate in most cases. Smaller spans are
also preferable because they result in loess fits that are less computationally intensive
since fewer data points are used for each fit.
The value ti in Equation 2.9 is a value between 0 and 1 that represents the
scaled Euclidean distance of a point xi from the center of the window. If there are
j ∈ {1, ..., J} technical covariates, then Equation 2.8 gives the formula for ti where
x∗ contains the coordinates for the center of the window, xi is the vector of technical
covariates for data point i, and h is the window half-width.
ti =
√∑J
j=1(xij − x∗j)2
h
(2.8)
ω(ti) =

(1− |ti|3)3 if |ti| ≤ 1
0 otherwise
(2.9)
Technical covariates included in our model include probe target sequence GC
content as well as average methylated and unmethylated signal intensities. The sur-
face fitting step proceeds separately for each of the two channels within each probe
type. First, signal intensities are transformed using log2(y+ 1) to reduce the skew in
their distributions which should result in a more stable surface. Then a robust average
methylation profile is computed for all probes using a 10% trimmed mean. Finally,
the local regression hyper-surface is fit to deviations from the average methylation
profile as a function of technical covariates (Equations 2.10 and 2.11). For either the
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log2 methylated channel signal M , or log2 unmethylated channel U and probe i in
sample j, deviations from the average intensity are modeled as a sample-specific local
regression surface fj that is a function of average log2 methylated signal (M¯), average
log2 unmethylated signal (U¯), and target sequence GC content (GC).
U∗ij = (Uij − U¯i)− fj(M¯i, U¯i,GCi) (2.10)
M∗ij = (Mij − M¯i)− fj(M¯i, U¯i,GCi) (2.11)
Once the fitted surfaces have been subtracted out and the residual matrices M ∗
and U ∗ are computed, normalized signals are then computed by adding average signal
profiles intensities back to obtain normalized signals on the log2 scale. These normal-
ized log2 signals are then transformed back from the log2 scale to obtain normalized
signal intensities which can be used to compute β-values. A formula for transforming
the normalized residuals back into normalized β-values is given in Equation 2.12 where
 is a small offset suggested by Illumina to stablize β-values when both methylated
and unmethylated signals are small.
β∗ij =
2M
∗
ij+M¯i
2M
∗
ij+M¯i + 2U
∗
ij+U¯i + 
(2.12)
2.4 Performance assessment
To assess the performance of the fresco normalization method, we compare it with
other popular between-array normalization methods across several metrics. While the
goal of within-array normalization methods is to reduce the enrichment bias of type
I probes relative to type II, the goal of between-array normalization is to improve
the biological signal-to-noise ratio. Since most normalization methods are performed
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without incorporating information on phenotype (with Surrogate Variable Analysis
being an exception), we believe improvement in signal-to-noise ratio should be a result
of reduction in noise, rather than amplification of biological signal (Leek and Storey
2007).
It is also important that a normalization method does not over-fit or over-adjust
in such a way that a substantial amount of true biological variability is tampered
with or removed. As mentioned previously, our goal is to have an effective method
that avoids over-fitting by using a very flexible model on a subset of data that should
be stable between samples. In the following sections we detail the data sets being
used, the metrics being used to assess performance, and results on the effects of
normalization. All data sets are read in and preprocessed from the .idat files using
the minfi package in R (Aryee et al. 2014).
2.4.1 Overview of data sets
The first data set from the BrainSpan Consortium contains 93 post-mortem
human brain samples taken from 6 individuals. Each individual is sampled at sixteen
brain regions. Of the original 96, three samples did not pass an initial quality control
check and were discarded. Two samples were outliers and had low signal intensities
for many probes. One cortical sample seemed to be mislabeled and clustered with
the cerebellum samples, which have a very distinct methylation profile. Brains were
sampled from eleven different cortical regions and 5 sub-cortical regions. Table I gives
a summary of the distinct brain regions sampled and their abbreviations. Samples
were randomized across eight batches of size twelve.
The second data set comes from a set of six peripheral blood samples taken from
six healthy males (Reinius et al. 2012). This set of six samples is assayed several times
after applying centrifugation and FACS in different combinations to isolate various
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Table I. Brain regions assayed in BrainSpan data
Brain Region Abbreviation Location
Primary Auditory Cortex A1C Temporal Lobe
Amygdala AMY Sub-cortical
Cerebellum CBC Sub-cortical
Dorsolateral Prefrontal Cortex DFC Frontal Lobe
Hippocampus HIP Sub-cortical
Inferior Parietal Cortex IPC Parietal Lobe
Inferior Temporal Cortex ITC Temporal Lobe
Thalamus MD Sub-cortical
Primary Motor Cortex M1C Frontal Lobe
Medial Prefrontal Cortex MFC Frontal Lobe
Orbitofrontal Cortex OFC Frontal Lobe
Primary Somatosensory Cortex S1C Parietal Lobe
Superior Temporal Cortex STC Temporal Cortex
Striatum STR Sub-cortical
Primary Visual Cortex V1C Occipital Lobe
Ventral Frontal Cortex VFC Frontal Lobe
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Table II. Sample types in Reinius blood data
Sample Type Preprocessing
Whole Blood None
Mononuclear Cells Centrifugation
Granulocytes Centrifugation
CD4+ T Cells FACS on Mononuclear Cells
CD8+ T Cells FACS on Mononuclear Cells
CD14+ Mononuclear Cells FACS on Mononuclear Cells
CD19+ B cells FACS on Mononuclear Cells
CD56+ Natural Killer Cells FACS on Mononuclear Cells
Neutrophils FACS on Granulocytes
Eosinophils FACS on Granulocytes
cell sub-populations. Table II gives an overview of the sample types for each of the 6
samples and how they were obtained. There are sixty arrays in total. Samples were
randomized across five batches of size twelve.
The third data set is a collection of 175 liver samples generated by the TCGA
Research Network (http://cancergenome.nih.gov). Samples are a mixture of 50
healthy livers and 123 livers with hepatocellular carcinoma that come from multiple
medical centers involved with TCGA. Table III gives details of the samples taken
from each study. Samples are randomized over 21 batches, but three batches contain
only HCC samples.
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Table III. Overview of hepatocellular carcinoma samples from TCGA data set
Center Number of Controls Number of Cases
Alberta Health Services 2 17
Asterand 0 3
Christiana Care Health System 2 7
Fox Chase Cancer Center 0 1
ILS Bioservices 0 13
International Genomics Consortium 2 11
Mayo Clinic 28 47
Ontario Institute for Cancer Research 0 1
Saint Joseph’s University 0 3
University of Florida 2 1
University of Minnesota 0 1
University of North Carolina 12 15
University of Pittsburgh 2 3
2.4.2 Methods for comparison
2.4.2.1 Reduction in batch effect
One intuitive method for assessing the effectiveness of a normalization method
is to see how well it is able to reduce batch effects (Chen et al. 2011). Batch effects
are significant differences among samples that occur across batches. If proper ran-
domization and experimental design are performed, and biological factors of interest
are mostly orthogonal to batch assignment, then batch effects are a good measure
of technical variability. Methods have been developed to specifically target batch
effects using empirical Bayes methods (Johnson and Li 2006). If it is the case that
batches are confounded with phenotypes, then reduction in batch effect is not as eas-
ily interpreted as a reduction in technical variability. There is minimal confounding
between batch and covariates of interest in the three data sets used for comparison
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of normalization methods.
For assessing reduction of batch effects, a one-way ANOVA is fit to each CpG on
the array with batch as a predictor. This then produces a distribution of p-values for
all CpG sites. If no batch effects are present, the p-value distribution should be as
close to uniform as possible. Deviations from the uniform density with an increased
number of small p-values indicates presence of batch effects. Empirical cumulative
p-value distributions are then obtained for the raw data and each of the normalization
methods for visual comparison.
2.4.2.2 Increase in apparent significance
The goal of genomic microarray studies is usually to compare samples across some
set of biological conditions. Therefore, it is desirable to have as much power as possible
to detect these differences. However, since we don’t know the true methylation states
of assayed CpGs, we have no way of objectively measuring power. Due to the intricacy
of some normalization methods, it is difficult to simulate a realistic scenario. We can
instead take the increase in the number of CpG sites as an indirect measure of power,
but this na¨ıve approach is not soley sufficient, as will be detailed in the next section.
We can begin to justify this approach by claiming that under appropriate exper-
imental design, technical artifacts, such as batch effects should be mostly orthogonal
to biological signal. If framed in the context of a t-test or F-test, technical variability
should be mostly contributing to the denominator, or error term of the test statistic.
Therefore, an increase in the significant number of CpG sites when testing across
covariates of interest should indicate a reduction in batch effects and also less easily
characterized sources of technical variability that are contributing to the error term.
In order to assess increases in apparent significance, a similar approach is taken
to the one for assessing batch effects. One-way ANOVAs are fit using β-values for
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each CpG and p-values are computed for each site. P-values are then adjusted using
the Benjamini-Hochberg procedure for controlling False Discovery Rates (Benjamini
and Hochberg 1995). If one particular normalization method improves the signal-
to-noise ratio better than another, then there should be more significant CpG sites
after normalization for the same FDR. However, an increase in significance does not
guarantee that the increase is due to a reduction in technical variability and more
real differences are being discovered. As mentioned previously, quantile normalization
methods can create reproducible false differences when comparing samples that have
different overall distributions of beta values.
2.4.2.3 Sensitivity of methods to distributional differences
While an improved signal-to-noise ratio is the main goal of a between-array
normalization, it is important to ensure that the resulting improvement is valid. The
noise component of the signal to noise ratio in microarray experiments is generally
not i.i.d. and has some kind of structure that can be attributed to technical artifact
such as cross-hybridization, probe GC content, or spatial variability on the chip.
The goal of normalization is to remove components of this structured noise. Aside
from quantile normalization, normalization methods generally use information that
should be independent of biology so as to not tamper with true biological signal.
Funnorm and Noob use the out-of-band probes. Our method uses technical covariates.
Therefore, a normalization that has a substantial effect on biological effect sizes should
be treated as suspect, especially if it is affecting a large number of CpG sites. In
order to assess whether increases in signficiance are due to a reduction in noise, or
an increase in effect size, we create what will be referred to as composite F-statistics.
Equation 2.13 shows the standard formula for an F-statistic from a one-way ANOVA.
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Fpq =
∑K
i=1 ni(Y¯i·−Y¯ )
K−1∑K
i=1
∑ni
j=1(Y¯ij−Y¯i·)
N−K
=
SSR
K−1
SSE
N−K
=
MSR
MSE
(2.13)
From looking at Equation 2.13, it is clear that there are two ways an F-statistic
can become larger, and therefore more significant: by an increase in the MSR (effect
size), or a decrease in the MSE (error noise). By picking apart these two pieces, we
can determine if an increase in effect size or a decrease in error noise is what is driving
the increase in significance after normalization.
To accomplish this, we create two composite F-scores using different components
of the F-statistic from before and after normalization. Let SSRRaw and SSERaw be
the numerator and denominator, respectively, of the F-statistic (given in Equation
2.13) computed from the raw data. Similarly, let SSRNorm and SSENorm be the
numerator and denominator of the test statistic computed from the same set of data
after performing a normalization. We can then define two composite F-statistics
FES and FErr given in Equation 2.14. FErr reflects the effect of normalization on
significance by reducing the error term, which we can think of as being reflective of
removing technical artifact. FES reflects the effect of normalization on signifiance by
increasing the observed effect size. Systematic increases in FES are probably due to
over-fitting of the normalization procedure rather than true increases in the biological
component of signals.
FES =
SSRNorm
SSERaw
FErr =
SSRRaw
SSENorm
(2.14)
In order to assess if normalization procedures are increasing apparent significance
by reducing the error variability or increasing effect sizes, we plot results from the two
sets of composite test statistics against results from the original statistics. Specifically,
we plot the −log10(p-values) from the two composite test statistics against each other.
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Resulting increases in significance in the composite F-statistics will result in points
falling above the y = x line.
2.4.3 Results
2.4.3.1 BrainSpan
The BrainSpan data consists of 93 samples randomized across 12 batches. While
batch effects should be mostly orthogonal to covariates of interest, it is still desirable
to mitigate batch effects to minimize the error variance. Figure 7 gives empirical
cumulative p-value distributions (ECDFs) from the one-way ANOVA testing for batch
effect.
Interestingly, Funnorm seems to substantially increase batch effects relative to
the raw data. Noob, and the various versions of our normalization procedure perform
similarly. SQN and the fresco using a 15% span provide the greatest reduction in
batch effects.
The ultimate goal of normalization is not to specifically remove batch effects,
but to improve the signal-to-noise ratio and overall data quality. Figure 8 gives a
plot of proportion of CpGs declared significant at a given FDR where p-values were
adjusted using the Benjamini-Hochberg method (Benjamini and Hochberg 1995). We
can see that most normalization methods perform similarly, calling roughly 20% of
CpGs significantly different across brain regions at an FDR = 0.1. All methods seem
to perform slightly better than Funnorm.
Figure 9 gives scatter plots of −log10(p-values) from composite F-scores plotted
against the original −log10(p-values) testing for differences in brain region. The top
row of figures plots FErr on the Y-axis and the bottom row plots FES.
From looking at the scatter plots of FErr, it appears that quantile normalization
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Fig. 7. Empirical cumulative p-value distributions from one-way ANOVAs for batch
effect in the BrainSpan data.
provides the greatest increase in power through reduction in the error variance term
of the F-statistics from the one-way ANOVA for brain region. Funnorm provides a
weaker, but similar reduction in the error variance. Our method seems to provide a
more moderate decrease in error variance.
The scatter plots of FES reveal that much of the observed increase in significance
from quantile normalization in Figure 8 is likely due to an increase in the numerator of
the F-statistics from the warping of overall β-value distributions. Surprisingly, none
of the methods, even Noob which is a background correction, are completely immune
to this phenomenon. Quantile normalization, and Funnorm to a lesser degree, appear
to reduce larger effect sizes. When incorporating the local regression hyper-surface,
our method also seems to suffer from over-fitting, in spite of the usage of empirical
controls.
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Fig. 8. Proportion of CpGs called significant for different FDR thresholds in the
BrainSpan data. Quantile normalization creates more apparent significance
relative to other methods.
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Fig. 9. Scatter plots of −log10(p-values) from composite F-statistics for regional differ-
ences the BrainSpan data. Subset quantile normalization can create apparent
significance by increasing effect sizes alone.
2.4.3.2 Reinius flow-sorted blood
Figure 10 gives empirical cumulative p-value distributions for batch effects in the
Reinius flow-sorted blood data which was mostly randomized across five batches. The
fifth batch consists exclusively of granulocyte samples and is excluded when assessing
reduction in batch effects due to confounding. Interestingly, Noob actually seems to
substantially increase the significance of batch effects relative to the raw data. fresco
methods using the local regression surface and SQN provide the greatest reduction
in batch effects, with smaller loess spans providing a greater reduction.
Figure 11 gives a plot of the proportion of CpGs declared significant at a given
FDR where p-values were adjusted using the Benjamini-Hochberg method (Benjamini
and Hochberg 1995). Noob appears to clearly outperform all methods in this context.
SQN offers the second best improvement in power, but as we will see again, much
of this increase in power is likely due to bias incurred in CpGs with intermediate
methylation values.
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Fig. 10. Empirical cumulative p-value distributions from one-way ANOVAs for batch
effect in the Reinius data.
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Fig. 11. Proportion of CpGs called significant for different FDR thresholds in the
Reinius data. Quantile normalization and noob create more apparent dif-
ferences.
It is odd that Noob seems to both improve power to detect real differences
as well as significance of batch effects. This is likely due not to technical artifact
between arrays, but perhaps to a lower overall level of signal relative to background
in all samples. In the context of overall weaker biological signals, a good background
correction may be more effective than a normalization method adjusting for technical
artifacts between arrays.
Figure 12 gives −log10(p-values) from composite F-scores. We again observe
quantile normalization providing the greatest overall increase in power due to reduc-
tion of error variance. When examining FErr, Noob provides a large increase in power
for less significant CpGs, while having a minimal effect on CpGs that already show
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Fig. 12. Scatter plots of −log10(p-values) from composite F-statistics for cell type dif-
ferences the Reinius data. Subset quantile normalization can create apparent
significance by increasing effect sizes alone.
some significance. This result agrees with the idea that many of these CpGs may have
signals that are weak relative to background levels, and that a background correction
provides a better improvement in signal quality than adjusting between samples.
If we look at FES, we again observe a similar phenomenon in quantile normaliza-
tion. Quantile normalization again appears to produce false significance from over-
fitting of the model.
2.4.3.3 TCGA Hepatocellular carcinoma
Figure 13 gives empirical cumulative p-value distributions for batch effects in the
TCGA cancer data. Samples taken from multiple medical centers were randomized
across 21 batches of varying size. Funnorm and Noob perform almost identically
when reducing significance of batch effects. The fresco method omitting the loess
surface fitting seems to perform the best. We should expect the cancer samples to
have substantially differing methylation profiles across samples, so this is a situation
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Fig. 13. Empirical cumulative p-value distributions from one-way ANOVAs for batch
effect in the TCGA data.
where fresco should perform well.
Figure 14 gives a plot of the proportion of CpGs declared significant at a given
FDR where p-values were adjusted using the Benjamini-Hochberg method (Benjamini
and Hochberg 1995). Quantile normalization gives the greatest improvement in appar-
ent significance, with fresco omitting surface fitting and Noob performing the second
best. Interestingly, Funnorm, which is advertised as being specifically a method for
cancer studies, performs less well in this scenario relative to the other methods.
Figure 15 gives −log10(p-values) from composite F-scores for the TCGA data.
SQN and Funnorm appear to provide the greatest reduction in error variance. How-
ever, when looking at the plots for FES, it appears that SQN may call a substantially
different set of CpGs significant after normalization due to over-fitting. Funnorm also
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Fig. 14. Proportion of CpGs called significant for different FDR thresholds in the
TCGA data. Quantile normalization creates more apparent significant dif-
ferences.
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Fig. 15. Scatter plots of −log10(p-values) from composite F-statistics for differences
between cancer and control in the TCGA data. Subset quantile normalization
can create apparent significance by increasing effect sizes alone, and dampen
real differences.
generally seems to suppress effect sizes in spite of reducing error variance.
2.5 Summary
Proper normalization of methylation samples with global distributional differ-
ences is important to obtain accurate results in epigenetic studies. We have demon-
strated that, particularly in cancer studies, our method is robust to these kinds of
biologically meaningful global differences. Quantile-based methods, particularly SQN,
are prone to over-fitting and may not only muﬄe real biological variability, but create
reproducible false differences. In the case of weaker biological signals, Noob appears
to be a very effective method for background correction.
59
CHAPTER 3
METHODS FOR INTEGRATIVE ANALYSIS
3.1 Statistical issues in integrative genomic analysis
An important statistical issue when dealing with genomic data is that the number
of samples (n) is generally much smaller than the number of parameters, or probes
on the microarray (p). For example, a set of n = 50 gene expression microarrays
may have p = 20, 000 or many more measures of gene expression. In this situation
where thousands of statistical models are being fit and significance tests are being
performed, classical methods that control for the family-wise error rate are far too
conservative (Nadon and Shoemaker 2002). Rather, methods have been developed
that can select a set of significant genes while allowing for some false positives, but
while asserting some control on the overall false-discovery rate, or FDR (Benjamini
and Hochberg 1995; Storey 2003). In the situation of working with exon-level data and
DNA methylation, each gene can now have tens and even hundreds of measurements
which result in multiplying the number of potential tests by roughly an order of
magnitude.
The increased number of probes on the DNA methylation array not only creates
a larger number of overall potential significance tests, but these tests can be highly
correlated. For a single gene, there may be multiple highly correlated CpG sites
within 1 kilobase (kb) of each other around a gene promoter that could be adequately
represented by simply using a summary measure such as their mean. However, this
is not always the case and specific CpG sites in a given region may be discrepant
with their surrounding neighbors. Jaffe et al. 2012 developed a method for automatic
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summarization of correlated nearby CpG sites to help reduce the overall number of
tests. While this is method is designed for specific scenarios just comparing DNA
methylation data, to our knowledge no analogous method for integrative analysis has
been developed. One goal of our proposed method is to provide dimension reduction
to reduce the overall number of tests.
Another issue is that genes come in different sizes and have different numbers of
exons and CpG sites. The Illumina 450k microarray only provides partial coverage of
genic CpGs and completeness can vary from gene to gene. Despite the multivariate
nature of genes, most standard downstream analyses after significance testing assume
a single p-value or summary measure for each gene. These methods include different
kinds of biological enrichment/pathway analyses such as Gene Set Enrichment Anal-
ysis (GSEA: Subramanian et al. 2005), topGO (Alexa, Rahnenfhrer, and Lengauer
2006), and Ingenuity Pathway Analysis (Abatangelo et al. 2009). Therefore, it is
desirable to have a method that is able to take a set of heterogeneous genes, conduct
the same omnibus test on each, and produce similar sets of results for each while not
suffering too much bias due to differences in size between genes. At the same time,
this omnibus test should not hinder identifying where within the gene the significant
associations are occurring.
The method we propose is a two-step process that first uses Principal Component
Analysis (PCA) for dimension reduction, and then Canonical Correlation Analysis
(CCA) for significance testing and subsequent biological interpretation. As part of
this research we have made the following methods presented in this chapter available
in the R package “gdi” (Genomic Data Integration) which is currently available as a
developmental version on GitHub (https://github.com/paulmanser/gdi).
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3.2 Prerequisite statistical methods
3.2.1 Principal component analysis
The goal of principal component analysis is to represent the majority of variabil-
ity in a data set in a lower-order linear subspace (Hotelling 1933). This is done by
computing orthogonal linear combinations of variables, with the first linear combina-
tion explaining the maximum amount of variability. This can be thought of as fitting
an ellipsoid to the data set with the axes of the ellipsoid corresponding to the vectors
used when creating the linear combinations.
Generally the first k of these linear combinations, called principal component
scores, are then kept as composites of the original variables. These composite principal
component scores retain some portion of the total variability in the data. Principal
component analysis is often the first step in an analysis, as in ours, before performing
another statistical method such as linear regression. Principal components can be
interpreted by how the linear combinations were computed, where variables with
higher coefficient loadings are seen as contributing more to that set of scores. There
are multiple ways of computing principal component scores including the Eigenvalue
decomposition and the Singular Value Decomposition (SVD). For our method, we use
the SVD which is detailed below.
Let X be an m× k matrix of real numbers. Then it can be decomposed in such
a way that there exists an m×m orthogonal matrix U and k × k orthogonal matrix
W obeying Equation 3.1
A = UΣW T (3.1)
where the m×k matrix Σ has all diagonal entries σi ≥ 0 for I ∈ {1, ...,min(m, k)} and
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the other entries are zero. The positive constants σi are called singular values. In R,
the singular value decomposition is computed using the dgesvd routine in LAPACK,
which uses a QR algorithm (Anderson et al. 1999).
The singular values σi, which are equivalent to the square root of the eigenvalues
of XTX when XTX is positive definite, can be interpreted as the standard deviations
of each of the principal components. They can be useful in determining how many
principal components to keep. Equation 3.2 below gives a measure of the amount of
variability kept in the first k of K possible components. One can then choose the
number of components to keep in order keep a certain amount of the total variability.
Variance Retained in first k of K PCs =
∑k
i=1 σ
2
i∑K
i=1 σ
2
i
(3.2)
Once the SVD has been performed, principal component scores T are then ob-
tained by taking linear combinations of the original data X using either the W or U
matrices given in Equation 3.3.
T = XW = (UΣW T )W = UΣ(W TW ) = UΣ (3.3)
3.2.2 Canonical correlation analysis
Canonical correlation analysis is an analogous method to principal component
analysis for finding linear combinations of data that explain the maximum amount
of correlation between two sets of variables (Hotelling 1936). It can also be seen as a
dimension reduction technique. Canonical correlation is a general method, and many
well-known statistical methods such as multiple linear regression can be considered
as special cases of canonical correlation.
The goal of canonical correlation analysis is to obtain sets of canonical covari-
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ate scores for each of the two data sets that are maximally correlated. These scores
can then be interpreted to find which variables are responsible for covariance be-
tween the two data sets by interpreting the communalities for each. Like principal
components analysis, covariance matrices can be decomposed using the SVD or the
spectral decomposition when computing the canonical covariates. For our purposes,
we use the classical formulation of canonical correlation analysis using the spectral
decomposition as detailed below.
Let X be a random vector of p variables and Y be a random vector of q variables.
We can then define their cross-covariance as ΣXY = cov(X, Y ) which is an p × q
matrix whose (i, j) entry is cov(xi, yj). ΣXY can also be thought of as the off-diagonal
component of the variance-covariance matrix when combining X and Y into a single
random vector Z as in Equation 3.4.
Z
(p+q)×1
=
X
Y
 (3.4)
ΣXY is then the off-diagonal of ΣZ given in Equation 3.5.
ΣZ =
ΣXX ΣXY
ΣY X ΣY Y
 (3.5)
The goal of canonical correlation analysis is to then find linear combinations
aTX and bTY such as to maximize ρ in cor(aTX, bTY ) = ρ. The linear combinations
U = aTX and V = bTY can be re-written as linear combinations of the standardized
variables. For i ∈ {1, ...,min(p, q)} sets of canonical covariate vectors Ui and Vi can
be written as Ui = e
T
i Σ
−1/2
XX X and Vi = f
T
i Σ
−1/2
Y Y Y . Here ρ
2
i are the first min(p, q)
eigenvalues of Σ
−1/2
XX ΣXY Σ
−1
Y Y ΣY XΣ
−1/2
XX and Σ
−1/2
Y Y ΣY XΣ
−1
XXΣXY Σ
−1/2
Y Y . Lastly, e
T
i and
fTi are the eigenvectors from the last two expressions in the previous sentence, re-
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spectively. The canonical covariates have the following properties given in Equation
3.6:
Var(Ui) = Var(Vi) = 1
Cov(Ui, Uj) = Cor(Ui, Uj) = 0 i 6= j
Cov(Vi, Vj) = Cor(Vi, Vj) = 0 i 6= j
Cov(Ui, Vj) = Cor(Ui, Vj) = 0 i 6= j
(3.6)
These sets of canonical covariates can then be interpreted by examining their
loadings LUi and LVi , which are a measure of how much each original variable is
related to canonical covariate i. The vector of loadings for canonical covariate Ui is
given in Equation 3.7.
LUi = Cor(Ui, X) =

Cor(Ui, X1)
...
Cor(Ui, Xn)
 (3.7)
Aside from being able to interpret canonical covariates using their loadings, we
want to be able to quantify how much variance each canonical covariate explains in
the original data. This is analogous to an R2 measure, except that it is asymmetric.
The correlation between Ui and Vi is given by ρi, but Ui and Vi are different linear
combinations of the original data. Therefore, we compute what is called a redundancy
coefficient (RC) separately for X and Y . The amount of variability explained in X
and Y by canonical covariates Vi and Ui are given by R
∗2
Xi
and R∗2Yi , respectively, in
Equation 3.8.
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R∗2X = ρ
2
i
p∑
j=1
L2Ui
R∗2Y = ρ
2
i
q∑
k=1
L2Vi
(3.8)
3.3 A gene-level likelihood ratio test for association
3.3.1 Development
Here we present a general method for testing for association between two multi-
variate data sets, with a specific application to alternative splicing and DNA methyla-
tion. Another genomic mark such as histone modification or DNase-I hypersensitivity
could be substituted for DNA methylation to conduct a similar analysis within the
same framework. We first introduce the statistical method used, and then justify
certain empirical assumptions using real data and simulation studies.
3.3.1.1 A likelihood ratio test for CCA
When performing canonical correlation analysis, we are using linear combinations
aTX and bTY to perform dimension reduction and model the cross-covariance ΣXY
from Equation 3.5. However, if ΣXY = 0 then there is no reason to perform canonical
correlation analysis. Therefore, we would like to have a statistical significance test
with H0 : ΣXY = 0 and H1 : ΣXY 6= 0. If we take SZ , SXX , SY Y , and ρˆ∗2i as sample
estimates of the population parameters ΣZ , ΣXX , ΣY Y , and ρ
∗2
i respectively, then we
can formulate the following likelihood ratio test statistic in Equation 3.9.
− 2 ln(Λ) = n ln
( |SXX ||SY Y |
|SZ |
)
= −n ln
min(p,q)∏
i=1
(1− ρˆ∗2i ) (3.9)
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This test statistic is distributed as χ2pq under the null hypothesis (Kshirsagar
1972; Lawley 1959; Johnson and Wichern 2007). We will replace the multiplicative
factor n in the likelihood ratio test statistic with n− 1 + 1
2
(p+ q + 1) to improve the
χ2 approximation as suggested by Bartlett 1939.
3.3.1.2 Using PCA for dimension reduction
The test statistic in Equation 3.9 is only feasible when SZ , SXX , and SY Y are
non-singular since determinants are being computed. This is often not the case in
genomic studies where a gene may have over 100 methylation loci for a given gene, but
only 20 samples. Even if sample covariance matrices are non-singular, the degrees
of freedom for the test statistic can become large very quickly and will vary from
gene to gene, which will result in a variable loss of power across genes. For example,
one gene may have p = 50 observed methylation sites and q = 5 exons, which will
result in a significance test with 5 × 50 = 250 degrees of freedom. Another gene
may have p = 15 observed methylation sites and q = 3 exons for a significance test
with 15 × 3 = 45 degrees of freedom. In order to make many of these significance
tests feasible and avoid a variable and biased loss of power across different genes,
we propose a preliminary dimension reduction step using PCA before performing the
likelihood ratio test.
To do this, we perform PCA using the SVD for each gene on each of the two
data sets separately keeping the first k principal components from each. We can then
replace SZ , SXX , and SY Y in Equation 3.9 with S
∗
Z , S
∗
XX , and S
∗
Y Y where S
∗
XX
and S∗Y Y are k × k covariance matrices for the first k principal component scores for
methylation and alternative splicing and S∗Z is as given in Equation 3.5, but using
S∗XX and S
∗
Y Y and their cross-covariance. We keep k = 3 principal components for
methylation and splicing from each gene. This choice will be justified empirically
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in the following paragraphs for DNA methylation and alternative splicing. A major
benefit of the dimension reduction step is that all significance tests will be similarly
powered with a χ29 limiting null distribution for all test statistics.
Roughly 70% of the variability in methylation can be contained in the first three
principal components regardless of the number of CpG sites in the gene. Figure 16
plots the proportion of variability explained by the first three PCs in methylation
in each gene versus the total number of original CpGs. The average proportion of
variance we would expect to keep from independently and identically distributed
normal data is given by the red line. We can see that after a certain point, roughly
70% of variability is retained regardless of the number of CpG sites in the gene.
The red line was computed by conducting 500 simulations of i.i.d. normal variables
and taking the average proportion of variation explained by the first three principal
components. It is important to note that much of the reason for the success of PCA
in this scenario is due to the fact that many of the probes are positioned very close
to each other on the gene and are highly correlated.
If we plot a similar figure for the splicing index from the Affymetrix HT 1.0 Exon
Array we get a slightly different picture in Figure 17. Many genes are close to the red
null line. However, we should expect genes that are not alternatively spliced to have
a similar amount of variability explained by the first 3 PCs as the independent data.
We do see a similar phenomenon in that after about 20 exons, the average amount of
variability explained remains relatively constant.
3.3.2 Controlling type I error
In order to assess the type I error rate for the likelihood ratio test, we conduct
a set of simulation studies. Chi and Muller 2013 conducted similar simulation stud-
ies to test the effectiveness of performing principal component analysis as a general
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Fig. 16. Proportion of variance explained by first 3 principal components for DNA
methylation. Mean results from a simulated i.i.d. normal distribution are
given as the red line. The first 3 principal components are generally able to
explain at least 70% of the variance in most genes regardless of the number
of CpGs.
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Fig. 17. Proportion of variance explained by first 3 principal components for splicing
index. Mean results from a simulated i.i.d. normal distribution are given as
the red line. The first 3 principal components are generally able to explain
at least 65% of the variance in most genes regardless of the number of exon
probesets.
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dimension reduction step before performing MANOVA when the variance-covariance
matrix of outcomes was singular. Our simulation studies are focused on a specific
application in genomics, so the data will be simulated as if it were coming from a
gene model with comparable variability to what is observed in the BrainSpan data.
Despite the overall distribution of β-values being bi-modal, individual CpGs sites
generally have a distribution that is uni-modal. For simplicity, we will simulate data
for both splicing indices and DNA methylation β-values as coming from a multivariate
normal distribution. For a random vector X of p CpG sites and random vector Y of
q exons, we simulate data using their joint covariance Σ in Equation 3.10.
Σ =
ΣXX ΣXY
ΣY X ΣY Y
 (3.10)
In the case of generating null data for testing type I error rates, ΣXY is set equal
to zero. ΣXX and ΣY Y are constructed using a compound symmetry correlation
structure with variances that vary linearly as a function of a slope parameter θ and
intercept parameter δ. The level of correlation between loci within a data modality
is determined by the parameter ρ. The general form used for generating ΣXX and
ΣY Y for the case of three loci is given for ΣXX in Equation 3.11.
ΣXX =

σ21 ρσ1σ2 ρσ1σ3
ρσ2σ1 σ
2
2 ρσ2σ3
ρσ3σ1 ρσ3σ2 σ
2
3
 (3.11)
Here σ2i = θ(i− 1) + δ allows for non-uniform variances such that some sites are
more variable than others. Other parameters of interest are the number of subjects n,
the number of methylation loci p and exons q, and the number of principal components
kept after the pre-processing step k. Separate parameters determined empirically from
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the BrainSpan data are used to simulate methylation and splicing data.
For σ2i , θ and δ are chosen so that the range of variances used in the simula-
tions corresponds to the inter-quartile range of the variances of all CpGs from the
BrainSpan samples. The within-gene correlation parameter ρ is determined from the
median correlation among CpG sites within the same gene. This was computed by
estimating a correlation matrix for each gene from the BrainSpan samples, concate-
nating all of the off-diagonal elements from all genes, and taking the median. For
I methylation sites, θ = 0.00313/(I − 1) and δ = 0.000437 covers the inter-quartile
range of methylation variances: {0.000437−0.00357} and the within gene correlation
is ρ = 0.25. For J exons, θ = 0.158/(J − 1) and δ = 0.086 covers the inter-quartile
range of inclusion ratio variances: {0.086 − 0.244} and the within gene correlation
is ρ = −.0678. The within gene correlation is slightly negative for splicing due to
the mean centering used to compute the splicing index. Simulation studies were con-
ducted using above parameters for a “typical” gene with p = 20 CpGs and q = 8
exons. Simulation studies are run for sample sizes n ∈ {26, 50, 100, 200, 500} and
keeping k ∈ {1, 3, 5, 10, 15} principal components. Table IV gives simulation results
for 10, 000 simulations. Type I error appears to be conserved in nearly all of the
various scenarios. Type I error appears to become inflated when keeping a large
number of principal components relative to the sample size, but this is a non-issue
since keeping more than three principal components markedly decreases power and
is not adviseable.
3.3.3 Assessing power
In order to simulate scenarios where a relationship exists between methylation
and splicing, we conduct similar simulation studies, but add in non-random coinciding
changes in methylation and splicing after generating random data where no relation-
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Table IV. Type I Error for n samples after retaining k principal components
n k Type I Error
26 1 0.04962
26 3 0.05164
26 5 0.05481
26 10 0.11752
26 15 0.46554
50 1 0.04966
50 3 0.04961
50 5 0.05086
50 10 0.05755
50 15 0.06932
100 1 0.04944
100 3 0.04993
100 5 0.05121
100 10 0.05055
100 15 0.05340
200 1 0.05037
200 3 0.05005
200 5 0.04904
200 10 0.04966
200 15 0.04985
500 1 0.04792
500 3 0.04891
500 5 0.04965
500 10 0.04984
500 15 0.05046
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ship exists. Here, the joint variance-covariance matrix takes on a simpler form where
all loci have the same variance which is estimated empirically from the data by taking
the median variance of all loci. All methylation loci are given variance σ2 = 0.00123
and exon inclusion ratios all have variance σ2 = 0.15. Equation 3.12 gives the form
of the variance-covariance matrix.
ΣXX =

σ2 ρσ2 ρσ2
ρσ2 σ2 ρσ2
ρσ2 ρσ2 σ2
 (3.12)
After multivariate normal random data has been generated, non-random differ-
ences are then added in to the data. When adding in these changes, two parameters
must be set for both methylation and splicing: the effect size and number of loci af-
fected. For the simulation study, we take the simplest approach of having the change
occur across two groups (i.e. case vs control). For example, a set of 3 CpGs will be
more methylated in one group than another which corresponds to an increase in exon
inclusion in a single exon. The “typical gene” from the previous simulation studies
with p = 20 CpGs and q = 8 exons is again used. In this scenario the parameters
that are allowed to vary are:
1. Number of PCs kept: k
2. Number of samples: n
3. Number of CpG sites affected: p∗
4. Methylation effect size: M∆
5. Number of exons affected: q∗
6. Splicing effect size: E∆
The effect size for methylation is set to M∆ = 0.2, and E∆ = 1.2 for splicing.
Results are given in Table V. The likelihood ratio test appears to be generally under-
powered in situations where a single CpG is correlated with a single exon. However,
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more pervasive effects that exist in multiple CpGs and exons are detected more of-
ten, particularly when three principal components are kept. This kind of scenario is
realistic in the case of alternative promoter usage resulting in the inclusion/exclusion
of multiple exons. These results echo those of Chi and Muller 2013, who found that
performing PCA as a dimension reduction step before MANOVA was most effective
when three principal components were kept. For sample sizes less than 50, it is likely
that we may miss sparse, specific correlations between methylation and splicing such
as the inclusion of a single cassette exon.
3.4 Interpreting results using canonical correlation
3.4.1 Canonical covariate regression
While the likelihood ratio test from the previous section provides a general test
for examining relationships between two sets of covariates, it does not provide infor-
mation on what may be responsible for these associations. Once a significant result is
found, the next logical step is to determine if differences in methylation and splicing
are co-occurring across covariates of interest. Canonical correlation analysis is able to
reduce the relationship between the two sets of principal component scores used for
the likelihood ratio test into pairs of canonical covariate vectors that are maximally
correlated with each other. Bartlett suggests a sequential set of χ2 tests for deter-
mining the number of canonical covariate pairs to keep, but the overall significance
level α is difficult to determine (Bartlett 1939; Johnson and Wichern 2007). We only
use the first set of canonical covariates for our purposes, but more could certainly be
included.
Now that we have a single set of scores each for methylation and splicing, we
can take a model-based approach to interpret the first set of canonical scores. This is
75
Table V. Power to detect case vs control relationships. For n samples with p∗ CpG
sites with a M∆ = 0.2 case-control difference and q
∗ exons with a E∆ = 1.2
case-control difference, k principal components are retained.
n k p∗ q∗ Power
26 1 1 1 0.33199
26 2 1 1 0.21412
26 3 1 1 0.14699
26 5 1 1 0.10506
26 1 3 4 0.87727
26 2 3 4 0.45073
26 3 3 4 0.25421
26 5 3 4 0.14981
50 1 1 1 0.33868
50 2 1 1 0.38685
50 3 1 1 0.27998
50 5 1 1 0.17378
50 1 3 4 0.99627
50 2 3 4 0.96162
50 3 3 4 0.80318
50 5 3 4 0.46619
100 1 1 1 0.12307
100 2 1 1 0.42592
100 3 1 1 0.33774
100 5 1 1 0.22755
100 1 3 4 0.99768
100 2 3 4 0.99754
100 3 3 4 0.98152
100 5 3 4 0.84821
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accomplished by regressing them against covariates of interest such as brain region or
age. Since the two sets of canonical covariates U1 and V1 are by definition maximally
correlated with each other, we cannot fit two separate models and combine their p-
values using Fisher’s method, which assumes independent tests (Fisher 1973). We
instead fit a single linear mixed effects model for both sets of canonical scores with
a random effect to account for their correlation. The model is fit using maximum
likelihood estimation. Equation 3.13 gives an example model for the ith observation
yi in Y = {U1, V1} with continuous covariate xi and categorical covariate at level j in
canonical covariate pair k.
yijk = αj + xiβ + bk + ei (3.13)
Here α is the parameter for a categorical covariate and β is the coefficient for a contin-
uous covariate xi. Since there is a pair of correlated canonical scores from methylation
and expression for each sample, a random effect bk is included. If canonical covariates
are arranged as Y = {u1, v1, ..., un, vn}, then adding the random effect b is equivalent
to specifying a block diagonal covariance structure in blocks of size two for the linear
model. Although maximum likelihood estimation gives biased estimates of random
effects in mixed effects models, it allows for testing of fixed effects using a likelihood
ratio test for nested models. The full model in Equation 3.13 can then be compared
to a reduced model omitting one or both α or β using the likelihood ratio test given
in Equation 3.14
2 (ˆ`full − ˆ`reduced) ∼ χ2(p−q) (3.14)
where ˆ`full and ˆ`reduced are the maximized log-likelihoods for the full and reduced
models, respectively and p− q is the difference between the number of parameters in
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Fig. 18. Example of canonical loadings plotted over a gene model for DNA methylation
and alternative splicing
the full and reduced models. If a coefficient is found to be statistically significant,
then the relationship between alternative splicing and methylation can be attributed
to their covariation across that variable. The χ2 approximation to the likelihood ratio
can be anti-conservative and a bootstrapping approach may need to be implemented
to obtain credible results.
3.4.2 Interpreting canonical loadings
Once a significant relationship is established via the likelihood ratio test, and a
putative mechanism for the relationship is determined from the linear mixed effects
model, the final step is to determine if specific CpG sites in the gene are related to
specific exons. A straightforward way to do this is to examine the canonical loadings
from Equation 3.7. Since each element of the canonical loading vectors corresponds
to a CpG site or exon with a specfic location in the gene, we can generate a bar plot
of the canonical loadings with bars positioned at their corresponding genic locations.
A gene model can then be added to aid in the visualization of where in the gene
strongly loading CpGs and exons exist and if they co-localize. Figure 18 gives an
example of a bar plot of canonical loadings with a gene model.
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While this is a convenient way to interpret results from a single gene, it is not
a viable option for interpreting the loadings of thousands of genes. In the follow-
ing section we introduce a permutation test that automatically tests for statistically
significant co-localization of high loadings on the gene model.
3.5 A gene-level permutation test for spatial co-localization
Once a set of genes have met some FDR threshold for significance from the
likelihood ratio test, we would like to have an automated way of testing whether
the relationships between alternative splicing and methylation co-localize at specific
places in the gene. An example of co-localization would be differential methylation in
the third exon affecting that exon’s inclusion ratio. Alternatively, differential methy-
lation in the promoter region could somehow be associated with the inclusion ratio
of the last exon. For this second case, it is perhaps less straightforward to give a pu-
tative biological explanation. Therefore, we would like to establish a statistical test
to be able to distinguish these two kinds of scenarios. We propose two similar tests
to do this: the first test is a global test for co-localization. The second test is specific
to a set of canonical covariates. This allows for further interpretation of canonical
covariates. We can establish a putative mechanism via the linear mixed model from
Equation 3.13, and then test whether the relationship appears to be cis-acting. To
be explicit, the null and alternative hypotheses are given in Equation 3.15.
H0 : Exon and CpG locations are interchangeable
H1 : Exons and CpG sites have cis relationships (3.15)
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3.5.0.1 A permutation test on R2 matrices
For a given gene, let R2XY be an p × q matrix whose ijth entry corresponds to
the coefficient of determination r2 between the ith CpG site and jth exon. Similarly,
let D be the p× q genomic distance matrix between each CpG site and exon. When
calculating distance between exons and CpG sites, the center of the exon and the
cytosine base in CpG sites are used as points of reference. For each exon/CpG site
pair we can then get a weighted measure of association tij that is a product of the
coefficient of determination r2ij and a function of genomic distance ω(dij) in Equation
3.16.
tij = r
2
ijω(dij) (3.16)
We then specify ω(·) as an exponentially decaying function given in Equation 3.17.
Since the Illumina 450k array provides incomplete coverage, a single CpG site is
often the only information available for whole regions of a gene. However, correlation
among CpG sites decays rapidly as a function of genomic distance with correlation
decreasing to approximately 0.4 after 400 bp (Zhang et al. 2013). Therefore, the half-
life of the exponential decay function ln(2)
λ
is specified to be 400 bp since we cannot be
confident that relationships between methylation and splicing much greater than 400
bases reflect a cis-acting effect. For different genomic assays, different appropriate
half-lives may be chosen.
ω(xij) = e
−λdij (3.17)
Once the half-life has been specified, a test statistic T can be computed by simply
taking the sum of the individual tij. This sum is an aggregate measure of spatial co-
localization between methylation and splicing. A permutation test is then performed
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by permuting the rows and columns of D, which is effectively permuting the locations
of exons and CpG sites. A formula for the permutation test statistic Tk is given in
Equation 3.18 where D∗ is the matrix of permuted distances.
Tk =
p∑
i=1
q∑
j=1
σij ω(d
∗
ij) (3.18)
A permutation p-value can then be computed from the permutation distribu-
tion of K permutation test statistics given in Equation 3.19. Permutation testing is
performed on several genes, and a distribution of permutation p-values is ultimately
obtained. Permutation p-values from different genes have different non-uniform null
distributions on different discrete supports. A method for estimating false discovery
rates for sequential permutation p-values has been proposed, which is similar to this
scenario (Bancroft, Du, and Nettleton 2013).
pperm =
∑K
k=1 1Tk>T
K
(3.19)
3.5.0.2 A permutation test on canonical communalities
A similar permutation test can also be performed for a specific pair of canoni-
cal covariates. The permutation test is almost identical, except the matrix R2XY is
replaced by the outer product of canonical loadings Ψ = LU1L
T
V1
from the first pair
of canonical covariates. A formula for the modified test statistic is given in Equation
3.20.
Tk =
p∑
i=1
q∑
j=1
ψijω(x
∗
ij) (3.20)
Performing a permutation test on canonical loadings allows the added benefit
of combining permutation test results and significance testing from the linear mixed
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effects model from Equation 3.13 to make claims about cis-acting relationships oc-
curring across specific factors such as brain region. It is possible to make these claims
because, while permutation testing using R2XY is a general test of loci-specificity, the
test on canonical communalities is specific only to that set of canonical covariates
that have associated scores. Therefore, if one or more signifiance testing results on
parameters from Equation 3.13 are significant, we can say a cis-acting relationship
occurs across those covariates.
3.6 Implementation
We implemented the above methods in R package “gdi” whose developmental
version is currently available on GitHub (https://github.com/paulmanser/gdi).
Since genomic data sets can be very large, the ff package is used to store genomic data
sets out of memory (Adler et al. 2014). Data are then read into memory in chunks,
analysis is performed, and results are written back out to disk. Conducting thousands
of tests can be quite computationally and time intensive. This is particularly true for
the permutation tests, especially when the number of permutations is large. To speed
up significance testing, the foreach package for parallel computing is used (Analytics
and Weston 2014). The ff and foreach packages play well together in that multiple
copies of the data are not created when performing parallel programming, each core
only takes what it needs, writes back to disk, and then reads in the next small piece.
Together, they allow the methods introduced in this chapter to scale to large data
sets both in terms of memory storage and computation time.
3.7 Summary
In this chapter we present a set of methods for integrating two different genomic
data sets on a gene-by-gene basis. These methods proceed in three steps for each gene.
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First, a likelihood ratio test on the sample variance-covariance matrix is performed
to test for general association between the two data sets. Next, canonical correla-
tion analysis is performed, and resulting canonical covariates are regressed against
covariates of interest using a linear mixed effects model to test whether general as-
sociations occur across factors of interest. Lastly, a permutation test is performed to
test whether significant relationships between the two data sets co-localize on specific
genic regions in a cis-acting manner.
83
CHAPTER 4
INTEGRATIVE ANALYSIS OF DEVELOPMENTAL BRAIN DATA
4.1 Overview of neuroscience and neurogenomics
4.1.1 Major neural cell types
While the neuron is the most commonly known and well-studied neural cell
type, they actually comprise substantially less than half of cells in the human brain.
Brain tissue consists of several other types of cells called glia. Glial cells support,
protect, and supply nutrients to neurons. Once thought of as simply the glue that
held the brain together, recent research has begun to show glial cells may be more
important than once thought (Fields 2009). The data used in this chapter arises
from microarray experiments performed on frozen post-mortem brains, and therefore
assayed tissue samples reflect an aggregate signal obtained from all cell types. While
most results in this chapter are interpreted from a neuron-centric point of view, it is
important to acknowledge that observed changes may not necessarily be the results
of differences within or between neurons. Therefore, it is important to give a brief
introduction to neurons as well as the different glial cell types and their respective
roles in brain tissue.
Neurons are specialized cells in the human brain that transmit signals via elec-
trical and chemical means. While there are many types and subtypes of neurons,
they all share a similar basic morphology. Neurons have three major components:
the cell body or soma, a single cellular extension called an axon that sends signals
out to other neurons, and a collection of thin branching structures called dendrites
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that receive information from other neurons. Information flow in neurons is uni-
directional. There are two major categories of neurons: excitatory neurons which
transmit information from neuron to neuron, and inhibitory neurons which act to
inhibit the activity of excitatory neurons. During development of the cerebral cortex,
neurons migrate and arrange themselves in specialized layers. Neurons connect with
each other via synapses which are junctions between an axon of one neuron and a
dendrite, or sometimes an axon, of another.
Oligodendrocytes are a type of glia that serve to protect and insulate neurons.
Specifically, they form a myelin sheath that wraps around axons to insulate them,
which improves axon efficiency. A single oligodendrocyte can insulate axons from
several neurons. Multiple sclerosis, a disease of the nervous system, is characterized
by the destruction of myelin sheaths of neurons.
Astrocytes are star-shaped glial cells that have several functions in the brain.
They are the most abundant cells in the brain and provide structural support. They
help to regulate the environment of neurons by regulating extracellular ion concen-
trations, as well as functioning in neurotransmitter re-uptake and release. Astrocytes
also provide metabolic support and nutrients to neurons.
Microglia are the resident macrophages of the brain. Due to the brain being
separated from the rest of the body by the blood-brain barrier, the microglia comprise
the brain’s own separate unique immune system. Besides defending against infectious
agents, microglia also function to remove unwanted cellular matter in the brain such
as damaged or dead cells as well as neurofibrillary tangles and function in synaptic
pruning.
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4.1.2 Issues in neurogenomics
Analysis of genomic data poses many unique problems in statistics, experimental
design, and data quality control. In addition to these problems, analysis of genomic
brain data creates additional concerns and caveats. Unlike other tissues, brain sam-
ples cannot be taken longitudinally from living subjects over time in the way blood
samples or cancer biopsies can be. Even in the case of animal models, animals are
generally sacrificed and the whole brain is recovered. This poses a problem in longitu-
dinal studies, like BrainSpan, because individual differences are then confounded with
temporal differences. In order to address this issue, additional constraints need to be
in place when analyzing the data. For example, fitting a saturated ANOVA model
treating time as categorical will result in many false positives that are actually due
to individual differences. If time is treated as continuous, a model with a reasonable
amount of smoothness such as a quadratic or cubic linear regression model should
yield fewer false positives due to individual differences.
Not only are brains donated once, but the patient must die in order to donate.
In the case of human brains, the cause and circumstances of death can have an effect
on data quality. This is particularly true for RNA, which is a less stable molecule
than DNA. The post mortem interval (PMI) is the interval of time between death
and when the brain is frozen to be used later. Longer PMIs are generally correlated
with lower RNA integrity which is measured using an RNA integrity number (RIN).
A lower RIN corresponds to smaller more fragmented pieces of RNA which are more
difficult to uniquely identify via sequencing or microarray hybridization. PMI and
RIN can be included as additional covariates in a linear model to mitigate for these
effects.
When comparing brains across psychiatric conditions, such as schizophrenia,
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there are additional concerns for confounding. Psychiatric patients are usually taking
one or more medications to treat their condition such as anti-psychotics. This usually
results in almost complete confounding between medication regimen and condition,
although amount and length of treatment will vary between patients. Additionally,
schizophrenic patients may not take good care of themselves and are more prone to
smoking cigarettes or having a poorer diet. Like PMI and RIN, if information on
medical history, smoking status, and diet are available they can also be included as
covariates in statistical models.
Given the additional caveats and confounding effects that come along with an-
alyzing post mortem brain samples, it is still possible to obtain meaningful results.
Proper experimental design, normalization, and quality control can help to ensure
data quality. Choosing appropriate statistical methods and including important co-
variates can help mitigate confounding factors.
4.2 Estimating cell type admixtures in brain tissue
4.2.1 Estimating the neuronal fraction
In order to estimate the relative abundance of neurons in the BrainSpan de-
velopmental samples, we use data coming from orbitofrontal cortex that has been
sorted using FACS to separate out NeuN+ cells (Kozlenkov et al. 2013). The data
set provides methylation profiles for 2 replicates of Neun+ and Neun- samples each
from six brains for a total of 24 samples. Since cerebellum is so distinct from other
brain regions, it is omitted from the cell proportion estimation procedure as estimates
may be unreliable. Average Neun+ and Neun- methylation profiles are then used as
predictors in a linear model where estimates of the neuronal and non-neuronal pro-
portions are constrained to sum to one (Houseman et al. 2012). Figure 19 gives box
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Fig. 19. Box plots of estimates of neuronal proportions by brain region in the
BrainSpan data
plots estimates of the neuronal fraction plotted by brain region using the regional
abbreviations from Table I.
Notably, visual cortex has the highest neuron density which is in agreement with
recent findings from a primate study (Collins et al. 2010). This increase in neuron
density can be attributed to a decrease in the average size of neurons, allowing more
of them to be packed into the same amount of volume. Sub-cortical regions tend to
have lower estimated neuronal densities than cortical regions. If we instead plot these
same estimates against age in Figure 20, we are able to observe a decreasing trend in
neuron density in both cortical and sub-cortical regions. This is likely a combination
of both astrocyte proliferation and neuron death.
88
Fig. 20. Estimates of neuronal proportions by age in years in the BrainSpan data
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4.2.2 Estimating proportions of microglia
Compared to the other neural cell types in the brain, microglia are relatively
small and likely generate less RNA than large neurons. However, they should have
a very distinct expression and methylation profiles with many unique immunological
genes being solely expressed in microglia. However, unlike in the previous section, we
do not have isolated methylation profiles on the Illumina 450k array for microglia.
This problem is further complicated by the fact that resting microglia, known as
ramified microglia, may have different markers than reactive microglia, which are the
active macrophages these resting microglia proliferate and transform into in response
to pathogens. In spite of this complication we use Integrin alpha M (ITGAM), also
known as CD11b, which is commonly used as a marker for microglia in an attempt
to characterize microglia proportions. The ITGAM protein is presnt on the surface
of many leukocytes involved in the innate immune system and regulates leukocyte
adhesion and migration.
Since ITGAM should be exclusively expressed in microglia, we might expect
its promoter to be methylated in all other cell types. If roughly 10-15% of cells
are microglia, then this should result in β-values for promoter CpGs in the range
of 0.8 to 0.9. We are able to obtain 5 CpG sites from the ITGAM promoter and
its CpG sites do fall within this range. If we take 1 − β¯ as a very rough estimate
of microglia proportion, where β¯ is the average promoter β-value for a sample, the
average proportion estimate for all samples is 16.3% with a standard deviations of
SD = 2.3%. Estimates do not seem to vary much over aging or brain region, but vary
somewhat between individuals. Estimates of microglia proportions using methylation
data correlated very poorly with ITGAM expresssion r = 0.061 which is expressed
at moderate levels and slightly increases with age r = 0.23. Given these results, it
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is difficult to make strong claims about the relative proportions of microglia. More
and better markers, or isolated methylation profiles of microglia will greatly improve
reliability of these results.
4.3 Overview of developmental BrainSpan data
BrainSpan is a multi-institute consortium devoted to studying the transcriptional
mechanisms of human brain development. Not only do they conduct and publish their
own research (Kang et al. 2011), but also host what is referred to as the Atlas of the
Developing Human Brain (www.brainspan.org). BrainSpan provides a wealth of
information including imaging, in situ hybridization, exon-level gene expression mi-
croarrays, RNA-Seq, as well as methylation microarrays from donated brain samples
from 16 brain regions spanning prenatal and developmental periods to old age.
For the purposes of this analysis, we use the publicly available DNA methylation
and gene expression data sets. Unfortunately, the DNA methylation microarrays are
available only for a subset of the samples at this time, so only nine individuals have
both methylation and expression data. Figure 21 provides an overview of available
samples. Currently, 87 samples with paired data spanning ages one to twenty years
old are available. For the remainder of this section be will perform a brief exploratory
analysis for each platform before looking more closely at changes in prefrontal cortex
over brain development.
4.3.1 DNA methylation
For an initial exploratory analysis of the DNA methylation data, we perform
clustering using multidimensional scaling (MDS) to observe how variable the data
are across age and brain region. Methylation was quantified using β-values. Figure
22 gives two MDS plots from autosomal regions of the methylation samples. The left
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Fig. 21. Publicly available BrainSpan samples that have paired data from methylation
and exon-level gene expression. Samples that are not filled in are available.
Age and sex are given along the top of the table. Brain regions using abbre-
viations from Table I are given along the left side.
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Fig. 22. Multidimensional scaling figures for methylation in the BrainSpan develop-
mental samples. All samples are plotted in the left panel colored by brain
region. All samples ommitting cerebellum are plotted in the right panel col-
ored by individual.
panel plots all samples colored by general brain region: neocortex (NCTX), cerebel-
lum (CBL), thalamus (THM), striatum (STR), hippocampus (HIP), and amygdala
(AMY). We can see that cerebellum is very distinct from all other samples. The right
panel plots samples excluding cerebellum colored by individual. Samples seem to
cluster by individual in a way that corresponds with age to some degree, with lower
ages tending to the left side of the plot, and older ages to the right side. However,
they are not strictly ordered left to right, as both the lowest and highest ages are
closer to the middle.
4.3.2 Gene expression
We create a similar figure for aggregate measures of gene expression using mul-
tidimensional scaling. Aggregate gene expression measures were computed by taking
93
Fig. 23. Multidimensional scaling figures for gene expression in the BrainSpan devel-
opmental samples. All samples are plotted in the left panel colored by brain
region. All samples ommitting cerebellum are plotted in the right panel col-
ored by individual
the mean of all exon-level RMA summarized signals for each gene in each sample.
Figure 23 gives the results. We observe somewhat similar clustering as in the methy-
lation data. In the left panel, cerebellum again appears to be distinct from other
samples, but to a lesser degree. When omitting cerebellum in the right panel, the
samples again cluster by individual, but in a different way. Specifically, they do not
seem to correspond to age or sex in any discernable way.
4.3.3 Exon inclusion
Alternative splicing patterns should not necessarily correspond to differences in
gene expression, so it is important to observe how samples cluster by alternative splic-
ing and compare the results to gene expression. Alternative splicing was quantified
using the the splicing index from Equation 1.5 using RMA summaries of exon expres-
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Fig. 24. Multidimensional scaling figures for splicing index in the BrainSpan develop-
mental samples. All samples are plotted in the left panel colored by brain
region. All samples ommitting cerebellum are plotted in the right panel col-
ored by individual. Cerebellum is not so distinct as it was in MDS plots of
expression
sion and the aggregate gene expression measure as computed in the previous section.
Figure 24 gives the resulting MDS plot. In the left panel, we can see that cerebellum
now clusters with the rest of the samples and is not distinct as it was before. This
suggests that gene expression differences, not differences in alternative splicing, are
what make cerebellum distinct. However, in the left plot, individuals cluster almost
identically to as before with gene expression.
4.3.4 Brain samples are clustered by individual
One issue in analyzing brain samples over time, as mentioned in Section 1.1.2, is
that individual differences are confounded with temporal differences. In the BrainSpan
samples, individuals are also sampled at several brain regions which are correlated
with each other. In a standard multiple regression setting where the outcome is
95
univariate, a mixed effects model is sufficient to address this issue. We employ this
method when integrating DNA methylation and gene expression. However in the sit-
uation of multivariate analysis, techniques such as canonical correlation analysis and
partial least squares (PLS) do not have widely used analogous methods for dealing
with clustered data. This becomes an issue when integrating alternative splicing and
DNA methylation.
A simple approach in the multivariate setting might be to perform a permutation
test using the test statistic from the likelihood ratio test proposed in Chapter 3 (Equa-
tion 3.9). However, since the samples are not independent, a simple permutation test
is not valid as the samples are not fully exchangeable under the null hypothesis. It
then might be possible to perform a blocked permutation test, where samples are
permuted within individuals to preserve the correlation structure. However, permut-
ing within individuals also preserves the effect of time since time and individual are
confounded. Therefore, if we are interested in testing for temporal relationships, a
permutation test is not appropriate in this scenario.
In order to get a sense of how individual clustering affects the asymptotic null
distribution of the likelihood ratio test statistic from Equation 3.9, we simulate data
and create an empirical null distribution. This is done by simulating the first three
principal components of both DNA methylation and exon inclusion from a multivari-
ate normal distribution. If we assume for simplicity that all principal component
scores follow the same multivariate normal distribution under the null hypothesis
(which is somewhat reasonable), we can estimate the parameters for the multivariate
normal distribution from the data. The mean vectors for principal components are
effectively zero since they are constrained to sum to one, so they are simply set to
zero in simulations. All that remains then is to estimate covariance matrices for each
of the first three principal components from methylation and alternative splicing.
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Covariance matrices are estimated using the following procedure:
• Perform principal component analysis on a gene-by-gene basis for both DNA
methylation and exon inclusion for all genes.
• Retain the first three sets of PC scores from each gene for both DNA methylation
and exon inclusion.
• For each principal component, estimate a single covariance matrix using that
principal component’s scores from all genes.
• For each covariance matrix, set all entries corresponding to covariance between
different individuals equal to zero.
The resulting set of covariance matrices obtained from this procedure can then
be used to simulate sets of principal component scores that are clustered within
individuals similar to observed data, but with no significant correlation between in-
dividuals. Principal components from methylation are independent to those from
expression. A second simulated null distribution is computed using only the diagonal
terms from the covariances to simulate the scenario with no clustering, but with the
same variances. Densities of 10,000 simulated test statistics from these two scenar-
ios are plotted against the theoretical χ29 null distribution in Figure 25. We can see
that the distribution simulated under independence is well-approximated by the χ29
distribution. However, the distribution simulated with clustering has a substantially
heavier tail.
This heavier tail is a result of an over-representation of the effective sample size in
the test statistic. This means that since samples are not independent, we get a smaller
amount of total variability in the data than would be expected from 26 independent
samples. Therefore, we effectively have fewer than 26 samples when computing the
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Fig. 25. Densities of 10,000 test statistics simulated from a clustered null distribution.
The theoretical χ29 distribution is given as the dashed line. In the case of
independence (red), the simulated distribution is well-approximated by the
theoretical. In the case of clustered data, the simulated distribution has a
much heavier tail
98
likelihood ratio test statistic. To account for this we can adjust the effective sample
size used in the test statistic. To do this we can fit a zero-intercept linear model to
compute a scaling factor θ as given in Equation 4.1 modeling the ith quantile of the
theoretical distribution χ29i as a function of the i
th quantile of the clustered simulated
distribution fˆi.
χ29i = θfˆi + i (4.1)
After fitting the linear model, we get an estimate of θ = 0.7145. We can do
a little algebra and solve for n∗ in Equation 4.2 to obtain the effective sample size.
The right side gives the formula for the corrected sample size used by Bartlett 1939
with the estimated scaling factor θ applied where the number of parameters (principal
components) p = q = 3 and n = 26. The left side gives the formula, but with the
effective sample size n∗ rather than using the scaling factor θ.
n∗ − 1− 1
2
(1 + p+ q) = θ (n− 1− 1
2
(1 + p+ q)) (4.2)
Solving for n∗ gives an effective sample size of n∗ = 19.55. If we replace the
original sample size in the correlated data with the adjusted effective sample size,
the χ29 approximation becomes appropriate. Figure 26 gives the density of the test
statistics simulated from correlated data using n∗ instead of n. The theoretical χ29
distribution is included as reference. For further analyses, we can instead use the
effective sample size (n∗ = 19.55) rather than the actual sample size (n = 26) when
conducting the likelihood ratio test from Equation 3.9.
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Fig. 26. Density of test statistics simulated from correlated data using the effective
sample size n∗ = 19.55. Once the effective sample size is used, the χ29 approx-
imation becomes appropriate.
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4.4 Integrating exon inclusion and DNA methylation
To analyze the relationship between alternative splicing and DNA methylation
in developing prefrontal cortex we apply a multi-step exploratory approach. First,
we test for overall association using the likelihood ratio test from Equation 3.9. We
then use the permutation test on R2 matrices to test for associations that co-localize
on the gene more than would be expected by chance. Finally we use the mixed
effects linear model from Equation 3.13 including both linear and quadratic effects
for age to test whether associations in the first set of canonical covariates occur across
development. Finally, we perform a reanalysis using methylation data that has been
adjusted for differences in tissue admixtures estimated in Section 4.2.1 to demonstrate
that significant findings are unlikely to be confounded with differences in proportions
of neural cell types.
As mentioned previously in Section 4.3.4, the 26 brain samples used in this
analysis are clustered by individual and cannot be treated as independent. However,
independence is an an assumption made by the likelihood ratio test from Equation
3.9 makes. To address this issue, we use an adjusted sample size of 19.55 when
computing test statistics. Figure 27 gives results from the likelihood ratio test on
all genes using both the original sample size as well as the adjusted effective sample
size computed in Section 4.3.4. The distribution of p-values obtained by using the
original sample size in the left panel are anti-conservative. However, when using the
adjusted effective sample size, the resulting p-value distribution in the right panel is
much more reasonable and some significance is still retained.
Once we have selected a set of significant genes, we can then ask whether the
association between alternative splicing and DNA methylation seems to co-localize to
the same regions on the genome. Figure 28 gives the density of permutation p-values
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Fig. 27. Histogram of p-values from likelihood ratio test for association. P-values using
the original sample size of 26 are given in the left panel. P-values using the
effective sample size of 19.55 are given in the right panel.
obtained using the R2 matrix in the left panel and plots the −log10(p-values) from the
permutation test against the −log10(p-values) from the likelihood ratio test. A small
offset of 10−6 was added to permutation p-values so permutation p-values equal to
zero could be plotted. Since both the permutation test and likelihood ratio test seem
to be somewhat under-powered due to the small sample size, we use a joint threshold
of p < 0.01 for both the likelihood ratio test and permutation test to selection a set
of genes that seem to have significant, cis-acting relationships between methylation
and splicing. Many of these genes seem to have changes that may be associated with
brain development, too. Table VI gives a list of these genes along with p-values and
a brief description.
While several of the genes from Table VI seem to be associated with aging,
there may be genes that are have a significant result from the likelihood ratio test
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Fig. 28. Results from permutation testing using R2 values between CpG sites and
exons. The left panel gives the histogram of permutation p-values. The right
panel plots −log10(permutation p-values) against −log10(LRT p-values). A
small offset of 10−6 was added to permutation p-values to plot p-values equal
to zero.
Table VI. Genes meeting threshold for significance from LRT and permutation test
Gene LRT P-val Perm P-val Mixed Effects P-val Details
CNTNAP2 0.000320 0.0028 0.109643 Contactin-associated protein-like 2
RPL10 0.000648 0.0000 0.176863 60S ribosomal protein L10
ST18 0.004022 0.0036 0.013308 Suppression of tumorigenicity 18 protein
NFIA 0.006474 0.0010 0.005944 Nuclear factor 1 A-type
KALRN 0.006474 0.0000 0.045387 Kalirin
DIO2 0.001853 0.0004 0.002720 Type II iodothyronine deiodinase
IL32 0.007823 0.0098 0.155751 Interleukin-32
TMEM144 0.000817 0.0082 0.003309 Transmembrane protein 144
ROBO1 0.003698 0.0016 0.052201 Roundabout, axon guidance receptor, homolog 1
URB1 0.007552 0.0006 0.950762 Nucleolar pre-ribosomal-associated protein 1
NLRP2 0.002891 0.0052 0.329450 NACHT, LRR and PYD domains-containing protein 2
ZNF229 0.003865 0.0064 0.002221 Zinc finger protein 229
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Table VII. Genes meeting threshold for significance from LRT and mixed effects LRT
Gene LRT P-val Perm P-val Mixed Effects P-val Details
RNF220 .000086 0.2382 0.002754 Ring finger protein 220
FMN2 .000019 0.4770 0.003756 Formin 2
HHATL .000097 0.2162 0.000445 Hedgehog acetyltransferase-like
RNASE1 .000039 0.4228 0.000918 Ribonuclease, RNase A family, 1
that are also significantly associated with age, but do not have a detectable cis-acting
relationship between DNA methylation and alternative splicing. This may be because
of incomplete coverage by the methylation microarray, or the relationship may just
be pervasive. Figure 29 gives the p-value histogram for the likelihood ratio test from
the linear mixed effects model in the left panel. P-values are more conservative than
those obtained from an ordinary least squares linear model, but are still highly anti-
conservative, which can be a shortcoming of the approach (Schielzeth and Forstmeier
2008). The right panel plots −log10(p-values from the likelihood ratio test from
the linear mixed effects model against the likelihood ratio test for general association.
Table VII gives a list of genes meeting an FDR = 0.1 threshold for both the likelihood
ratio test for association and the linear mixed effects model.
As mentioned in Section 4.2.1, cerebral cortex is composed of several cell types
that may vary both across individual and aging. Therefore, many of these apparent
changes may be reflecting differences in cell proportions across samples rather than
real changes in methylation. To address this issue we perform a reanalysis using
mixture-adjusted methylation data. This reanalysis is performed by regressing out the
average neuronal and non-neuronal methylation profiles from Kozlenkov et al. 2013
which is equivalent to using the residuals from the linear model given in Equation 2.4.
Residuals from this linear model should reflect variation in methylation that cannot
be attributed to differences in neuronal proportion.
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Fig. 29. Results from mixed effect model on canonical covariate scores. P-values
from the likelihood ratio test for nested models is given in the left panel.
The χ2 approximation to the likelihood ratio is anti-conservative. In the
right panel −log10(p-values from the mixed effects LRT are plotted against
−log10(p-values from the LRT for association of methylation and splicing in-
dex.
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It is more difficult to adjust for differences in gene expression and alternative
splicing. While each cell contributes an equal amount of DNA, and therefore an
equal amount of methylation signal, neurons are relatively larger cells compared to
glial cells and contribute more RNA. Also, many marker genes of neurons lie in
synapses which can vary without the actual neural proportion changing. For now,
we are limited to adjusting only the methylation data for proportions. Figure 30
gives the results from using the likelihood ratio test with the adjusted methylation
residuals. The left panel gives a histogram of p-values which is very similar to the
one using the original β-values. The right panel plots −log10(p-values) using mixture
adjusted residuals against the −log10(p-values) from the original likelihood ratio test.
There does not appear to be a large change in significance, with the exception of one
gene that becomes highly significant after adjustment: PRRC1, a gene that is highly
expressed in the brain and has been recently implicated as having an effect on liquid
intelligence over brain development (Rowe et al. 2013). We will elaborate more on
this gene in the following section.
4.5 Detailed analysis of specific genes
Results from the previous section have highlighted specific genes as having spa-
tially co-localized relationships between alternative splicing and DNA methylation
that co-vary over time. However, this still does not specify the exact nature of the
relationship. In this section we use the results from canonical correlation analysis to
interpret loadings of specific genes and try to make claims about how exon inclusion
and DNA methylation may be related in these genes over brain development. It ap-
pears more likely that observed significant genes are a result of alternative promoter
usage rather than alternative splicing. This makes sense since alternative promoter
usage should be easier to detect since it can affect multiple exons, making it easier
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Fig. 30. Results from likelihood ratio test for association of methylation and splicing
index after adjusting for neuron proportions in the methylation data. The
left panel gives the p-value histogram. The right panel plots −log10(p-values)
from the mixture adjusted test against the −log10(p-values) from the original.
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to detect. We are likely missing many slight changes in splicing patterns, especially
with a sample size of 26.
4.5.1 Kalirin
Kalirin (KLRN), also known as Huntingtin-associated protein-interacting pro-
tein (HAPIP), was first identified in 1997 as a protein interacting with huntingtin-
associated protein 1 (Colomer et al. 1997). Is also known to play an important role in
nerve growth and axonal development (Chakrabarti et al. 2005). It is named after the
multiple-handed Hindu goddess Kali for its ability to interact with numerous other
proteins. The predominant isoform of Kalirin, Kalirin-7, was found to be necessary
for the remodeling and growth of synapses and dendritic spines in mature cortical
neurons and is thought to be important in the development of schizophrenia (Xie
et al. 2007).
Kalirin is highly expressed in the brain and has mean gene expression greater
than roughly 85% of genes in samples assayed. Expression levels dip slightly during
early childhood, but begin to rise again after 9 years of age. Figure 31 gives the
expression trajectory. Figure 32 gives loadings for the first set of canonical covariates
and their trajectory over age. Splicing patterns of Kalirin seem to follow expression
closely. Redundancy coefficients (RCs) for methylation β-values and splicing indices
given in the right panel show that roughly 31% of total methylation varibility and
about 10% of splicing variability in this gene is explained by the first set of canonical
covariates. An increase in a specific methylation site in an intron seems to correspond
to decreased expression and preferential expression of a shorter isoform of the gene.
Closer inspection reveals that this CpG is located in a known enhancer for this gene.
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Fig. 31. log2(Gene Expression) profile of Kalirin over age
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Fig. 32. Splicing pattern in Kalirin over age given by the first set of canonical covari-
ates. A decrease in methylation in an enhancer in an intronic region in the
middle of the gene results in increased expression of a shorter version of the
gene
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4.5.2 Chimerin 2
Chimerin 2 (CHN2) is a nerve tissue protein that has GTPase-activating protein
activity that is regulated by phospholipid binding and binding of diacylglycerol in-
duces translocation of the protein from the cytosol to the Golgi apparatus membrane.
Many variants arising from alternative splicing have been characterized. A missense
mutation of Chimerin 2 has been associated with schizophrenia in men (Hashimoto
et al. 2005).
Chimerin 2 is highly expressed in the brain at similar levels to Kalirin. It also
follows a similar expression trajectory as given in Figure 33. However, unlike Kalirin,
the splicing trajectories obtained from the first set of canonical covariates given in
Figure 34 do not follow the expression trajectory. The gene seems to be generally
losing methylation over age, but particularly at a specific exon towards the end of
the gene which also functions as an alternative start site. Demethylation of this site
seems to correspond to increased expression of a shorter version of the gene that starts
transcription there and perhaps terminates sooner.
4.5.3 Roundabout homolog 1
Roundabout homolog 1 (ROBO1) encodes an integral membrane protein that
is both an axon guidance receptor and a cell adhesion receptor. It is specifically
involved in long range axon guidance when axons decide to cross the central nervous
system (CNS) midline. A translocation in ROBO1 was implicated in communication
disorder based on a Finnish pedigree with severe dyslexia (Bates et al. 2011).
ROBO1 is also highly expressed in the Brain, with a minor dip in expression
occuring after 2 years of age that rebounds after 9 years of age (Figure 35). Due to
limited microarray coverage, we are only able to assay methylation status from the
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Fig. 33. log2(Gene Expression) profile of Chimerin 2 over age
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Fig. 34. Splicing pattern in Chimerin 2 over age given by the first set of canonical
covariates. General loss of methylation, particularly at an alternative start site
near the end of the gene results in increased expression of a shorter isoform.
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Fig. 35. log2(Gene Expression) profile of Roundabout homolog 1 over age
first upstream half of the gene. However, from Figure 36, we can see the highest load-
ings for methylation correspond to the promoter region at the beginning of the gene.
Moderately high loadings also appear at the middle exon with the highest loading for
exon inclusion. This exon is a known alternative start site for this gene. Therefore,
it appears that over brain development, a shorter isoform of this gene starting from
this alternative start site is being preferentially transcribed. This phenomenon does
not correspond similarly to changes in the expression profile.
114
Fig. 36. Splicing pattern in Roundabout homolog 1 over age given by the first set of
canonical covariates. Differential methylation at two different transcription
start sites results in an increased expression of a shorter gene isoform.
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4.5.4 Proline-rich coiled-coil 1
Proline-rich coiled-coil 1 (PRRC1) is a golgi-associated protein with unknown
function in the brain. A recent study has implicated PRRC1 as potentially affecting
fluid intelligence in humans (Rowe et al. 2013). PRRC1 is currently not otherwise
well-studied or understood.
PRRC1 is highly expressed in samples observed, but at lower levels than previous
genes mentioned. Unlike the other genes, PRRC1 seems to be consistently increasing
in expression over age (Figure 37). The Illumina 450k array provides limited coverage
of the gene body of PRRC1. However, a decrease in observed promoter methylation
correlates with the increase in expression.
4.6 Summary
In Chapter 4, we have given a brief overview of necessary neurobiology and issues
particular to the analysis of neurogenomic data. We have used isolated methylation
profiles from Kozlenkov et al. 2013 to estimate the relative abundance of neurons over
brain development. We have performed exploratory analysis and found that DNA
methylation, gene expression, and splicing index all tend to cluster most strongly
according to individual in a way that is not directly related to aging. We have
adapted the methods introduced in Chapter 3 that assume independence of samples
to account for this clustering. While somewhat underpowered, our analysis was able
to detect a subset of genes that had statistically significant, co-localizing relationships
between DNA methylation and splicing index. These genes tended to be involved in
axon guidance. Due to the small sample size, most significant findings appear to be
generally the result of alternative promoter usage rather than differential usage of
single cassette exons.
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Fig. 37. log2(Gene Expression) profile of Proline-rich coiled-coil 1 over age
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Fig. 38. Splicing pattern in Proline-rich coiled-coil 1 over age given by the first set
of canonical covariates. A decrease in promoter methylation corresponds to
increase gene expression and perhaps preferential usage of a longer 3′ UTR
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CHAPTER 5
INTEGRATIVE ANALYSIS OF STANLEY BRAIN SAMPLES
Schizophrenia and bipolar disorder are widely believed to be heritable complex traits
with potentially thousands of SNPs contributing to the phenotype (Lee et al. 2012;
McGuffin et al. 2003; Sullivan, Kendler, and Neale 2003). However, genome-wide
association studies using common SNPs have been able to account for only a frac-
tion of total heritability (Dongen and Boomsma 2013). There are several plausible
explanations for this discrepancy: underpowered studies, heterogenous phenotypes,
rare unobserved SNPs, epigenetic factors such as DNA methylation, or probably some
combination of several of these things. In this chapter our goal is to detect differ-
ences between schizophrenics, bipolars, and neurotypical controls that co-occur across
three data modalities taken from brain samples from the Stanley Medical Research
Institute brain tissue repository:
• RNA-Seq measurements of genome-wide gene expression
• MBD-Seq measurements of genome-wide DNA methylation
• Imputed genotypes from roughly 16 million SNPs
The Stanley Medical Research Institute (SMRI) is a nonprofit organization sup-
porting research on the causes of, and treatments for, schizophrenia and bipolar dis-
order. SMRI houses a repository of post-mortem brains taken from schizophrenic and
bipolar patients as well as neurotypical controls that has been widely used in hundreds
of publications in psychiatric research (http://www2.stanleyresearch.org).
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In this chapter, we are again interested performing an integrative analysis to find
genes with changes in expression that have corresponding changes in DNA methy-
lation. There are a couple of points worth highlighting in this analysis that differ
from Chapter 4. In this scenario, the primary focus is comparing groups of patients
rather than looking at differences across age. Second, sequencing data provides richer
coverage of sites in the genome, but presents different challenges for summarization
and normalization than microarrays. Both statistical and bioinformatic methods will
be detailed in the following sections.
5.1 Overview of data
5.1.1 DNA methylation
MBD-Seq was performed on 100 samples obtained from dorsolateral prefrontal
cortex. Two different sequencing protocols were used: most batches were sequenced
using 50 bp reads, while batches five and six used longer 75 bp reads. After sequencing,
samples were aligned to the hg19 human reference genome. Since the MBD protein
can bind upstream or downstream of the actual methylated locus, aligned reads were
extended to 250 bases to allow for the imprecision of MBD protein binding. Reads
were binned in 300 base intervals. An equal fraction of each non-uniquely mapped
read was counted toward each of its possible map sites. Since only a subset of the
human genome contains CpG sites, many intervals had counts close to or equal to zero.
All intervals with mean counts ≤ 10 across all samples were filtered out. Remaining
intervals were scaled by total sample read depth and multiplied by one million to
obtain a final measure of methylation for each interval given in “reads per million”
(RPM).
There was an issue with mismatched samples during initial sample processing,
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so there are fewer than one hundred unique samples and several technical replicates.
After correctly identifying samples, there were 76 unique samples with 16 having a
technical replicate and one sample being done in triplicate. Four samples were not
identifiable and were omitted, and one sample has been identified by SMRI as having
an unknown phenotype. This resulted in a total of 95 samples in total.
After data summarization and filtering, samples were clustered using multidi-
mensional scaling using intervals from annotated genic regions in Figure 39. Points
are given as batch numbers and are colored by sequencing protocol in the left panel.
Samples cluster strongly by batch. The earlier four batches seem to be more variable
and cluster separately from the rest of the data. Samples from batches 1 through
4 in the top left corner of the MDS plot have been identified as samples with lower
DNA concentrations. Due to the relatively poorer quality of the first 4 batches, a
secondary analysis is also performed omitting batches 1 through 4. The right panel
of Figure 39 colors samples by disease phenotype. We can see that there is some
degree of confounding of disease phenotype with batches. A MDS plot showing only
the later batches is given in Figure 40. Samples in later batches don’t seem to clearly
cluster by batch or disease phenotype.
Before performing an integrative analysis, we first perform an initial exploratory
analysis using the MBD-Seq data. For each interval that met the filtering criteria,
a one-way ANOVA for disease phenotype is fit. After p-values are obtained, the
false-discovery rate is controlled at FDR= 0.1 using the Benjamini-Hochberg method
(Benjamini and Hochberg 1995). Figure 41 gives the resulting p-value histograms
when using all samples (left panel) and the subset of samples from later batches that
were deemed to be of higher quality (right panel). In both scenarios, no intervals were
significant at FDR = 0.1. Non-uniform p-value distributions are likely the result of
a combination of confounding batch effects and correlated tests of nearby genomic
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Fig. 39. Multidimensional scaling plots of genic regions of methylation samples in the
Stanley data. Samples points are given as batch number in the left figure
and are colored by read protocol. Samples in the right panel are colored by
phenotype.
Fig. 40. Multidimensional scaling plots of genic regions of methylation samples from
batches five through nine in the Stanley data. Samples points are given as
batch number in the left figure and are colored by read protocol. Samples in
the right panel are colored by phenotype.
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Fig. 41. Distributions of p-values for one-way ANOVA testing for significance of dis-
ease phenotype in MBD-Seq data. MBD-Seq was binned in 300 bp intervals.
Intervals with mean counts ¡ 10 across all samples were excluded.
intervals.
5.1.2 Gene expression
RNA-Seq was performed on 82 samples taken from a similar, but different region
of cerebral cortex: cingulate cortex. Data was processed in 6 batches of varying sizes.
Reads were aligned to the hg19 reference genome and counts were aggregated by gene.
RPKM was computed for each gene using the formula from Equation 1.9. Samples
were sequenced at varying read depths, but samples taken from bipolar patients were
systematically sequenced at lower depths as seen in Figure 42. Despite scaling for
read depth using RPKM, differences due to read depth can still persist (Robinson
and Oshlack 2010), so additional normalization steps are taken. Figure 43 shows an
MDS plot of samples colored by disease phenotype and numbered by batch.
For the RNA-Seq data, we have processing information for each sample including
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Fig. 42. Boxplots of sample read depths by disease phenotype. Samples from bipolar
patients were sequenced at lower read depths
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Fig. 43. Multidimensional scaling plot of RNA-Seq samples in the Stanley data. Sam-
ples are numbered by batch and colored by disease phenotype.
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Fig. 44. Density plots of R2 between technical covariates and
√
RPKM for each gene.
RNA integrity number (RIN: Schroede et al. 2006), post-mortem interval (PMI), brain
pH, RNA concentration, and sequencing depth. Figure 44 gives densities of R2 values
for each covariate with
√
RPKM from each gene. We can see that several of these
covariates are able to explain ∼ 10% of the variability or more in √RPKM for some
genes. These technical covariates are also minimally correlated with each other, so
an additive linear model was used to regress out the effects of technical covariates for
each gene from
√
RPKM. Figure 45 gives an MDS plot for samples after technical
covariates have been regressed out.
Similar to MBD-Seq, we first perform an initial exploratory analysis using only
the RNA-Seq data. For each gene, a one-way ANOVA for disease phenotype is fit
to
√
RPKM after regressing out technical covariates. After p-values are obtained,
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Fig. 45. Multidimensional scaling plot of RNA-Seq samples after regressing out tech-
nical covariates. Samples are numbered by batch and colored by disease phe-
notype.
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Fig. 46. Distribution of p-values from one-way ANOVAs for each gene testing for sig-
nificance of disease phenotype in RNA-Seq data.
the false-discovery rate is controlled at (FDR= 0.1) using the Benjamini-Hochberg
method. Figure 46 gives the resulting p-value histogram. 189 genes were significant
at FDR = 0.1. Table VIII gives the top results from a gene ontology analysis using
Fisher’s Exact Test and the weight01 algorithm from the topGO package in R (Alexa,
Rahnenfhrer, and Lengauer 2006). Differences are enriched for neurotransmitter, cell
vesicle, and synaptic categories.
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Table VIII. Top enriched GO categories using q-values from a one-way ANOVA for
disease phenotype
GO.ID Term Annotated Significant Expected P-value
GO:0072659 protein localization to plasma membrane 90 6 2.09 0.00019
GO:0019285 glycine betaine biosynthetic process fro... 2 2 0.05 0.00054
GO:0051932 synaptic transmission, GABAergic 23 5 0.53 0.00156
GO:0016082 synaptic vesicle priming 6 4 0.14 0.00156
GO:0032252 secretory granule localization 3 2 0.07 0.00159
GO:0010807 regulation of synaptic vesicle priming 3 2 0.07 0.00159
GO:0014047 glutamate secretion 24 4 0.56 0.0021
GO:0007214 gamma-aminobutyric acid signaling pathwa... 12 3 0.28 0.00234
GO:0007268 synaptic transmission 520 34 12.09 0.00242
GO:0016188 synaptic vesicle maturation 4 2 0.09 0.00313
5.1.3 Genotypes
Genotypes were obtained for 70 samples and imputed to 16,174,402 total SNPs.
Sample files did not include rs IDs (accession numbers used to refer to specific SNPs
standing for Reference SNP cluster ID). Because of this, SNPs were then mapped to
imputed genotypes from the 1000 Genomes Project by genomic coordinates. Since
we are specifically interested in eQTL analysis, we use a list of identified eQTLs from
Gibbs et al. 2010 to subset the whole set of SNPs to perform a focused analysis and
reduce computational burden and number of statistical tests.
Gibbs et al. 2010 identified roughly 20 thousand eQTLs specific to the brain in
a study using 120 brains spanning ages 20 to 101 years old sampled at four distinct
brain regions: prefrontal cortex, temporal cortex, cerebellum, and pons. If we subset
their list of eQTLs by those specific to the two cortical regions, 6.5k unique eQTLs
affecting the expression of 597 genes remain. We then select the subset of Stanley
SNPs that have been identified as eQTLs by the Gibbs study. 3.7k SNPs map over
from the Stanley samples that are present in the Gibbs eQTL list. However, many of
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the SNPs in the Stanley samples contain a large number of missing values and SNPs
with more than 10 missing values were omitted. This leaves a final set of 2.1k SNPs
corresponding to 83 genes. In the next section we detail the analysis used to validate
the putative eQTLs extracted using information from Gibbs et al. 2010.
5.2 Detecting quantitative trait loci
55 samples from the Stanley data had both RNA-Seq and genotype data. In
order to test whether eQTLs from Gibbs et al. 2010 had an effect on gene expression
in the Stanley samples, a simple linear model was fit for each gene i in sample j with
disease phenotype k using normalized yi =
√
RPKMij as the dependent variable,
and genotype and disease phenotype as independent variables. Genotype was coded
as xij = {0, 1, or 2} corresponding to the number of minor alleles and was treated
as ordinal. Separate models were fit for each eQTL since some models may become
over-parameterized due to some genes having a large number of eQTLs. Since disease
phenotype will also likely affect gene expression, it was included in the model as a
categorical variable αik. Equation 5.1 gives the linear model used for each SNP.
yijk = αik + xijβi + ij (5.1)
Figure 47 gives the resulting p-value histograms from Wald tests for the signifi-
cance of β and α from Equation 5.1. While completely redundant SNPs were filtered
out, P-value distributions may be non-uniform due to SNPs being in linkage dise-
quilibrium with each other, and therefore correlated. No eQTLs from Gibbs et al.
2010 were significant at FDR = 0.1 when using the Benjamini-Hochberg correction
(Benjamini and Hochberg 1995).
While some of the lack of significance may be attributed to a smaller sample
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Fig. 47. P-value histograms from Wald tests for eQTL effect and disease phenotype
from Equation 5.1.
size and linkage disequilibrium of non-significant SNPs, the majority of SNPs should
be significant since they come from a preselected set of eQTLs. Lack of significance
cannot be attributed to the larger effect of disease phenotype since it was included in
the model and has a similar level of significance.
5.3 Integrating DNA methylation and gene expression
5.3.1 Principal component regression
58 samples had both RNA-Seq and MBD-Seq data available. As in the case of the
BrainSpan data, there is an issue in the Stanley MBD-Seq data that for each gene, the
number of samples n is generally smaller than the number of 300 bp intervals p. For
example, the GABA-A Receptor Subunit Alpha-5 (GABRA5) gene which is roughly
80 kb has 267 intervals when binned in 300 bp intervals. Many of these intervals
may not contain methylation sites or have low counts, so the final number of intervals
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included for the analysis ends up being 92, but this is still well above the sample size
of 58. Many of these nearby intervals should be correlated, so a method like principal
component analysis should be an effective tool for dimension reduction. We can then
employ a similar approach of using principal component analysis on a gene-by-gene
basis as a tool for dimension reduction in the MBD-Seq data. The first k = 1, ..., 3
PC scores xijk for each gene i and sample j are then used as independent variables
in the linear model given in Equation 5.2 where yij is covariate-adjusted
√
RPKM.
yij =
3∑
k=1
xijkβik + ij (5.2)
5.3.2 Results
5.3.2.1 Analysis on all samples
First, an analysis was performed using all 58 samples with paired MBD-Seq
and RNA-Seq data. Figure 48 gives the resulting p-value histograms and adjusted
R2 distributions from two separate models. The left panel gives p-values from the
F-statistic constructed from the linear model in Equation 5.2 testing the full model
including all three principal component scores from methylation versus the null model.
The middle panel gives the p-value distribution from a one-way ANOVA testing for
group effect for gene expression for each gene which is identical to Figure 46. The
right panel gives the distribution of adjusted R2 values from the two models since
the ANOVA model uses two degrees of freedom and the methylation linear model
uses three. We have already seen that disease phenotype is significantly associated
with differences in gene expression for many genes, but it appears that methylation is
generally not predictive of expression. This may be in part due to poorer data quality
in earlier batches which may be obscuring results. In the next section we perform an
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Fig. 48. Results of integrative analysis of DNA methylation and gene expression in
the Stanley data. The left panel gives the resulting p-value distribution for
regressing gene expression against the first 3 principal components of DNA
methylation. The middle panel gives the p-value distribution from a one-way
ANOVA for gene expression as a function of disease phenotype. The right
panel gives densities of adjusted R2 from the two models
identical reanalysis after subsetting methylation samples using only the later batches
5 through 9.
5.3.2.2 Reanalysis omitting earlier batches
Since some MBD-Seq samples in earlier batches may be of questionable quality,
we perform a focused reanalysis using only the later batches 5 through 9. After
subsetting by later batches, 63 MBD-Seq samples remain. After matching these up
to corresponding RNA-Seq samples, there are 37 samples left with paired data. An
identical analysis to the one performed in the previous section was then performed
using this subset of samples. Figure 49 gives the same results figure giving p-value
histograms and adjusted R2 densities. Unfortunately, using only later batches does
not seem to remedy the problem, and the decreased power from a smaller sample size
seems to remove much of the significance due to differences in disease phenotype.
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Fig. 49. Results of integrative analysis of DNA methylation and gene expression in the
Stanley data using samples from higher quality batches. The left panel gives
the resulting p-value distribution for regressing gene expression against the
first 3 principal components of DNA methylation. The middle panel gives the
p-value distribution from a one-way ANOVA for gene expression as a function
of disease phenotype. The right panel gives densities of adjusted R2 from the
two models
5.4 Summary
In this section we performed an integrative analysis of samples obtained from
the Stanley Medical Research Institute brain tissue repository. Initial exploratory
analysis and quality control of MBD-Seq samples indicated that some samples may
be of questionable quality. After quality control and normalization, we observed no
significant changes in MBD-Seq across disease phenotype, but observed 189 genes sig-
nificantly associated with disease phenotype in the RNA-Seq data that were enriched
for neurotransmitter, synapse, and synaptic vesicle Gene Ontology categories. When
integrating the RNA-Seq data with genotypes, we were unable to obtain similar results
to those of Gibbs et al. 2010 who discovered roughly 6.5k eQTLs in cerebral cortex.
When integrating gene expression and DNA methylation using principal component
regression, we found no statistically significant relationships.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
6.1 Conclusions
In this dissertation we have introduced methods for normalization and integra-
tive analysis of multiple genomic data sets. In the process, we have introduced a
novel normalization method “Flexible local regression on empirically selected con-
trols” (fresco) in Chapter 2 that uses a local regression surface to model and adjust
for technical covariates in microarray signal intensities. By empirical control probes,
fresco is robust to global shifts in DNA methylation profiles that can occur due to
aberrant methylation or shifting abundances in cell type admixtures. We were able
to demonstrate this robustness on several data sets using composite F-statistics to
characterize causes for increase in apparent significance after normalization. Using
several other performance metrics we showed that our method performed favorably
when compared with other current methods.
In Chapter 3, we proposed a gene-centric suite of methods for the integrative
analysis of genomic and epigenetic data with a specific focus on DNA methylation
and alternative splicing. We introduced a likelihood ratio test based on the covariance
matrices of principal component scores of DNA methylation and alternative splicing.
Through simulation studies we showed that for modest sample sizes our method is
not particularly sensitive to detecting alternative splicing of single cassette exons,
but can effectively detect alternative promoter usage affecting multiple exons. After
performing the likelihood ratio test, we proposed regressing canonical scores against
covariates of interest using linear mixed-effects linear model and plotting canonical
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communalities on a gene model to interpret results. Lastly, we proposed a permuta-
tion testing method to systematically test for co-localization of associations between
DNA methylation β-values and splicing index in the gene.
In Chapter 4, we apply the methods introduced in Chapter 3 to a set of de-
velopmental brain samples obtained from the BrainSpan consortium. We estimated
relative proportions of neurons and showed that relative neuron abundance decreases
over age. We performed exploratory analysis of DNA methylation, alternative splic-
ing, and gene expression and found samples to cluster most strongly by individual,
with the exception of cerebellum which was distinct. We developed a method to adapt
the likelihood ratio test in Chapter 3 to the situation of clustered data. Despite having
little power with a small sample size, genes that had a significant association between
alternative splicing and DNA methylation over brain development were primarily in-
volved in axon guidance. We investigated the mechanisms of these relationships in
several example genes.
In Chapter 5, we performed a second integrative analysis on a set of brain sam-
ples from the Stanley Medical Research Institute containing schizophrenic, bipolar,
and neurotypical brain samples. We performed an exploratory analysis of MBD-Seq
methylation data and found batch effects to be the main factor influencing cluster-
ing. Integrating DNA methylation and RNA-Seq measures of gene expression using
principal component regression yielded no signficant genes when controlling the false
discovery rate at FDR = 0.1 using the Benjamini-Hochberg method. A second inte-
grative analysis was performed integrating genotypes and gene expression using an
ANCOVA model on a subset of SNPs that had been identified as eQTLs in a data
set from Gibbs et al. 2010.
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6.2 Future work
In Chapter 2 we considered 3 different performance metrics for assessing the ef-
fectiveness of normalization methods: reduction in batch effects, increase in apparent
significance, and change in composite F statistics post normalization. While these
methods provide some insight into the performance of these methods, none of them
directly assess the issue of statistical power. Due to the complexity of the microar-
ray and variety of current normalization methods it is difficult to simulate a realistic
scenario where true methylation states are known but technical artifacts and noise
are realistically simulated, especially for out-of-band probes used by funnorm and
noob. Furthermore, since reproducible artifacts can occur as a result of normaliza-
tion, reproducibility of findings in independent data sets after normalization is not
a sufficient metric. It would be desirable to have some sort of “spike-in” data set
of 450k arrays, where the truth is known and more dependable comparisons can be
made. Lastly, since our method fits a multivariate local regression surface, it can of-
ten be slower than other methods. Implementation of a parallel framework for model
fitting, or perhaps a different surface fitting algorithm may ameliorate this issue. We
plan to release an implementation of the methods in Chapter 2 as R package fresco.
In Chapter 3 we introduced a suite of methods for the integrative analysis of
genomic and epigenetic data. In order to conduct a likelihood ratio test on a large
number of covariance parameters in the case of n < p, principal component analy-
sis was first used to reduce the number of parameters before performing canonical
correlation analysis. However, sparse L1 penalized methods exist for canonical corre-
lation analysis that may also aid in the interpretation of canonical loadings. The use
of sparse L1 penalized methods generally involves cross-validation in order to select
appropriate tuning parameters. In the case of CCA, two tuning parameters must
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be selected, one for each data set. Selecting two tuning parameters for each gene
becomes a very computationally intensive task and may not scale well to large data
sets. After canonical correlation, we proposed a permutation test for co-localization
of associations between two data sets to specific locations on the gene. This test takes
into account pairwise distances between the two data sets, but does not account for
the fact that all loci lie on a continuous line. A method that accounts for this in some
way by perhaps using a smoothing method may prove to be more powerful, especially
in the case of sequencing data where coverage and resolution may be higher than for
the 450k array. We plan to release an implementation of the methods in Chapter 3
as R package gdi.
In Chapter 4, we implemented the methods from Chapter 3 to a set of devel-
opmental brain samples obtained from the BrainSpan consortium. We limited the
analysis to four brain regions from prefrontal cortex and focused on developmental
changes rather than differences in brain regions. The motivation for analyzing this
subset was in part due to several samples lacking paired data from both DNA methy-
lation and the exon array. In the future, more samples will become available including
prenatal samples that will allow for an analysis with both a larger sample size and a
spanning a wider range of ages.
Current results are also restricted by limited means for estimating cell type abun-
dances in brain samples. Currently, we are only able to estimate neuron abundance
with any degree of reliability, but perhaps data sets in the future will provide isolated
methylation profiles for the different glial types and allow for estimation of propor-
tions of glial sub-populations and perhaps different neuronal subtypes. For many
genes, the Illumina 450k array does not provide adequate coverage in gene bodies
to detect potential relationships between alternative splicing, alternative promoter
usage, and DNA methylation. Future studies using sequencing technologies will add
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improved coverage and resolution and hopefully illuminate many relationships that
have potentially gone unobserved.
In Chapter 5, we performed an integrative analysis of brain samples obtained
from the Stanley Medical Research Institute. Preprocessing of MBD-Seq data was
crude and reads we binned in 300 bp intervals that were agnostic to coding DNA
sequences and genomic locations of regulatory sites. Reads that mapped to multi-
ple locations were evenly divided among the multiple locations. A more sophisticated
preprocessing method may improve downstream data quality. While the set of eQTLs
from Gibbs et al. 2010 did not seem to carry over to the Stanley samples, perhaps a
more thorough eQTL analysis or another eQTL list might provide more interesting
results. We also only used gene-level summaries of RNA-Seq data. Perhaps aggregat-
ing reads by at the exon level would allow for the discovery of changes in alternative
splicing across disease phenotypes.
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Appendix A
ABBREVIATIONS
AMY Amygdala
ANOSVA Analysis of splice variation
ANOVA Analysis of variance
BMIQ Beta mixture quantile normalization
bp base pairs
CBL/CBC Cerebellum
CCA Canonical correlation analysis
CHN2 Chimerin 2
CNS Central nervous system
COSIE Corrected Splicing Indices for Exon Arrays
DFC Dorsolateral prefrontal cortex
DR Detection rate
ECDF Empirical cumulative density function
eQTL Expression quantitative trait loci
FACS Fluorescence activated cell sorting
FDR False-discovery rate
FIRMA Finding isoforms using robust multichip analysis
FRESCO Flexible local regression on empirically selected control probes
gdi Genomic data integration
GEO Gene Expression Omnibus
GO Gene Ontology
GSEA Gene Set Enrichment Analysis
GWAS Genome-wide association study
HCC Hepatocellular Carcinoma
HIP Hippocampus
i.i.d. independently and identically distributed
kb kilobase
KLRN Kalirin
LRT Likelihood ratio test
MAD Median absolute deviation
MADS Microarray analysis of differential splicing
MBD Methyl-CpG-binding domain
MDS Multidimensional scaling
MFC Medial prefrontal cortex
mQTL Methylation quantiative trait loci
NCTX Neocortex
NGS Next generation sequencing
Noob Normal-exponential using out-of-band probes
OFC Orbitofrontal cortex
PCA Principal component analysis
PLS Partial least squares
PMI Post-mortem interval
QTL Quantitative trait loci
RC Redundancy coefficient
RIN RNA integrity number
RMA Robust multi-chip average
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ROBO1 Roundabout homolog 1
RPKM Reads per kilobase per million
RPM Reads per million
rsID Reference SNP cluster ID
SMRI Stanley Medical Research Institute
SNP Single nucleotide polymorphism
SQN Subset quantile normalization
STR Striatum
SVD Singular value decomposition
SWAN Subset-quantile within array normalization
TCGA The Cancer Genome Atlas
TF Transcription factor
THM Thalamus
TPR True positive rate
UTR Untranslated region
VFC Ventral prefrontal cortex
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Appendix B
CODE FROM R PACKAGE FRESCO
# ’
# ’ @param o b j e c t \ c o d e {Me t h y l S e t } o b j e c t
# ’ @param u s e C o n t r o l s S h o u l d e m p i r i c a l c o n t r o l s be u s e d t o a l i g n and f i t l o e s s
s u r f a c e s ?
# ’ @param l o e s s S p a n Supp l y s p an f o r f i t t i n g l o e s s s u r f a c e
# ’ @param f i t L o e s s S h o u l d l o e s s c u r v e be f i t t e d a f t e r i n i t i a l a l i g nm e n t and
s c a l i n g ?
# ’ @param s d T h r e s h o l d T h r e s h o l d t o f i l t e r e m p i r i c a l c o n t r o l s by s t a n d a r d d e v i a t i o n
# ’
# ’ @ e xp o r t p r e p r o c e s s F r e s c o
preproce s sFre s co ←function ( object , useContro l s = TRUE, loes sSpan = . 1 5 ,
f i t L o e s s = TRUE, sdThreshold = . 1 5 , verbose = TRUE) {
i f ( ! i s ( object , ” MethylSet ” ) ) stop ( ” ’ ob ject ’ needs to be a ’ MethylSet ’ ” )
i f ( loes sSpan > 1 | l oe s sSpan < 0) stop ( ” loes sSpan must be between zero and one”
)
data ( f r e scoData )
ob j e c t ← f i xMethOut l i e r s ( ob j e c t )
# c r e a t e o b j e c t f o r m e t h y l a t e d and u nm e t h y l a t e d c h a n n e l s
−−−−−−−−−−−−−−−−−−−−−−−−−
s i g n a l s ← array (dim = c (dim( ob j e c t ) , 2) )
s i g n a l s [ , , 1 ] ← getUnmeth ( ob j e c t )
s i g n a l s [ , , 2 ] ← getMeth ( ob j e c t )
f r e scoData ← f r e scoData [match(rownames( ob j e c t ) , rownames( f r e scoData ) ) , ]
GC← f r e scoData$targetGC
# g e t s e t o f e m p i r i c a l c o n t r o l s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( useContro l s ) {
probeSD ← rowSds ( getBeta ( ob j e c t ) )
c o n t r o l s ← which( ! i s .na( f r e scoData$ eContro l s ) & probeSD < sdThreshold )
i f ( verbose ) cat ( length ( c o n t r o l s ) , ’ e m p i r i c a l c o n t r o l probes s e l e c t e d \n ’ )
}
# d i v i d e p r o b e s and c o n t r o l s up by p r o b e t y p e
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
whichSet I I ← which( f r e scoData$probeType == ’ I I ’ )
whichSetI ← which( f r e scoData$probeType == ’ I ’ )
i f ( useContro l s ) {
whichContro l s I I ← intersect ( whichSetII , c o n t r o l s )
whichContro l s I ← intersect ( whichSetI , c o n t r o l s )
} else {
whichContro l s I I ← whichSet I I
whichContro l s I ← whichSetI
}
# f i n d l o w e r p e a k s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
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i f ( verbose ) cat ( ’ A l ign ing s i g n a l i n t e n s i t i e s \n ’ )
typeIpeaks ← apply ( s i g n a l s [ whichControlsI , , ] , c (2 , 3) , getLowerPeak )
type I Ipeaks ← apply ( s i g n a l s [ whichContro l s I I , , ] , c (2 , 3) , getLowerPeak )
typeIpeakMeans ← colMeans ( typeIpeaks )
typeIIpeakMeans ← colMeans ( type I Ipeaks )
# l i n e up s am p l e s by t h e i r l o w e r p e a k s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
s i g n a l s [ whichSetI , , 1 ] ← sweep( s i g n a l s [ whichSetI , , 1 ] , 2 , typeIpeaks [ , 1 ] , ’− ’
)
s i g n a l s [ whichSetI , , 2 ] ← sweep( s i g n a l s [ whichSetI , , 2 ] , 2 , typeIpeaks [ , 2 ] , ’− ’
)
s i g n a l s [ whichSetII , , 1 ] ← sweep( s i g n a l s [ whichSetII , , 1 ] , 2 , type I Ipeaks [ , 1 ] ,
’− ’ )
s i g n a l s [ whichSetII , , 2 ] ← sweep( s i g n a l s [ whichSetII , , 2 ] , 2 , type I Ipeaks [ , 2 ] ,
’− ’ )
# s c a l e s i g n a l s t o m i n im i z e d e v i a n c e f r om c o n t r o l a v e r a g e s
−−−−−−−−−−−−−−−−−−−−−−−
i f ( verbose ) cat ( ’ Applying l i n e a r s c a l i n g f a c t o r \n ’ )
typeIcontro lAvg ← apply ( s i g n a l s [ whichControlsI , , ] , c (1 , 3) , mean)
type I I contro lAvg ← apply ( s i g n a l s [ whichContro l s I I , , ] , c (1 , 3) , mean)
c o e f s I 1 ← lm( s i g n a l s [ whichControlsI , , 1 ] ∼ typeIcontro lAvg [ , 1 ] + 0)$coef
c o e f s I 2 ← lm( s i g n a l s [ whichControlsI , , 2 ] ∼ typeIcontro lAvg [ , 2 ] + 0)$coef
c o e f s I I 1 ← lm( s i g n a l s [ whichContro l s I I , , 1 ] ∼ typeI I contro lAvg [ , 1 ] + 0)$coef
c o e f s I I 2 ← lm( s i g n a l s [ whichContro l s I I , , 2 ] ∼ typeI I contro lAvg [ , 2 ] + 0)$coef
s c a l e d S i g n a l s ← array (dim = dim( s i g n a l s ) )
s c a l e d S i g n a l s [ whichSetI , , 1 ] ← sweep( s i g n a l s [ whichSetI , , 1 ] , 2 , c o e f s I 1 , ’/ ’ )
+ typeIpeakMeans [ 1 ]
s c a l e d S i g n a l s [ whichSetI , , 2 ] ← sweep( s i g n a l s [ whichSetI , , 2 ] , 2 , c o e f s I 2 , ’/ ’ )
+ typeIpeakMeans [ 2 ]
s c a l e d S i g n a l s [ whichSetII , , 1 ] ←sweep( s i g n a l s [ whichSetII , , 1 ] , 2 , c o e f s I I 1 , ’/ ’
) + typeIIpeakMeans [ 1 ]
s c a l e d S i g n a l s [ whichSetII , , 2 ] ←sweep( s i g n a l s [ whichSetII , , 2 ] , 2 , c o e f s I I 2 , ’/ ’
) + typeIIpeakMeans [ 2 ]
s c a l e d S i g n a l s [ s c a l e d S i g n a l s < 0 ] ← 0
# s t o p h e r e i f o m i t t i n g l o e s s f i t t i n g −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( ! f i t L o e s s ) {
out ← ob j e c t
normedUnmeth ← s c a l e d S i g n a l s [ , , 1 ]
normedMeth ← s c a l e d S i g n a l s [ , , 2 ]
rownames(normedUnmeth ) ← rownames( normedMeth ) ← rownames( ob j e c t )
colnames (normedUnmeth ) ← colnames ( normedMeth ) ← colnames ( ob j e c t )
assayDataElement ( out , ’Unmeth ’ ) ← normedUnmeth
assayDataElement ( out , ’Meth ’ ) ← normedMeth
out@preprocessMethod ← c ( rg . norm = s p r i n t f ( ” f r e s c o al ignment and s c a l i n g (
based on a MethylSet preproce s s ed as ’%s ’ ” ,
preprocessMethod ( ob j e c t ) [ 1 ] ) ,
min f i = as . character ( packageVers ion ( ’ min f i ’ ) ) ,
mani f e s t = as . character ( packageVers ion ( ’
I l luminaHumanMethylation450kmanifest ’ ) ) )
return ( out )
}
# comput e r o b u s t e x p e r i m e n t a v e r a g e
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( verbose ) cat ( ’ Computing robust experiment−wise average \n ’ )
log2Centered ← log2 ( s c a l e d S i g n a l s + 1)
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sexInd ← factor ( suppressWarnings ( getSex (mapToGenome( ob j e c t ) ) [ , 3 ] ) )
XYind ← which( f r e scoData$chromosome %in% c ( ’X ’ , ’Y ’ ) )
log2Standard ← apply ( log2Centered , c (1 , 3) , mean, tr im = . 1 )
i f ( nlevels ( sexInd ) == 2) {
mInd ← which( sexInd == ’M’ )
f Ind ← which( sexInd == ’F ’ )
log2StandardM ← log2StandardF ← log2Standard
log2StandardM [ XYind , ] ← apply ( log2Centered [ XYind , mInd , ] , c (1 , 3) , mean,
tr im = . 1 )
log2StandardF [ XYind , ] ← apply ( log2Centered [ XYind , fInd , ] , c (1 , 3) , mean,
tr im = . 1 )
}
# comput e d e v i a t i o n s f r om a v e r a g e −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( verbose ) cat ( ’ Computing d e v i a t i o n s from average \n ’ )
l og2Dev ia t i on s ← array (dim = dim( log2Centered ) )
for ( kk in 1 : 2 )
l og2Dev ia t i on s [ , , kk ] ← log2Centered [ , , kk ] − log2Standard [ , kk ]
i f ( nlevels ( sexInd ) == 2) {
for ( kk in 1 : 2 ) {
l og2Dev ia t i on s [ XYind , mInd , kk ] ← log2Centered [ XYind , mInd , kk ] −
log2StandardM [ XYind , kk ]
l og2Dev ia t i on s [ XYind , fInd , kk ] ← log2Centered [ XYind , fInd , kk ] −
log2StandardF [ XYind , kk ]
}
}
# w i n s o r i z e by p r o b e t y p e
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( useContro l s ) {
i f ( verbose ) cat ( ’ Winsor iz ing probes out o f p r e d i c t i o n range \n ’ )
GC[ whichSetI ] ← winsor izeBySubset (GC, whichSetI , whichContro l s I )
GC[ whichSet I I ] ← winsor izeBySubset (GC, whichSetII , wh ichContro l s I I )
for ( kk in 1 : 2 ) {
log2Standard [ whichSetI , kk ] ← winsor izeBySubset ( log2Standard [ , kk ] ,
whichSetI , whichContro l s I )
log2Standard [ whichSetII , kk ] ← winsor izeBySubset ( log2Standard [ , kk ] ,
whichSetII , wh ichContro l s I I )
}
}
# c r e a t e i n d e p e n d e n t v a r i a b l e d a t a f r am e f o r l o e s s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
indepVars ← data . frame (GC = GC, UMavg = log2Standard [ , 1 ] , Mavg = log2Standard [ ,
2 ] )
i f ( nlevels ( sexInd ) == 2) {
indepVarsM ← data . frame (GC = GC, UMavg = log2StandardM [ , 1 ] , Mavg =
log2StandardM [ , 2 ] )
indepVarsF ← data . frame (GC = GC, UMavg = log2StandardF [ , 1 ] , Mavg =
log2StandardF [ , 2 ] )
}
# f i t l o e s s s u r f a c e s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( verbose ) cat ( ’ F i t t i n g & sub t ra c t i ng out l o e s s \n ’ )
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i f ( nlevels ( sexInd ) == 1) {
log2NormedDevs ← array (dim = dim( l og2Dev ia t i on s ) )
i f ( verbose ) cat ( ’ Normal iz ing type I probes \n ’ )
log2NormedDevs [ whichSetI , , ] ← apply ( l og2Dev iat ions , c (2 , 3) , funLoess ,
indepVars = indepVars , whichControls =
whichControlsI ,
whichSet = whichSetI ,
smoothingParameter = loessSpan )
i f ( verbose ) cat ( ’ Normal iz ing type I I probes \n ’ )
log2NormedDevs [ whichSetII , , ] ← apply ( l og2Dev iat ions , c (2 , 3) , funLoess ,
indepVars = indepVars , whichControls =
whichContro l s I I ,
whichSet = whichSetII ,
smoothingParameter = loessSpan )
}
i f ( nlevels ( sexInd ) == 2) {
log2NormedDevs ← array (dim = dim( l og2Dev ia t i on s ) )
i f ( verbose ) cat ( ’ Normal iz ing type I probes \n ’ )
# t y p e I
log2NormedDevs [ whichSetI , mInd , ] ← apply ( l og2Dev ia t i on s [ , mInd , ] , c (2 , 3) ,
funLoess ,
indepVars = indepVarsM ,
whichControls = whichControlsI ,
whichSet = whichSetI ,
smoothingParameter = loessSpan )
log2NormedDevs [ whichSetI , f Ind , ] ← apply ( l og2Dev ia t i on s [ , f Ind , ] , c (2 , 3) ,
funLoess ,
indepVars = indepVarsF ,
whichControls = whichControlsI ,
whichSet = whichSetI ,
smoothingParameter = loessSpan )
# t y p e I I
i f ( verbose ) cat ( ’ Normal iz ing type I I probes \n ’ )
log2NormedDevs [ whichSetII , mInd , ] ← apply ( l og2Dev ia t i on s [ , mInd , ] , c (2 , 3) ,
funLoess ,
indepVars = indepVarsM ,
whichControls =
whichContro l s I I ,
whichSet = whichSetII ,
smoothingParameter = loessSpan
)
log2NormedDevs [ whichSetII , f Ind , ] ← apply ( l og2Dev ia t i on s [ , f Ind , ] , c (2 , 3) ,
funLoess ,
indepVars = indepVarsF ,
whichControls =
whichContro l s I I ,
whichSet = whichSetII ,
smoothingParameter = loessSpan
)
}
# comput e n o r m a l i z e d l o g 2 s i g n a l s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
log2NormedSignals ← array (dim = dim( log2Centered ) )
i f ( nlevels ( sexInd ) == 1) {
for ( kk in 1 : 2 ) log2NormedSignals [ , , kk ] ← log2NormedDevs [ , , kk ] +
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log2Standard [ , kk ]
rm( log2NormedDevs , log2Standard ) ; gc ( )
}
i f ( nlevels ( sexInd ) == 2) {
for ( kk in 1 : 2 ) {
log2NormedSignals [ , mInd , kk ] ← log2NormedDevs [ , mInd , kk ] + log2StandardM [ ,
kk ]
log2NormedSignals [ , f Ind , kk ] ← log2NormedDevs [ , f Ind , kk ] + log2StandardF [ ,
kk ]
}
rm( log2NormedDevs , log2StandardM , log2StandardF ) ; gc ( )
}
# c r e a t e new Me t h y l S e t f o r o u t p u t
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
out ← ob j e c t
normedUnmeth ← 2ˆ log2NormedSignals [ , , 1 ]
normedMeth ← 2ˆ log2NormedSignals [ , , 2 ]
rownames(normedUnmeth ) ← rownames( normedMeth ) ← rownames( ob j e c t )
colnames (normedUnmeth ) ← colnames ( normedMeth ) ← colnames ( ob j e c t )
assayDataElement ( out , ’Unmeth ’ ) ← normedUnmeth
assayDataElement ( out , ’Meth ’ ) ← normedMeth
out@preprocessMethod ← c ( rg . norm = s p r i n t f ( ” f r e s c o alignment , s c a l i n g , and
s u r f a c e f i t t i n g ( based on a MethylSet preproce s s ed as ’%s ’ ” ,
preprocessMethod ( ob j e c t ) [ 1 ] ) ,
min f i = as . character ( packageVers ion ( ’ min f i ’ ) ) ,
mani f e s t = as . character ( packageVers ion ( ’
I l luminaHumanMethylation450kmanifest ’ ) ) )
out
}
# d e c l a r e p e ak f i n d i n g f u n c t i o n −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
getLowerPeak ← function ( x ) {
i n t e n s i t y D e n s i t y ← density ( x )
peaksInd ← which( d i f f ( sign ( d i f f ( i n t e n s i t y D e n s i t y$y ) ) )==−2)+1
lowerPeak ← which .min( i n t e n s i t y D e n s i t y$x [ peaksInd ] )
return ( i n t e n s i t y D e n s i t y$x [ peaksInd [ lowerPeak ] ] )
}
# d e c l a r e w i n s o r i z a t i o n f u n c t i o n −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
winsor izeBySubset ← function (x , whichSet , whichControls ) {
x [ whichSet ] [which( x [ whichSet ] > max( x [ whichControls ] ) ) ] ← max( x [ whichControls ] )
x [ whichSet ] [which( x [ whichSet ] < min( x [ whichControls ] ) ) ] ← min( x [ whichControls ] )
x [ whichSet ]
}
# d e c l a r e l o e s s f u n c t i o n
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
funLoess ← function (y , indepVars , whichControls , whichSet , smoothingParameter ) {
modelDat ← as . data . frame (cbind (y , indepVars ) )
tempFit ← l o e s s ( y ∼ GC ∗ Mavg ∗ UMavg, trace . hat = ’ approx ’ ,
span = smoothingParameter ,
modelDat , subset = whichControls )
r e s i d s ← y [ whichSet ] − predict ( tempFit , modelDat [ whichSet , ] )
return ( r e s i d s )
}
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horseRace ← function ( object , batchVarName = NULL,
covariateNames = NULL, covar iateTypes = NULL,
compositeF=FALSE) {
i f ( ! i s ( object , ”RGChannelSet” ) )
stop ( ” ob j e c t needs to be a ’ RGChannelSet ’ ” )
i f ( i s . null ( batchVarName ) & is . null ( covariateNames ) )
stop ( ” Please prov ide v a r i a b l e name f o r e i t h e r batch or c o v a r i a t e s o f i n t e r e s t ”
)
i f ( ! i s . null ( covariateNames ) & is . null ( covar iateTypes ) )
stop ( ” Please prov ide cor respond ing vec to r o f c o v a r i a t e types : e i t h e r
’ c a t e g o r i c a l ’ or ’ continuous ’ ” )
i f ( ! i s . null ( covar iateTypes ) & any( ! covar iateTypes %in% c ( ’ c a t e g o r i c a l ’ , ’
cont inuous ’ ) ) )
stop ( ” covar iateTypes must be one o f ’ c a t e g o r i c a l ’ or ’ continuous ’ ” )
# n o r m a l i z e −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
normList ← l i s t ( )
normList$Raw ← p r e p r o c e s s I l l u m i n a ( updateObject ( ob j e c t ) )
normList$FRESCO 15 ← preproce s sFre s co ( normList$Raw, loes sSpan = . 1 5 , sdThreshold
= . 1 )
normList$FRESCO 50 ← preproce s sFre s co ( normList$Raw, loes sSpan = . 5 , sdThreshold
= . 1 )
normList$FRESCO 85 ← preproce s sFre s co ( normList$Raw, loes sSpan = . 8 5 , sdThreshold
= . 1 )
normList$FRESCO NL ← preproce s sFre s co ( normList$Raw, f i t L o e s s = FALSE,
sdThreshold = . 1 )
normList$SQN ← preproce s sQuant i l e (mapToGenome( ob j e c t ) )
normList$Funnorm ← preprocessFunnorm ( ob j e c t )
normList$Noob ← preprocessNoob ( ob j e c t )
# t e s t f o r b a t c h e f f e c t s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( ! i s . null ( batchVarName ) ) {
f . r e s u l t s ← lapply ( normList , . catTest , cvn=batchVarName )
roc . r e s u l t s ← lapply ( f . r e s u l t s , function ( x ) . rocComp(na . omit ( x [ , 2 ] ) ) )
# p−v a l u e e c d f
plot (0 , 0 , xl im = c (0 , 1) , yl im = c (0 , 1) , type=’n ’ ,
x lab = ’P−value ’ , y lab = ’ECDF’ ,
main = ’P−value ECDF f o r Batch E f f e c t s ’ )
abline (0 , 1 , l t y = 3)
for ( i i in 1 : length ( roc . r e s u l t s ) )
l ines ( seq (0 , 1 , . 0 1 ) , roc . r e s u l t s [ [ i i ] ] , col = i i )
legend ( ’ bottomright ’ , legend = names( roc . r e s u l t s ) , f i l l = 1 : length ( roc . r e s u l t s
) )
}
# l o o k a t powe r f o r c o v a r i a t e s o f i n t e r e s t −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( ! i s . null ( covariateNames ) & ! compositeF ) {
for ( i i in 1 : length ( covariateNames ) ) {
i f ( covar iateTypes [ i i ] == ’ c a t e g o r i c a l ’ ) {
f . r e s u l t s ← lapply ( normList , . catTest , cvn=covariateNames [ i i ] )
roc . r e s u l t s ← lapply ( f . r e s u l t s , function ( x ) . rocComp(na . omit ( x [ , 2 ] ) , BH.
adj = TRUE) )
}
i f ( covar iateTypes [ i i ] == ’ cont inuous ’ ) {
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f . r e s u l t s ← lapply ( normList , . contTest , cvn=covariateNames [ i i ] )
roc . r e s u l t s ← lapply ( f . r e s u l t s , function (X) . rocComp(na . omit ( x [ , 2 ] ) , BH.
adj = TRUE) )
}
# p l o t
plot (0 , 0 , xl im = c (0 , 1) , yl im = c (0 , 1) , type=’n ’ ,
x lab = ’FDR Threshold ’ , y lab = ’ Prop s i g at g iven FDR’ ,
main = paste ( ’ S i g n i f i c a n t D i f f e r e n c e s f o r ’ , covariateNames [ i i ] ) )
abline (0 , 1 , l t y = 3)
for ( i i in 1 : length ( roc . r e s u l t s ) )
l ines ( seq (0 , 1 , . 0 1 ) , roc . r e s u l t s [ [ i i ] ] , col = i i )
legend ( ’ bottomright ’ , legend = names( roc . r e s u l t s ) , f i l l = 1 : length ( roc .
r e s u l t s ) )
}
}
# l o o k a t c om p o s i t e F− s c o r e s f o r c o v a r i a t e s o f i n t e r e s t −−−−−−−−−−−−−−−−−−−−
i f ( ! i s . null ( covariateNames ) & compositeF ) {
for ( i i in 1 : length ( covariateNames ) ) {
i f ( covar iateTypes [ i i ] == ’ c a t e g o r i c a l ’ ) {
# comput e anova sum o f s q u a r e s and g e t d e g r e e s o f f r e e d om
f . r e s u l t s ← lapply ( normList , . compSS , cvn=covariateNames [ i i ] )
p ← nlevels ( factor ( pData ( normList [ [ 1 ] ] ) [ , covariateNames [ i i ] ] ) )
n ← ncol ( normList [ [ 1 ] ] )
# re− o r d e r f− r e s u l t s b e c a u s e mapToGenome re− o r d e r s t h e CpGs
for ( j j in 2 : length ( f . r e s u l t s ) ) {
f . r e s u l t s [ [ j j ] ] ← f . r e s u l t s [ [ j j ] ] [match(rownames( normList [ [ 1 ] ] ) ,
rownames( normList [ [ j j ] ] ) ) , ]
}
p . v a l s ← l i s t ( )
for ( j j in 2 : length ( normList ) ) {
# comput e c om p o s i t e F s c o r e s and p− v a l u e s
comp . pva l s ← comp . f . s t a t s ← matrix ( nr=nrow( normList [ [ 1 ] ] ) , nc=3)
colnames (comp . pva l s ) ← colnames (comp . f . s t a t s ) ← c ( ’ o r i g ’ , ’ s s r raw ’ , ’
s s e raw ’ )
comp . f . s t a t s [ , 1 ] ← ( f . r e s u l t s [ [ 1 ] ] [ , 1 ] / (p−1) ) / ( f . r e s u l t s [ [ 1
] ] [ , 2 ] / (n−p) )
comp . f . s t a t s [ , 2 ] ← ( f . r e s u l t s [ [ 1 ] ] [ , 1 ] / (p−1) ) / ( f . r e s u l t s [ [ j j
] ] [ , 2 ] / (n−p) )
comp . f . s t a t s [ , 3 ] ← ( f . r e s u l t s [ [ j j ] ] [ , 1 ] / (p−1) ) / ( f . r e s u l t s [ [ 1
] ] [ , 2 ] / (n−p) )
comp . pva l s ← pf (comp . f . s t a t s , df1=p−1, df2=n−p , lower . t a i l=FALSE)
p . v a l s [ [ ( j j −1) ] ] ← comp . pva l s
}
names(p . v a l s ) ← names( normList ) [−1]
# p l o t
axis . l ims ← −log10 ( unlist (p . v a l s ) )
axis . l ims ← max( axis . l ims [which( i s . f i n i t e ( axis . l ims ) ) ] )
par ( mfcol = c (2 , 5) , mar=c (5 , 4 , 4 , 1 . 5 ) )
for ( j j in c (1 , 4 : 7 ) ) {
plot ( −log10 (p . v a l s [ [ j j ] ] [ , 1 ] ) , −log10 (p . v a l s [ [ j j ] ] [ , 2 ] ) ,
pch=16, cex =.2 , col=rgb ( 0 , 0 , 1 , alpha =.4) ,
xlab = ’ Or i g i na l F S t a t i s t i c ’ , y lab = expression ( ’F ’ [ ’ Err ’ ] ) ,
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main=names(p . v a l s ) [ j j ] , xl im=c (0 , axis . l ims ) , yl im=c (0 , axis . l ims ) ,
cex . axis = 1 . 7 , cex . lab = 1 . 7 )
abline (0 , 1 , col=’ red ’ )
plot ( −log10 (p . v a l s [ [ j j ] ] [ , 1 ] ) , −log10 (p . v a l s [ [ j j ] ] [ , 3 ] ) ,
pch=16, cex =.2 , col=rgb ( 0 , 0 , 1 , alpha =.4) ,
xlab = ’ Or i g i na l F S t a t i s t i c ’ , y lab = expression ( ’F ’ [ ’ES ’ ] ) ,
xl im=c (0 , axis . l ims ) , yl im=c (0 , axis . l ims ) ,
cex . axis = 1 . 7 , cex . lab = 1 . 7 )
abline (0 , 1 , col=’ red ’ )
}
}
i f ( covar iateTypes [ i i ] == ’ cont inuous ’ ) {
cat ( ’ Not yet supported ’ )
}
}
}
}
. rocComp ← function (x , eval = seq (0 , 1 , . 0 1 ) , BH. adj = FALSE) {
i f (BH. adj ) x ← p . ad jus t (x , method = ’BH’ )
sapply ( eval , function ( z ) sum( x < z ) / length ( x ) )
}
. catTest ← function (x , cvn ) rowFtests ( getBeta ( x ) , factor ( pData ( x ) [ , cvn ] ) )
. contTest ← function (x , cvn ) {
cont . cov ← as .numeric ( pData ( x ) [ , cvn ] )
apply ( getBeta ( x ) , 1 , function ( z ) biglm ( z ∼ cont . cov ) )
}
. compSS ← function (x , cvn ) {
cat . cov ← factor ( pData ( x ) [ , cvn ] )
betas ← getBeta ( x )
f a c . means ← matrix ( nr=nrow( betas ) , nc=nlevels ( cat . cov ) )
r e s .mat ← matrix ( nr=nrow( betas ) , nc=ncol ( betas ) )
mean . vec ← rowMeans ( betas )
for ( i i in 1 : nlevels ( cat . cov ) ) {
f a c . l e v e l ← which( cat . cov == levels ( cat . cov ) [ i i ] )
f a c . means [ , i i ] ← rowMeans ( betas [ , f a c . l e v e l ] )
r e s .mat [ , f a c . l e v e l ] ← betas [ , f a c . l e v e l ] − f a c . means [ , i i ]
}
s s e ← rowSums( r e s .matˆ2)
s s r ← rowSums(sweep ( ( f a c . means − mean . vec ) ˆ2 , 2 , table ( cat . cov ) , ’∗ ’ ) )
out ← cbind ( s s r , s s e )
out
}
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# ’
# ’ @param o b j e c t \ c o d e {Me t h y l S e t } o b j e c t
# ’ @param u s e C o n t r o l s S h o u l d e m p i r i c a l c o n t r o l s be u s e d t o a l i g n and f i t l o e s s
s u r f a c e s ?
# ’ @param l o e s s S p a n Supp l y s p an f o r f i t t i n g l o e s s s u r f a c e
# ’ @param s d T h r e s h o l d T h r e s h o l d t o f i l t e r e m p i r i c a l c o n t r o l s by s t a n d a r d d e v i a t i o n
r e t u r n F i t S t a t s ←function ( object , useContro l s = TRUE, loes sSpan = . 1 5 ,
sdThreshold = . 1 5 , verbose = FALSE) {
i f ( loes sSpan > 1 | l oe s sSpan < 0) stop ( ” loes sSpan must be between zero and one”
)
data ( f r e scoData )
ob j e c t ← f i xMethOut l i e r s ( ob j e c t )
# c r e a t e o b j e c t f o r m e t h y l a t e d and u nm e t h y l a t e d c h a n n e l s
−−−−−−−−−−−−−−−−−−−−−−−−−
s i g n a l s ← array (dim = c (dim( ob j e c t ) , 2) )
s i g n a l s [ , , 1 ] ← getUnmeth ( ob j e c t )
s i g n a l s [ , , 2 ] ← getMeth ( ob j e c t )
f r e scoData ← f r e scoData [match(rownames( ob j e c t ) , rownames( f r e scoData ) ) , ]
GC← f r e scoData$targetGC
# g e t s e t o f e m p i r i c a l c o n t r o l s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( useContro l s ) {
probeSD ← rowSds ( getBeta ( ob j e c t ) )
c o n t r o l s ← which( ! i s .na( f r e scoData$ eContro l s ) & probeSD < sdThreshold )
i f ( verbose ) cat ( length ( c o n t r o l s ) , ’ e m p i r i c a l c o n t r o l probes s e l e c t e d \n ’ )
}
# d i v i d e p r o b e s and c o n t r o l s up by p r o b e t y p e
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
whichSet I I ← which( f r e scoData$probeType == ’ I I ’ )
whichSetI ← which( f r e scoData$probeType == ’ I ’ )
i f ( useContro l s ) {
whichContro l s I I ← intersect ( whichSetII , c o n t r o l s )
whichContro l s I ← intersect ( whichSetI , c o n t r o l s )
} else {
whichContro l s I I ← whichSet I I
whichContro l s I ← whichSetI
}
# f i n d l o w e r p e a k s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( verbose ) cat ( ’ A l ign ing s i g n a l i n t e n s i t i e s \n ’ )
typeIpeaks ← apply ( s i g n a l s [ whichControlsI , , ] , c (2 , 3) , getLowerPeak )
type I Ipeaks ← apply ( s i g n a l s [ whichContro l s I I , , ] , c (2 , 3) , getLowerPeak )
typeIpeakMeans ← colMeans ( typeIpeaks )
typeIIpeakMeans ← colMeans ( type I Ipeaks )
# l i n e up s am p l e s by t h e i r l o w e r p e a k s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
s i g n a l s [ whichSetI , , 1 ] ← sweep( s i g n a l s [ whichSetI , , 1 ] , 2 , typeIpeaks [ , 1 ] , ’− ’
)
s i g n a l s [ whichSetI , , 2 ] ← sweep( s i g n a l s [ whichSetI , , 2 ] , 2 , typeIpeaks [ , 2 ] , ’− ’
)
s i g n a l s [ whichSetII , , 1 ] ← sweep( s i g n a l s [ whichSetII , , 1 ] , 2 , type I Ipeaks [ , 1 ] ,
’− ’ )
s i g n a l s [ whichSetII , , 2 ] ← sweep( s i g n a l s [ whichSetII , , 2 ] , 2 , type I Ipeaks [ , 2 ] ,
’− ’ )
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# s c a l e s i g n a l s t o m i n im i z e d e v i a n c e f r om c o n t r o l a v e r a g e s
−−−−−−−−−−−−−−−−−−−−−−−
i f ( verbose ) cat ( ’ Applying l i n e a r s c a l i n g f a c t o r \n ’ )
typeIcontro lAvg ← apply ( s i g n a l s [ whichControlsI , , ] , c (1 , 3) , mean)
type I I contro lAvg ← apply ( s i g n a l s [ whichContro l s I I , , ] , c (1 , 3) , mean)
c o e f s I 1 ← lm( s i g n a l s [ whichControlsI , , 1 ] ∼ typeIcontro lAvg [ , 1 ] + 0)$coef
c o e f s I 2 ← lm( s i g n a l s [ whichControlsI , , 2 ] ∼ typeIcontro lAvg [ , 2 ] + 0)$coef
c o e f s I I 1 ← lm( s i g n a l s [ whichContro l s I I , , 1 ] ∼ typeI I contro lAvg [ , 1 ] + 0)$coef
c o e f s I I 2 ← lm( s i g n a l s [ whichContro l s I I , , 2 ] ∼ typeI I contro lAvg [ , 2 ] + 0)$coef
s c a l e d S i g n a l s ← array (dim = dim( s i g n a l s ) )
s c a l e d S i g n a l s [ whichSetI , , 1 ] ← sweep( s i g n a l s [ whichSetI , , 1 ] , 2 , c o e f s I 1 , ’/ ’ )
+ typeIpeakMeans [ 1 ]
s c a l e d S i g n a l s [ whichSetI , , 2 ] ← sweep( s i g n a l s [ whichSetI , , 2 ] , 2 , c o e f s I 2 , ’/ ’ )
+ typeIpeakMeans [ 2 ]
s c a l e d S i g n a l s [ whichSetII , , 1 ] ←sweep( s i g n a l s [ whichSetII , , 1 ] , 2 , c o e f s I I 1 , ’/ ’
) + typeIIpeakMeans [ 1 ]
s c a l e d S i g n a l s [ whichSetII , , 2 ] ←sweep( s i g n a l s [ whichSetII , , 2 ] , 2 , c o e f s I I 2 , ’/ ’
) + typeIIpeakMeans [ 2 ]
s c a l e d S i g n a l s [ s c a l e d S i g n a l s < 0 ] ← 0
# comput e r o b u s t e x p e r i m e n t a v e r a g e
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( verbose ) cat ( ’ Computing robust experiment−wise average \n ’ )
log2Centered ← log2 ( s c a l e d S i g n a l s + 1)
sexInd ← factor ( suppressWarnings ( getSex (mapToGenome( ob j e c t ) ) [ , 3 ] ) )
XYind ← which( f r e scoData$chromosome %in% c ( ’X ’ , ’Y ’ ) )
log2Standard ← apply ( log2Centered , c (1 , 3) , mean, tr im = . 1 )
i f ( nlevels ( sexInd ) == 2) {
mInd ← which( sexInd == ’M’ )
f Ind ← which( sexInd == ’F ’ )
log2StandardM ← log2StandardF ← log2Standard
log2StandardM [ XYind , ] ← apply ( log2Centered [ XYind , mInd , ] , c (1 , 3) , mean,
tr im = . 1 )
log2StandardF [ XYind , ] ← apply ( log2Centered [ XYind , fInd , ] , c (1 , 3) , mean,
tr im = . 1 )
}
# comput e d e v i a t i o n s f r om a v e r a g e −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( verbose ) cat ( ’ Computing d e v i a t i o n s from average \n ’ )
l og2Dev ia t i on s ← array (dim = dim( log2Centered ) )
for ( kk in 1 : 2 )
l og2Dev ia t i on s [ , , kk ] ← log2Centered [ , , kk ] − log2Standard [ , kk ]
i f ( nlevels ( sexInd ) == 2) {
for ( kk in 1 : 2 ) {
l og2Dev ia t i on s [ XYind , mInd , kk ] ← log2Centered [ XYind , mInd , kk ] −
log2StandardM [ XYind , kk ]
l og2Dev ia t i on s [ XYind , fInd , kk ] ← log2Centered [ XYind , fInd , kk ] −
log2StandardF [ XYind , kk ]
}
}
# w i n s o r i z e by p r o b e t y p e
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( useContro l s ) {
i f ( verbose ) cat ( ’ Winsor iz ing probes out o f p r e d i c t i o n range \n ’ )
GC[ whichSetI ] ← winsor izeBySubset (GC, whichSetI , whichContro l s I )
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GC[ whichSet I I ] ← winsor izeBySubset (GC, whichSetII , wh ichContro l s I I )
for ( kk in 1 : 2 ) {
log2Standard [ whichSetI , kk ] ← winsor izeBySubset ( log2Standard [ , kk ] ,
whichSetI , whichContro l s I )
log2Standard [ whichSetII , kk ] ← winsor izeBySubset ( log2Standard [ , kk ] ,
whichSetII , wh ichContro l s I I )
}
}
# c r e a t e i n d e p e n d e n t v a r i a b l e d a t a f r am e f o r l o e s s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
indepVars ← data . frame (GC = GC, UMavg = log2Standard [ , 1 ] , Mavg = log2Standard [ ,
2 ] )
i f ( nlevels ( sexInd ) == 2) {
indepVarsM ← data . frame (GC = GC, UMavg = log2StandardM [ , 1 ] , Mavg =
log2StandardM [ , 2 ] )
indepVarsF ← data . frame (GC = GC, UMavg = log2StandardF [ , 1 ] , Mavg =
log2StandardF [ , 2 ] )
}
# f i t l o e s s s u r f a c e s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
i f ( verbose ) cat ( ’ F i t t i n g & sub t ra c t i ng out l o e s s \n ’ )
i f ( nlevels ( sexInd ) == 1) {
i f ( verbose ) cat ( ’ Normal iz ing type I probes \n ’ )
typeInormed ← apply ( l og2Dev iat ions , c (2 , 3) , funLoessSS ,
indepVars = indepVars , whichControls = whichControlsI ,
whichSet = whichSetI , smoothingParameter = loessSpan )
i f ( verbose ) cat ( ’ Normal iz ing type I I probes \n ’ )
typeIInormed ← apply ( l og2Dev iat ions , c (2 , 3) , funLoessSS ,
indepVars = indepVars , whichControls = whichContro l s I I ,
whichSet = whichSetII , smoothingParameter = loessSpan )
est imatedErrorVar ← l i s t ( typeInormed , typeIInormed )
return ( est imatedErrorVar )
}
i f ( nlevels ( sexInd ) == 2) {
i f ( verbose ) cat ( ’ Normal iz ing type I probes \n ’ )
typeInormed ← typeIInormed ← array (dim = c (3 , dim( l og2Dev ia t i on s ) [ 2 ] , 2) )
# t y p e I
typeInormed [ , mInd , ] ← apply ( l og2Dev ia t i on s [ , mInd , ] , c (2 , 3) , funLoessSS ,
indepVars = indepVarsM , whichControls =
whichControlsI ,
whichSet = whichSetI , smoothingParameter =
loessSpan )
typeInormed [ , f Ind , ] ← apply ( l og2Dev ia t i on s [ , f Ind , ] , c (2 , 3) , funLoessSS ,
indepVars = indepVarsF , whichControls =
whichControlsI ,
whichSet = whichSetI , smoothingParameter =
loessSpan )
# t y p e I I
i f ( verbose ) cat ( ’ Normal iz ing type I I probes \n ’ )
typeIInormed [ , mInd , ] ← apply ( l og2Dev ia t i on s [ , mInd , ] , c (2 , 3) , funLoessSS ,
indepVars = indepVarsM , whichControls =
whichContro l s I I ,
whichSet = whichSetII , smoothingParameter =
loessSpan )
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typeIInormed [ , f Ind , ] ← apply ( l og2Dev ia t i on s [ , f Ind , ] , c (2 , 3) , funLoessSS ,
indepVars = indepVarsF , whichControls =
whichContro l s I I ,
whichSet = whichSetII , smoothingParameter =
loessSpan )
est imatedErrorVar ← l i s t ( typeInormed , typeIInormed )
return ( est imatedErrorVar )
}
}
# d e c l a r e l o e s s f u n c t i o n
funLoessSS ← function (y , indepVars , whichControls , whichSet , smoothingParameter ) {
modelDat ← as . data . frame (cbind (y , indepVars ) )
tempFit ← l o e s s ( y ∼ GC ∗ Mavg ∗ UMavg, trace . hat = ’ approx ’ , span =
smoothingParameter ,
modelDat , subset = whichControls )
traceL ← tempFit$trace . hat
sigma2 ← sum( tempFit$residuals ˆ2)/ ( tempFit$n − 1)
a i c c ← log ( sigma2 ) + 1 + 2 ∗ (2 ∗ ( traceL + 1) )/ ( tempFit$n − traceL − 2)
gcv ← tempFit$n ∗ sigma2/ ( tempFit$n − traceL ) ˆ2
r2 ← cor ( tempFit$y , tempFit$f itted ) ˆ2
return (c ( a i cc , gcv , r2 ) )
}
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# ’
# ’ @param o b j e c t \ c o d e {Me t h y l S e t } o b j e c t
# ’ @param s d T h r e s h o l d S t a n d a r d d e v i a t i o n cu t− o f f f o r f i l t e r i n g e m p i r i c a l c o n t r o l s
# ’
# ’ @ e xp o r t e m p i r i c a l C o n t r o l C o v e r a g e
empir i ca lContro lCoverage ← function ( object , sdThreshold = . 1 5 ) {
i f ( ! i s ( object , ” MethylSet ” ) ) stop ( ” ’ ob ject ’ needs to be a ’ MethylSet ’ ” )
data ( f r e scoData )
# c r e a t e o b j e c t f o r m e t h y l a t e d and u nm e t h y l a t e d c h a n n e l s −−−−−−−−−−−−−−−−−−
methTmp ← getMeth ( ob j e c t )
probeIDs ← rownames(methTmp)
s i g n a l s ← array (dim = c (dim(methTmp) , 2) )
s i g n a l s [ , , 1 ] ← getUnmeth ( ob j e c t )
s i g n a l s [ , , 2 ] ← methTmp
fre scoData ← f r e scoData [match( probeIDs , rownames( f r e scoData ) ) , ]
GC← f r e scoData$targetGC
log2Centered ← apply ( log2 ( s i g n a l s + 1) , c (1 , 3) , mean)
# f i l t e r c o n t r o l s and c r e a t e i n d i c a t o r v a r i a b l e s −−−−−−−−−−−−−−−−−−−−−−−−−−
probeSD ← rowSds ( getBeta ( ob j e c t ) )
f r e scoData$ eContro l s [ probeSD > sdThreshold ] ← NA
typeI ← which( f r e scoData$probeType == ’ I ’ )
t ype I I ← which( f r e scoData$probeType == ’ I I ’ )
hemEC ← which( f r e scoData$ eContro l s == ’ Hemimethylated ’ )
methEC ← which( f r e scoData$ eContro l s == ’ Methylated ’ )
umethEC ← which( f r e scoData$ eContro l s == ’ Unmethylated ’ )
par ( mfrow = c (2 , 3) )
contro lCex ← . 7
# t y p e I p r o b e s M & UM
smoothScatter ( log2Centered [ typeI , 2 : 1 ] , x lab = ’ log2 ( Methylated S igna l ) ’ ,
y lab = ’ log2 ( Unmethylated S igna l ) ’ )
points ( log2Centered [ intersect (methEC , typeI ) , 2 : 1 ] ,
pch = 16 , cex = controlCex , col = ’ red ’ )
points ( log2Centered [ intersect (umethEC , typeI ) , 2 : 1 ] ,
pch = 16 , cex = controlCex , col = ’ green ’ )
points ( log2Centered [ intersect (hemEC, typeI ) , 2 : 1 ] ,
pch = 16 , cex = controlCex , col = ’ ye l low ’ )
# t y p e I p r o b e s M & GC
smoothScatter ( log2Centered [ typeI , 2 ] , GC[ typeI ] ,
x lab = ’ log2 ( Methylated S igna l ) ’ ,
y lab = ’ Target GC Content ’ ,
main = ’Type I Probes ’ )
points ( log2Centered [ intersect (methEC , typeI ) , 2 ] ,
GC[ intersect (methEC , typeI ) ] ,
pch = 16 , cex = controlCex , col = ’ red ’ )
points ( log2Centered [ intersect (umethEC , typeI ) , 2 ] ,
GC[ intersect (umethEC , typeI ) ] ,
pch = 16 , cex = controlCex , col = ’ green ’ )
points ( log2Centered [ intersect (hemEC, typeI ) , 2 ] ,
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GC[ intersect (hemEC, typeI ) ] ,
pch = 16 , cex = controlCex , col = ’ ye l low ’ )
# t y p e I UM & GC
smoothScatter ( log2Centered [ typeI , 1 ] , GC[ typeI ] ,
x lab = ’ log2 ( Unmethylated S igna l ) ’ ,
y lab = ’ Target GC Content ’ )
points ( log2Centered [ intersect (methEC , typeI ) , 1 ] ,
GC[ intersect (methEC , typeI ) ] ,
pch = 16 , cex = controlCex , col = ’ red ’ )
points ( log2Centered [ intersect (umethEC , typeI ) , 1 ] ,
GC[ intersect (umethEC , typeI ) ] ,
pch = 16 , cex = controlCex , col = ’ green ’ )
points ( log2Centered [ intersect (hemEC, typeI ) , 1 ] ,
GC[ intersect (hemEC, typeI ) ] ,
pch = 16 , cex = controlCex , col = ’ ye l low ’ )
# t y p e I I p r o b e s M & UM
smoothScatter ( log2Centered [ typeI I , 2 : 1 ] , x lab = ’ log2 ( Methylated S igna l ) ’ ,
y lab = ’ log2 ( Unmethylated S igna l ) ’ )
points ( log2Centered [ intersect (methEC , type I I ) , 2 : 1 ] ,
pch = 16 , cex = controlCex , col = ’ red ’ )
points ( log2Centered [ intersect (umethEC , type I I ) , 2 : 1 ] ,
pch = 16 , cex = controlCex , col = ’ green ’ )
points ( log2Centered [ intersect (hemEC, type I I ) , 2 : 1 ] ,
pch = 16 , cex = controlCex , col = ’ ye l low ’ )
# t y p e I I M & GC
smoothScatter ( log2Centered [ typeI I , 2 ] , GC[ type I I ] ,
x lab = ’ log2 ( Methylated S igna l ) ’ ,
y lab = ’ Target GC Content ’ ,
main = ’Type I I Probes ’ )
points ( log2Centered [ intersect (methEC , type I I ) , 2 ] ,
GC[ intersect (methEC , type I I ) ] ,
pch = 16 , cex = controlCex , col = ’ red ’ )
points ( log2Centered [ intersect (umethEC , type I I ) , 2 ] ,
GC[ intersect (umethEC , type I I ) ] ,
pch = 16 , cex = controlCex , col = ’ green ’ )
points ( log2Centered [ intersect (hemEC, type I I ) , 2 ] ,
GC[ intersect (hemEC, type I I ) ] ,
pch = 16 , cex = controlCex , col = ’ ye l low ’ )
# t y p e I I UM & GC
smoothScatter ( log2Centered [ typeI I , 1 ] , GC[ type I I ] ,
x lab = ’ log2 ( Unmethylated S igna l ) ’ ,
y lab = ’ Target GC Content ’ )
points ( log2Centered [ intersect (methEC , type I I ) , 1 ] ,
GC[ intersect (methEC , type I I ) ] ,
pch = 16 , cex = controlCex , col = ’ red ’ )
points ( log2Centered [ intersect (umethEC , type I I ) , 1 ] ,
GC[ intersect (umethEC , type I I ) ] ,
pch = 16 , cex = controlCex , col = ’ green ’ )
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points ( log2Centered [ intersect (hemEC, type I I ) , 1 ] ,
GC[ intersect (hemEC, type I I ) ] ,
pch = 16 , cex = controlCex , col = ’ ye l low ’ )
}
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# ’
# ’ @param o b j e c t \ c o d e {Me t h y l S e t } o b j e c t
# ’ @param s d T h r e s h o l d S t a n d a r d d e v i a t i o n cu t− o f f f o r f i l t e r i n g e m p i r i c a l c o n t r o l s
# ’
# ’ @ e xp o r t e m p i r i c a l C o n t r o l QA
empiricalControlQA ← function ( object , sdThreshold = . 1 5 ) {
i f ( ! i s ( object , ” MethylSet ” ) ) stop ( ” ’ ob ject ’ needs to be a ’ MethylSet ’ ” )
data ( f r e scoData )
# p u l l o u t c o n t r o l p r o b e s and g e t a v e r a g e −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
betaVals ← getBeta ( ob j e c t )
f r e scoData ← f r e scoData [match(rownames( betaVals ) , rownames( f r e scoData ) ) , ]
c on t ro l Ind ← which( ! i s .na( f r e scoData$ eContro l s ) )
con t ro l Ind ← intersect ( contro l Ind , which( rowSums( i s .na( betaVals ) ) == 0) )
means ← rowMeans ( betaVals [ contro l Ind , ] )
# p l o t s o r t e d c o n t r o l p r o b e s a s h e a t map −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
par ( mfrow = c (1 , 3) )
image( betaVals [ con t ro l Ind [ order ( means ) ] , ] , axes = FALSE,
main = ’ Empir ica l Control Probe QC’ ,
xlab = ’CpGs ordered by avg methylat ion ’ ,
y lab = ’ Samples ’ )
l ines ( seq (0 , 1 , length . out = length ( means ) ) ,
means [ order ( means ) ] , col = 1)
# p l o t c o n t r o l p r o b e s t a n d a r d d e v i a t i o n s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
contro lsSD ← rowSds ( betaVals [ con t ro l Ind [ order ( means ) ] , ] )
plot (density ( contro lsSD ) ,
main = ’ Empir ica l Control Probe Standard Dev iat ions ’ ,
x lab=’ Standard Deviat ion ’ )
abline ( v = sdThreshold )
cat (paste (sum( contro lsSD < sdThreshold ) , ’ o f ’ ,
length ( cont ro l Ind ) , ’ c o n t r o l s remaining ’ ) )
image( betaVals [ con t ro l Ind [ order ( means ) ] , ] [which( contro lsSD < sdThreshold ) , ] ,
axes = FALSE,
main = ’ F i l t e r e d Empir ica l Control Probes ’ ,
x lab = ’CpGs ordered by avg methylat ion ’ ,
y lab = ’ Samples ’ )
l ines ( seq (0 , 1 , length . out = length (which( contro lsSD < sdThreshold ) ) ) ,
means [ order ( means ) ] [which( contro lsSD < sdThreshold ) ] , col = 1)
}
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# ’
# ’ @param o b j e c t \ c o d e {Me t h y l S e t } o r \ c o d e { Ge n om i cR a t i o S e t } o b j e c t
# ’ @param r emoveCh romo some s A c h a r a c t e r s t r i n g o f c h r om o s e s t o r emove
# ’ @param f i l t e r C r o s s H y b F i l t e r a u t o s om a l p r o b e s t h a t c r o s s − h y b r i d i z e t o s e x
c h r omo s ome s ?
# ’ @param f i l t e r N A F i l t e r p r o b e s c o n t a i n i n g a t l e a s t on e NA?
# ’ @param f i l t e r S N P F i l t e r p r o b e s c o n t a i n i n g SNPs ?
# ’ @param m i n o r A l l e l e F r e q What i s t h e l a r g e s t m i n o r a l l e l e f r e q u e n c y we a r e
w i l l i n g t o t o l e r a t e ?
# ’ @param p o p u l a t i o n What p o p u l a t i o n s h o u l d be u s e d t o comput e m i n o r a l l e l e
f r e q u e n c y ?
# ’ D e f a u l t i s ’ A l l ’
# ’
# ’ @ e xp o r t f i l t e r C p G s
f i l t e rCpGs ← function ( object , removeChromosomes = NULL, f i l t e rC ro s s Hy b = TRUE,
f i l t e rNA = TRUE, f i l t e rSNP = TRUE,
minorAl l e l eFreq = 0 , populat ion = ’ Al l ’ ) {
i f (sum( ! c lass ( ob j e c t ) %in% c ( ” MethylSet ” , ”GenomicRatioSet” ) ) > 0) {
stop ( ” ’ ob ject ’ needs to be a ’ MethylSet ’ or ’ GenomicRatioSet ’ ” )
}
populationAF ← c ( ’ A l l ’ , ’ Af r i can ’ , ’ American ’ , ’ Asian ’ , ’ European ’ )
i f ( ! populat ion %in% populationAF ) {
stop ( ” populat ion ’ must be one o f : ’ All ’ , ’ Afr ican ’ , ’ American ’ , ’ Asian ’ , or ’
European ’ ” )
}
i f (sum( ! removeChromosomes %in% c ( ’X ’ , ’Y ’ , 1 : 22 ) ) > 0) {
stop ( ” ’ removeChromosomes ’ needs to be a l i s t o f
chromosomes to remove e . g . c ( ’X’ , ’ 1 ’ ) ” )
}
data ( f r e scoData )
removeProbes ← NULL
i f ( i s ( object , ’ MethylSet ’ ) ) probeIDs ← rownames( getMeth ( ob j e c t ) )
i f ( i s ( object , ’ GenomicRatioSet ’ ) ) probeIDs ← rownames( getM( ob j e c t ) )
f r e scoData ← f r e scoData [match( probeIDs , rownames( f r e scoData ) ) , ]
i f ( length ( removeChromosomes ) > 0) {
removeProbes ← c ( removeProbes , probeIDs [which( f r e scoData$chromosome %in%
removeChromosomes ) ] )
}
i f ( f i l t e r Cr o s s Hy b ) {
removeProbes ← c ( removeProbes , probeIDs [which( f r e scoData$crossHyb ) ] )
}
i f ( f i l t e rNA ) {
NAind ← probeIDs [which( rowSums( i s .na( getBeta ( ob j e c t ) ) ) > 0) ]
removeProbes ← c ( removeProbes , probeIDs [ NAind ] )
}
i f ( f i l t e rSNP ) {
AFtype ← match( populat ion , populationAF ) + 4
SNPind ← which( f r e scoData [ , AFtype ] > minorAl l e l eFreq )
removeProbes ← c ( removeProbes , probeIDs [ SNPind ] )
}
removeProbes ← unique ( removeProbes )
keepCpGs ← setd i f f ( probeIDs , removeProbes )
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i f ( i s ( object , ’ MethylSet ’ ) ) {
out ← ob j e c t
assayDataElement ( out , ’Unmeth ’ ) ← getUnmeth ( ob j e c t ) [ keepCpGs , ]
assayDataElement ( out , ’Meth ’ ) ← getMeth ( ob j e c t ) [ keepCpGs , ]
return ( out )
}
i f ( i s ( object , ’ GenomicRatioSet ’ ) ) {
out ← GenomicRatioSet ( gr = rowData ( ob j e c t ) [ keepCpGs ] ,
Beta = NULL,
M = getM( ob j e c t ) [ keepCpGs , ] ,
CN = getCN( ob j e c t [ keepCpGs , ] ) ,
pData = pData ( ob j e c t ) ,
annotat ion = annotat ion ( ob j e c t ) ,
preprocessMethod = preprocessMethod ( ob j e c t ) )
return ( out )
}
}
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# ’
# ’ @param o b j e c t a \ c o d e {Me t h y l S e t } o b j e c t
# ’ @param u s e C o n t r o l s S h o u l d e m p i r i c a l c o n t r o l s be u s e d t o a l i g n and f i t l o e s s
s u r f a c e s ?
# ’ @param l o e s s S p a n Supp l y v e c t o r o f p o s s i b l e s p a n s f o r f i t t i n g l o e s s s u r f a c e
# ’ @param s d T h r e s h o l d T h r e s h o l d t o f i l t e r e m p i r i c a l c o n t r o l s by s t a n d a r d d e v i a t i o n
# ’
# ’ @ e xp o r t p l o t F i t S t a t s
p l o t F i t S t a t s ← function ( object , useContro l s = TRUE,
loessSpan = seq ( . 0 5 , . 9 5 , . 1 5 ) , sdThreshold = . 1 5 ) {
i f ( ! i s ( object , ” MethylSet ” ) ) stop ( ” ’ ob ject ’ needs to be a ’ MethylSet ’ ” )
f i t s t a t s ← l i s t ( )
# g e n e r a t e f i t s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
for ( i i in 1 : length ( loes sSpan ) ) {
f i t s t a t s [ [ i i ] ] ← r e t u r n F i t S t a t s ( object , useContro l s = useContro ls ,
l oes sSpan = loessSpan [ i i ] , sdThreshold =
sdThreshold )
cat ( i i , ’ o f ’ , length ( loes sSpan ) , ’ \n\n ’ )
}
par ( mfrow = c ( 2 , 2 ) )
# g e n e r a t e g c v c u r v e s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
chType ← c ( ’UM’ , ’M’ )
statType ← c ( ’AICC ’ , ’GCV’ , ’Rˆ2 ’ )
for ( t h i s S t a t in 1 : 3 ) {
for ( probeType in 1 : 2 ) {
for ( channelType in 1 : 2 ) {
gcvCurves ← NULL
for ( i i in 1 : length ( f i t s t a t s ) )
gcvCurves ← cbind ( gcvCurves , f i t s t a t s [ [ i i ] ] [ [ probeType ] ] [ th i sS ta t , ,
channelType ] )
matplot ( loessSpan , t ( gcvCurves ) , type=’ l ’ ,
main = paste ( ’Type ’ , probeType , ’ : ’ ,
chType [ channelType ] , ’ channel : ’ ,
statType [ t h i s S t a t ] , sep = ’ ’ )
)
}
}
}
}
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Appendix C
CODE FROM R PACKAGE GDI
# D e f i n e −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
# ’ @ e x p o r t C l a s s GDset
se tOldClass ( ’ f f d f ’ )
se tOldClass ( ” data . frame” )
setClassUnion ( ” data . frameORffdf ” , c ( ” data . frame” , ” f f d f ” ) )
s e t C l a s s ( ”GDset” ,
s l o t s = c ( dat = ’ data . frameORffdf ’ ,
annot = ”GRanges” ,
pheno = ’ data . frame ’ ,
p lat form = ” charac t e r ”
) )
# V a l i d a t e −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
. val idGDset ← function ( ob j e c t ) {
# Re q u i r e d a n n o t a t i o n c o l umn s
annot . req ← c ( en t r e z . id = ” charac t e r ” )
# Check f o r r e q u i r e d a n n o t a t i o n co l umn ( s )
md ← mcols ( object@annot )
i f ( ! a l l (names( annot . req ) %in% names(md) ) ) {
stop ( ”GDset s l o t ’ annot ’ must conta in a l l o f the f o l l o w i n g columns :\n” ,
paste (names( annot . req ) , c o l l a p s e = ”\n” ) , ca l l . = FALSE)
}
# Check t h a t a n n o t a t i o n ma t c h e s d a t a
i f ( ! i d e n t i c a l (rownames( object@dat ) , names( object@annot ) ) ) {
stop ( ”Names o f ’ annot ’ must match rownames o f ’ experimentData ’ ” , ca l l . = FALSE
)
}
# Check t h a t meta d a t a ma t c h e s d a t a
i f ( ! i d e n t i c a l (colnames ( object@dat ) , rownames( object@pheno ) ) ) {
stop ( ” colnames o f ’ dat ’ must match rownames o f ’ pheno ’ ” )
}
return (TRUE)
}
s e t V a l i d i t y ( ”GDset” , . val idGDset )
# C o n s t r u c t o r s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
GDset ← function ( dat , annot , pheno , p lat form ) {
new( ”GDset” ,
dat = dat ,
pheno = pheno ,
p lat form = platform ,
annot = annot )
}
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# A c c e s s o r s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
# ’ @exp o r t g e t P l a t f o r m
setMethod ( ” getPlat form ” , ”GDset” , function ( ob j e c t ) object@plat form )
# ’ @exp o r t g e tAnn o t
setMethod ( ”getAnnot” , ”GDset” , function ( ob j e c t ) object@annot )
# ’ @exp o r t g e t P h e n o
setMethod ( ”getPheno” , ”GDset” , function ( ob j e c t ) object@pheno )
# ’ @exp o r t g e tD a t
setMethod ( ”getDat” , ”GDset” , function ( ob j e c t ) object@dat )
setMethod ( ” [ ” , c ( ”GDset” , ”ANY” , ”ANY” ) ,
function (x , i , j , . . . , drop = FALSE) {
new . dat ← x@dat [ i , j , drop=FALSE]
new( ”GDset” , annot = x@annot [ i ] ,
dat = new . dat ,
pheno = x@pheno [ j , , drop=FALSE] ,
p lat form = x@platform )
})
setMethod ( ” [ ” , c ( ”GDset” , ” miss ing ” , ”ANY” ) ,
function (x , i , j , . . . , drop = FALSE) {
new . dat ← new . dat ← x@dat [ , j , drop=FALSE]
new( ”GDset” , annot = x@annot ,
dat = new . dat ,
pheno = x@pheno [ j , , drop=FALSE] ,
p lat form = x@platform )
})
setMethod ( ” [ ” , c ( ”GDset” , ”ANY” , ” miss ing ” ) ,
function (x , i , j , . . . , drop = FALSE) {
new . dat ← x@dat [ i , , drop=FALSE]
new( ”GDset” , annot = x@annot [ i ] ,
dat = new . dat ,
pheno = x@pheno [ , , drop=FALSE] ,
p lat form = x@platform )
})
# Summar i e s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
setMethod ( ”show” , ”GDset” , function ( ob j e c t ) {
cat ( ”A GDset ob j e c t \n” )
cat ( ” Platform : ” , object@platform , ”\n” )
cat ( ”Data conta in s : \n” )
cat ( ” ” , nrow( object@dat ) , ” l o c i \n” )
cat ( ” ” , ncol ( object@dat ) , ” samples \n” )
cat ( ”With” , ncol ( object@pheno ) , ” Covar ia tes :\n” )
cat (colnames ( object@pheno ) , ’ \n ’ )
})
setMethod ( ”dim” , ”GDset” , function ( x ) {
c ( l o c i = nrow( x@dat ) , samples = ncol ( x@dat ) )
})
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# D e f i n e −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
# ’ @ e x p o r t C l a s s GDI s e t
s e t C l a s s ( ”GDIset” , s l o t s = c ( s e t1 = ”GDset” , s e t2 = ”GDset” ) )
# V a l i d a t e −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
. va l idGDIset ← function ( ob j e c t ) {
i f ( ! i d e n t i c a l ( object@set1@pheno , object@set2@pheno ) )
stop ( ” ’ pheno ’ must match between GDsets” , ca l l . = FALSE)
return (TRUE)
}
s e t V a l i d i t y ( ”GDIset” , . val idGDIset )
# C o n s t r u c t o r s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
GDIset ← function (x , y ) {
new( ”GDIset” , s e t1 = x , s e t2 = y )
}
# A c c e s s o r s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
# ’ @expo r tMe thod g e t P h e n o
setMethod ( ”getPheno” , ”GDIset” , function ( ob j e c t ) object@set1@pheno )
# ’ @expo r tMe thod g e tD a t
setMethod ( ”getDat” , ”GDIset” , function ( ob j e c t ) {
out ← l i s t ( object@set1@dat , object@set2@dat )
names( out ) ← c ( object@set1@platform , object@set2@plat form )
out
})
# ’ @expo r tMe thod g e t P l a t f o r m
setMethod ( ” getPlat form ” , ”GDIset” , function ( ob j e c t ) {
l i s t ( s e t1 = object@set1@platform , s e t2 = object@set2@plat form ) })
# ’ @expo r tMe thod g e tAnn o t
setMethod ( ”getAnnot” , ”GDIset” , function ( ob j e c t ) {
out ← l i s t ( object@set1@annot , object@set2@annot )
names( out ) ← c ( object@set1@platform , object@set2@plat form )
out
})
setMethod ( ” [ ” , c ( ”GDIset” , ”ANY” , ”ANY” ) , function (x , i , j , . . . , drop = FALSE) {
i f ( ! i s ( i , ’ cha rac t e r ’ ) ) {
stop ( ’Row index must be a vec to r o f en t r e z i d s ’ )
} else {
print ( ’ P lease make sure you are s u b s e t t i n g by ent r e z id ’ )
}
GDset1 ← x@set1 [which( x@set1@annot$ ent r e z . id %in% i ) , j ]
GDset2 ← x@set2 [which( x@set2@annot$ ent r e z . id %in% i ) , j ]
new( ”GDIset” , s e t1 = GDset1 , s e t2 = GDset2 )
})
setMethod ( ” [ ” , c ( ”GDIset” , ” miss ing ” , ”ANY” ) , function (x , i , j , . . . , drop = FALSE)
{
GDset1 ← x@set1 [ , j ]
GDset2 ← x@set2 [ , j ]
new( ”GDIset” , s e t1 = GDset1 , s e t2 = GDset2 )
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})
setMethod ( ” [ ” , c ( ”GDIset” , ”ANY” , ” miss ing ” ) , function (x , i , j , . . . , drop = FALSE)
{
i f ( ! i s ( i , ’ cha rac t e r ’ ) ) {
stop ( ’Row index must be a vec to r o f en t r e z i d s ’ )
} else {
print ( ’ P lease make sure you are s u b s e t t i n g by ent r e z id ’ )
}
GDset1 ← x@set1 [which( x@set1@annot$ ent r e z . id %in% i ) , ]
GDset2 ← x@set2 [which( x@set2@annot$ ent r e z . id %in% i ) , ]
new( ”GDIset” , s e t1 = GDset1 , s e t2 = GDset2 )
})
ge tSet ← function ( object , whichset = 1) {
i f ( ! i s ( object , ”GDIset” ) )
stop ( ” ob j e c t must be a ’ GDIset ’ ” )
i f ( whichset == 1) return ( ob ject@set1 )
i f ( whichset == 2) return ( ob ject@set2 )
}
# Summar i e s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
setMethod ( ”show” , ”GDIset” , function ( ob j e c t ) {
cat ( ”A GDIset ob j e c t conta in ing \n\n” )
print ( ob ject@set1 )
cat ( ”\n\n” )
print ( ob ject@set2 )
})
setMethod ( ”dim” , ”GDIset” , function ( x ) {
out ← l i s t (c ( l o c i = nrow( x@set1@dat ) , samples = ncol ( x@set1@dat ) ) ,
c ( l o c i = nrow( x@set2@dat ) , samples = ncol ( x@set2@dat ) ) )
names( out ) ← getPlat form ( x )
out
})
# c o n s o l i d a t e GDI s e t −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
c o n s o l i d a t e ← function ( ob j e c t ) {
i f ( ! i s ( object , ”GDIset” ) ) stop ( ” ob j e c t needs to be a ’ GDIset ’ ” )
genes ← lapply ( getAnnot ( ob j e c t ) , function ( x ) x$ ent r e z . id )
has . both ← intersect ( genes [ [ 1 ] ] , genes [ [ 2 ] ] )
s e t1 . i n c lude ← which( genes [ [ 1 ] ] %in% has . both )
s e t2 . i n c lude ← which( genes [ [ 2 ] ] %in% has . both )
s e t1 . annot ← object@set1@annot [ s e t1 . i n c lude ]
s e t2 . annot ← object@set2@annot [ s e t2 . i n c lude ]
subs1 ← 1 :nrow( object@set1@dat ) %in% se t1 . i n c lude
subs2 ← 1 :nrow( object@set2@dat ) %in% se t2 . i n c lude
s e t1 . dat ← subset ( object@set1@dat , subset=subs1 )
s e t2 . dat ← subset ( object@set2@dat , subset=subs2 )
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rownames( s e t1 . dat ) ← rownames( object@set1@dat ) [ s e t1 . i n c lude ]
rownames( s e t2 . dat ) ← rownames( object@set2@dat ) [ s e t2 . i n c lude ]
GDset1 ← GDset ( dat = se t1 . dat ,
annot = se t1 . annot ,
pheno = object@set1@pheno ,
p lat form = object@set1@plat form )
GDset2 ← GDset ( dat = se t2 . dat ,
annot = se t2 . annot ,
pheno = object@set2@pheno ,
p lat form = object@set2@plat form )
GDIset ( GDset1 , GDset2 )
}
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### c r o s s c o v a r i a n c e t e s t
ccaTest ← function ( object , npcs = 5 , min . s e t 1 =5, min . s e t 2 =3, cc . pvalue . th r e sho ld
=.1){
i f ( ! i s ( object , ’ GDIset ’ ) ) stop ( ” ob j e c t must be a ’ GDIset ’ ” )
# comb i n e d a t a s e t s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
s e t1 . df ← object@set1@dat
i f ( i s ( object@set1@dat , ’ f f d f ’ ) ) {
s e t1 . df$set ← f f ( factor ( rep ( ’ s e t 1 ’ , nrow( s e t1 . df ) ) ) )
} else {
s e t1 . df$set ← factor ( rep ( ’ s e t 1 ’ , nrow( s e t1 . df ) ) )
}
s e t2 . df ← object@set2@dat
i f ( i s ( object@set2@dat , ’ f f d f ’ ) ) {
s e t2 . df$set ← f f ( factor ( rep ( ’ s e t 2 ’ , nrow( s e t2 . df ) ) ) )
} else {
s e t2 . df$set ← factor ( rep ( ’ s e t 2 ’ , nrow( s e t2 . df ) ) )
}
i f ( i s ( s e t1 . df , ’ f f d f ’ ) & is ( s e t2 . df , ’ f f d f ’ ) ) {
f u l l . set ← f fd fappend ( s e t1 . df , s e t 2 . df )
} else {
f u l l . set ← rbind (as . data . frame ( s e t1 . df ) , as . data . frame ( s e t2 . df ) )
}
# do a n a l y s i s g r o u p e d by g e n e −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
ent r e z . i d s ← c ( object@set1@annot$ ent r e z . id , object@set2@annot$ ent r e z . id )
i d s . in . both ← intersect ( object@set1@annot$ ent r e z . id , object@set2@annot$ ent r e z . id
)
unique . i d s ← unique ( i d s . in . both )
ind ← 1
out . return ← l i s t ( )
# ou t ← f o r e a c h ( g e n e = u n i q u e . i d s , . p a c k a g e s = ’ gd i ’ ) %do% {
for ( gene in unique . i d s ) {
cat ( gene , ’ ’ , ind )
dat ← f u l l . set [which( en t r e z . i d s == gene ) , ]
n . s i t e s ← table ( dat$set )
s e t1 ← as .matrix ( dat [ dat$set == ’ se t1 ’ , −ncol ( dat ) ] )
s e t2 ← as .matrix ( dat [ dat$set == ’ se t2 ’ , −ncol ( dat ) ] )
s e t1 ← apply ( set1 , 1 , na2mean )
s e t2 ← apply ( set2 , 1 , na2mean )
i f (n . s i t e s [ 1 ] < min . s e t 1 | n . s i t e s [ 2 ] < min . s e t 2 ) {
out . return [ [ gene ] ] ← NA
cat ( ’ omitted ’ )
} else {
# p e r f o rm PCA f o r e a c h s e t
pca . s e t1 ← prcomp ( s e t1 )
pca . s e t2 ← prcomp ( s e t2 )
# do CCA on PC s c o r e s
cc . r e s ← cancor ( pca . s e t1$x [ , 1 : npcs ] , pca . s e t2$x [ , 1 : npcs ] )
# do LRT w/ b a r t l e t t c o r r e c t i o n f o r CCA
n ← nrow( s e t1 )
cc . rho2 ← rev ( cc . r e s$cor ˆ2)
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t e s t . stat ← (−1)∗ (n − 1 − . 5 ∗ ( npcs + npcs + 1) ) ∗ log (cumprod(1 − cc . rho2 )
)
df ← ( npcs − length ( cc . rho2 ) : 1 + 1 ) ∗ ( npcs − length ( cc . rho2 ) : 1 + 1 )
p . va lue ← (1 − pchisq ( t e s t . stat , df ) )
t e s t . stat ← rev ( t e s t . stat )
df ← rev (df )
p . va lue ← rev (p . va lue )
n . c c s ← npcs
# comput e c a n o n i c a l c o v a r i a t e s c o r e s and l o a d i n g s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
s e t1 . s c o r e s ← pca . s e t1$x [ , 1 : npcs , drop=FALSE] %∗% cc . r e s$xcoe f [ , 1 : n . ccs ,
drop=FALSE]
s e t2 . s c o r e s ← pca . s e t2$x [ , 1 : npcs , drop=FALSE] %∗% cc . r e s$ycoe f [ , 1 : n . ccs ,
drop=FALSE]
s e t1 . l oads ← cor ( set1 , s e t1 . s c o r e s )
s e t2 . l oads ← cor ( set2 , s e t2 . s c o r e s )
# r e d u n d a n c y i n d e x
dat2cc . s e t1 ← colSums ( ( co lVars ( s e t1 ) ∗ s e t1 . l oads ˆ2)/sum( co lVars ( s e t1 ) ) )
dat2cc . s e t2 ← colSums ( ( co lVars ( s e t2 ) ∗ s e t2 . l oads ˆ2)/sum( co lVars ( s e t2 ) ) )
s e t1 . redundancy ← dat2cc . s e t1∗ ( cc . r e s$cor ˆ2) [ 1 : n . c c s ]
s e t2 . redundancy ← dat2cc . s e t2∗ ( cc . r e s$cor ˆ2) [ 1 : n . c c s ]
# c o n s o l i d a t e r e s u l t s i n t o a l i s t −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
output ← l i s t ( )
output$ t e s t . r e s u l t s ← cbind ( ch i sq stat=t e s t . stat ,
df=df ,
p va lue=p . value ,
s e t1 r2=se t1 . redundancy ,
s e t2 r2=se t2 . redundancy )
output$ l o ad ing s ← l i s t ( )
output$ l o ad ing s$ s e t1 ← s e t1 . l oads
output$ l o ad ing s$ s e t2 ← s e t2 . l oads
output$ s c o r e s ← l i s t ( )
output$ s c o r e s$ s e t1 ← s e t1 . s c o r e s
output$ s c o r e s$ s e t2 ← s e t2 . s c o r e s
out . return [ [ gene ] ] ← output
}
ind ← ind + 1
cat ( ’ \n ’ )
}
# c o n s o l i d a t e r e s u l t s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
out . f i n a l ← l i s t ( )
# t e s t i n g r e s u l t s
out . f i n a l $ t e s t i n g . r e s u l t s ← lapply ( out . return , function ( x ) {
i f ( ! i s .na( x ) ) {
x$ t e s t . r e s u l t s
} else {
rep (NA, 5)
}
})
# s e t 1 c c s c o r e s
out . f i n a l $ s e t1 . s c o r e s ← lapply ( out . return , function (x , n . c ) {
i f ( ! i s .na( x ) ) {
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x$ s c o r e s$ s e t1
} else {
rep (NA, n . c )
}
} , n . c=dim( f u l l . set ) [ 2 ] )
# s e t 2 c c s c o r e s
out . f i n a l $ s e t2 . s c o r e s ← lapply ( out . return , function (x , n . c ) {
i f ( ! i s .na( x ) ) {
x$ s c o r e s$ s e t2
} else {
rep (NA, n . c )
}
} , n . c=dim( f u l l . set ) [ 2 ] )
# s e t 1 l o a d i n g s
out . f i n a l $ s e t1 . l o ad ing s ← lapply ( out . return , function ( x ) {
i f ( ! i s .na( x ) ) {
x$ l o ad ing s$ s e t1
} else {
NA
}
})
# s e t 2 l o a d i n g s
out . f i n a l $ s e t2 . l o ad ing s ← lapply ( out . return , function ( x ) {
i f ( ! i s .na( x ) ) {
x$ l o ad ing s$ s e t2
} else {
NA
}
})
out . f i n a l
}
na2mean ← function ( x ) {
x [ i s .na( x ) ] ← mean(na . omit ( x ) )
return ( x )
}
pca ← function ( x ) prcomp ( t ( x [ , −ncol ( x ) ] ) )
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permTest ← function ( object , cca . r e s u l t s = NULL, n . perm = 1000 , h a l f . l i f e = 400) {
i f ( ! i s ( object , ’ GDIset ’ ) ) stop ( ” ob j e c t must be a ’ GDIset ’ ” )
i f ( ! i s . null ( cca . r e s u l t s ) ) {
cat ( ’ Performing permutation t e s t on communal it ies \n ’ )
i n c l . ind ← which( unlist ( lapply ( cca . r e s$ t e s t i n g . r e s u l t s , function ( x ) ! i s .na( x
[ 1 ] ) ) ) )
unique . i d s ← names( cca . r e s u l t s $ t e s t i n g . r e s u l t s ) [ i n c l . ind ]
} else {
cat ( ’ Performing permutation t e s t on R−squared va lue s \n ’ )
s e t1 .names ← names( table ( getAnnot ( ob j e c t ) [ [ 1 ] ] $ ent r e z . id ) > 3)
s e t2 .names ← names( table ( getAnnot ( ob j e c t ) [ [ 2 ] ] $ ent r e z . id ) > 3)
unique . i d s ← intersect ( getAnnot ( ob j e c t ) [ [ 1 ] ] $ ent r e z . id ,
getAnnot ( ob j e c t ) [ [ 2 ] ] $ ent r e z . id )
}
out ← f o r each ( gene=unique . ids , . packages=’ gdi ’ , . combine=’ c ’ ) %dopar% {
# g e t l o c a t i o n s o f s i t e s
s e t1 . ind ← which( object@set1@annot$ ent r e z . id %in% gene )
s e t1 . l o c ← (end( object@set1@annot [ s e t1 . ind ] ) + start ( object@set1@annot [ s e t1 .
ind ] ) )/2
names( s e t1 . l o c ) ← names( object@set1@annot [ s e t1 . ind ] )
s e t2 . ind ← which( object@set2@annot$ ent r e z . id %in% gene )
s e t2 . l o c ← (end( object@set2@annot [ s e t2 . ind ] ) + start ( object@set2@annot [ s e t2 .
ind ] ) )/2
names( s e t2 . l o c ) ← names( object@set2@annot [ s e t2 . ind ] )
i f ( ! i s . null ( cca . r e s u l t s ) ) {
# s a v e c o mm u n a l i t i e s w i t h s h o r t v a r i a b l e names
s e t1 .comm ← cca . r e s u l t s $ s e t1 . l o ad ing s [ [ gene ] ] [ , 1 , drop=FALSE]ˆ2
s e t2 .comm ← cca . r e s u l t s $ s e t2 . l o ad ing s [ [ gene ] ] [ , 1 , drop=FALSE]ˆ2
# g e t o u t e r p r o d u c t o f c o mm u n a l i t i e s
comm. outer ← s e t1 .comm %∗% t ( s e t2 .comm)
} else {
# comput e Rˆ2 m a t r i x f r om a c t u a l d a t a
comm. outer ← cor ( t ( object@set1@dat [ s e t1 . ind , ] ) ,
t ( object@set2@dat [ s e t2 . ind , ] ) ) ˆ2
}
# g e t d i s t a n c e m a t r i x
d i s t .mat ← matrix ( s e t1 . loc , nr = length ( s e t1 . l o c ) ,
nc=length ( s e t2 . l o c ) )
d i s t .mat ← abs (sweep( d i s t .mat , 2 , s e t2 . loc , ’− ’ ) )
# ap p l y e x p o n e n t i a l d e c a y f u n c t i o n t o g e t w e i g h t s
lambda ← log (2 )/h a l f . l i f e
weight .mat ← exp(−d i s t .mat∗lambda )
obs . stat ← sum(comm. outer ∗ weight .mat)
# pe rmu t e w e i g h t s and comput e s t a t s
perm . s t a t s ← numeric (n . perm )
for ( j j in 1 : n . perm ) {
perm . s t a t s [ j j ] ← sum(comm. outer ∗ weight .mat [ sample (nrow( weight .mat) ) , ] [ ,
sample (ncol ( weight .mat) ) ] )
}
perm . pval ← sum( perm . s t a t s > obs . stat )/n . perm
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perm . pval
}
names( out ) ← unique . i d s
out
}
180
Appendix D
CODE FOR CHAPTER 3 SIMULATION STUDIES
l ibrary ( f o r each )
l ibrary (doMC)
# S i m u l a t i o n t o t e s t f o r t y p e I e r r o r −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
# s e t s i m u l a t i o n p a r am e t e r s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
n ← c (26 , 50 , 100 , 200 , 500) # number o f s am p l e s w i t h mat ch ed d a t a
l o c i 1 ← 30 # number o f CpG s i t e s
l o c i 2 ← 8 # number o f e x o n s
rho1 ← . 25 # n u l l CpG c o r r e l a t i o n f o r compound
symmet ry c o v a r i a n c e
rho2 ← −.0678 # n u l l e x on c o r r e l a t i o n f o r compound
symmet ry c o v a r i a n c e
s l ope1 ← . 00313/ ( l o c i 1 −1) # s l o p e t o s p an r a n g e o f CpG v a r i a n c e s
i n t e r c e p t 1 ← .000437 # i n t e r c e p t t o s p an r a n g e o f CpG v a r i a n c e s
s l ope2 ← . 158/ ( l o c i 2 −1) # s l o p e t o s p an r a n g e o f e x on v a r i a n c e s
i n t e r c e p t 2 ← . 086 # i n t e r c e p t t o s p an r a n g e o f e x on v a r i a n c e s
npcs ← c (1 , 3 , 5 , 10 , 15) # number o f PCs t o k e e p a f t e r PCA f o r CCA
s t e p
n . sims ← 1e5 # number o f s i m s f o r e a c h param combo
n . co r e s ← f loor (2∗detectCores ( )/3)
registerDoMC (n . co r e s )
r e s u l t s ← f o r each (n . i i = n , . packages=’MASS ’ ) %dopar% {
cat ( ’ s t a r t e d ’ , n . i i , ’ . . . \ n ’ )
compute . typeI ← function (x , n , n . sim ) {
mean1 ← numeric ( x [ 1 ] )
mean2 ← numeric ( x [ 2 ] )
sigma1 ← matrix ( x [ 3 ] , nr = x [ 1 ] , nc = x [ 1 ] )
sigma2 ← matrix ( x [ 4 ] , nr = x [ 2 ] , nc = x [ 2 ] )
diag ( sigma1 ) ← ( 1 :nrow( sigma1 )−1) ∗ x [ 5 ] + x [ 7 ]
diag ( sigma2 ) ← ( 1 :nrow( sigma2 )−1) ∗ x [ 6 ] + x [ 8 ]
for ( i i in 1 :nrow( sigma1 ) ) {
for ( j j in 1 :nrow( sigma1 ) ) {
i f ( i i != j j ) sigma1 [ i i , j j ] ← sigma1 [ i i , j j ] ∗sqrt ( sigma1 [ i i , i i ] ) ∗sqrt (
sigma1 [ j j , j j ] )
}
}
for ( i i in 1 :nrow( sigma2 ) ) {
for ( j j in 1 :nrow( sigma2 ) ) {
i f ( i i != j j ) sigma2 [ i i , j j ] ← sigma2 [ i i , j j ] ∗sqrt ( sigma2 [ i i , i i ] ) ∗sqrt (
sigma2 [ j j , j j ] )
}
}
typeI ← numeric (n . s ims )
for ( i i in 1 : n . s ims ) {
s e t1 ← mvrnorm(n=n , mu=mean1 , Sigma=sigma1 )
s e t2 ← mvrnorm(n=n , mu=mean2 , Sigma=sigma2 )
s c o r e s 1 ← prcomp ( s e t1 )$x [ , 1 :min( x [ 9 ] , ncol ( s e t1 ) ) ]
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s c o r e s 2 ← prcomp ( s e t2 )$x [ , 1 :min( x [ 9 ] , ncol ( s e t2 ) ) ]
cc . r e s ← cancor ( score s1 , s c o r e s 2 )
min . s e t 1 ← nrow( cc . r e s$xcoe f )
min . s e t 2 ← nrow( cc . r e s$ycoe f )
cc . rho2 ← rev ( cc . r e s$cor ˆ2)
t e s t . stat ← (−1)∗ (n − 1 − . 5 ∗ (min . s e t 1 + min . s e t 2 + 1) ) ∗ log (cumprod(1 −
cc . rho2 ) )
df ← (min . s e t 1 − length ( cc . rho2 ) : 1 + 1 ) ∗ (min . s e t 2 − length ( cc . rho2 ) : 1 + 1
)
p . va lue ← (1 − pchisq ( t e s t . stat , df ) )
typeI [ i i ] ← t a i l (p . value , 1)
}
sum( typeI < . 0 5 )/n . sims
}
r e s u l t .mat ← as .matrix (expand . grid ( l o c i 1 , l o c i 2 , rho1 , rho2 , s lope1 , s lope2 ,
i n t e r c ep t1 , i n t e r c ep t2 , npcs ) )
colnames ( r e s u l t .mat) ← c ( ’ l o c i 1 ’ , ’ l o c i 2 ’ , ’ rho1 ’ , ’ rho2 ’ , ’ s l ope1 ’ , ’ s l ope2 ’ , ’
i n t e r c e p t 1 ’ , ’ i n t e r c e p t 2 ’ , ’ npcs ’ )
typeI . e r r o r ← apply ( r e s u l t .mat , 1 , compute . typeI , n = n . i i , n . sim = n . sims )
r e s u l t .mat ← cbind ( r e s u l t .mat , typeI . e r r o r )
cat ( ’ f i n i s h e d ’ , n . i i , ’ \n ’ )
r e s u l t .mat
}
names( r e s u l t s ) ← n
r e s u l t s . df ← NULL
for ( i i in 1 : length (n) ) {
r e s u l t s . df ← rbind ( r e s u l t s . df ,
cbind ( rep (n [ i i ] , nrow( r e s u l t s [ [ i i ] ] ) )
, r e s u l t s [ [ i i ] ] ) )
}
setwd ( ’/home/manserpt/gdi ch3/data ’ )
save ( r e s u l t s . df , f i l e=’ cca−t e s t−typeI−r e s u l t s−r e a l i s t i c . rda ’ )
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l ibrary ( f o r each )
l ibrary (doMC)
# S i m u l a t i o n t o t e s t f o r powe r −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
# s e t s i m u l a t i o n p a r am e t e r s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
n ← c (26 , 50 , 100 , 200) # number o f s am p l e s w i t h mat ch ed d a t a
l o c i 1 ← 20 # number o f CpG s i t e s
l o c i 2 ← 8 # number o f e x o n s
rho1 ← . 25 # n u l l CpG c o r r e l a t i o n f o r compound
symmet ry c o v a r i a n c e
rho2 ← −.0678 # n u l l e x on c o r r e l a t i o n f o r compound
symmet ry c o v a r i a n c e
s l ope1 ← 0 # s l o p e t o s p an r a n g e o f CpG v a r i a n c e s
i n t e r c e p t 1 ← . 00123 # i n t e r c e p t t o s p an r a n g e o f CpG v a r i a n c e s
s l ope2 ← 0 # s l o p e t o s p an r a n g e o f e x on v a r i a n c e s
i n t e r c e p t 2 ← 0 .15 # i n t e r c e p t t o s p an r a n g e o f e x on v a r i a n c e s
npcs ← c (1 , 3 , 5) # number o f PCs t o k e e p a f t e r PCA f o r CCA
s t e p
methy . change ← . 2 # mean d i f f e r e n c e b e tw e e n c a s e and c o n t r o l
n . cpgs ← c (1 , 3 , 5) # how many CpGs c h a n g e ?
s p l i c e . change ← 1 .2 # mean d i f f e r e n c e b e tw e e n c a s e and c o n t r o l
n . exons ← c (1 , 4) # how many e x o n s c h a n g e ?
n . sims ← 1e5 # number o f s i m s f o r e a c h param combo
n . co r e s ← f loor (2∗detectCores ( )/3)
registerDoMC (n . co r e s )
r e s u l t s ← f o r each (n . i i = n , . packages=’MASS ’ ) %dopar% {
cat ( ’ s t a r t e d ’ , n . i i , ’ . . . \ n ’ )
compute . typeI ← function (x , n , n . sim ) {
mean1 ← numeric ( x [ 1 ] )
mean2 ← numeric ( x [ 2 ] )
sigma1 ← matrix ( x [ 3 ] , nr = x [ 1 ] , nc = x [ 1 ] )
sigma2 ← matrix ( x [ 4 ] , nr = x [ 2 ] , nc = x [ 2 ] )
diag ( sigma1 ) ← ( 1 :nrow( sigma1 )−1) ∗ x [ 5 ] + x [ 7 ]
diag ( sigma2 ) ← ( 1 :nrow( sigma2 )−1) ∗ x [ 6 ] + x [ 8 ]
for ( i i in 1 :nrow( sigma1 ) ) {
for ( j j in 1 :nrow( sigma1 ) ) {
i f ( i i != j j ) sigma1 [ i i , j j ] ← sigma1 [ i i , j j ] ∗sqrt ( sigma1 [ i i , i i ] ) ∗sqrt (
sigma1 [ j j , j j ] )
}
}
for ( i i in 1 :nrow( sigma2 ) ) {
for ( j j in 1 :nrow( sigma2 ) ) {
i f ( i i != j j ) sigma2 [ i i , j j ] ← sigma2 [ i i , j j ] ∗sqrt ( sigma2 [ i i , i i ] ) ∗sqrt (
sigma2 [ j j , j j ] )
}
}
typeI ← numeric (n . s ims )
for ( i i in 1 : n . s ims ) {
s e t1 ← mvrnorm(n=n , mu=mean1 , Sigma=sigma1 )
s e t2 ← mvrnorm(n=n , mu=mean2 , Sigma=sigma2 )
s e t1 [ 1 : ( ncol ( s e t1 )/2) , 1 : x [ 1 1 ] ] ← s e t1 [ 1 : ( ncol ( s e t1 )/2) , 1 : x [ 1 1 ] ] + x [ 1 0 ]
s e t2 [ 1 : ( ncol ( s e t2 )/2) , 1 : x [ 1 3 ] ] ← s e t2 [ 1 : ( ncol ( s e t2 )/2) , 1 : x [ 1 3 ] ] + x [ 1 2 ]
s c o r e s 1 ← prcomp ( s e t1 )$x [ , 1 :min( x [ 9 ] , ncol ( s e t1 ) ) ]
s c o r e s 2 ← prcomp ( s e t2 )$x [ , 1 :min( x [ 9 ] , ncol ( s e t2 ) ) ]
cc . r e s ← cancor ( score s1 , s c o r e s 2 )
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min . s e t 1 ← nrow( cc . r e s$xcoe f )
min . s e t 2 ← nrow( cc . r e s$ycoe f )
cc . rho2 ← rev ( cc . r e s$cor ˆ2)
t e s t . stat ← (−1)∗ (n − 1 − . 5 ∗ (min . s e t 1 + min . s e t 2 + 1) ) ∗ log (cumprod(1 −
cc . rho2 ) )
df ← (min . s e t 1 − length ( cc . rho2 ) : 1 + 1 ) ∗ (min . s e t 2 − length ( cc . rho2 ) : 1 + 1
)
p . va lue ← (1 − pchisq ( t e s t . stat , df ) )
typeI [ i i ] ← t a i l (p . value , 1)
}
sum( typeI < . 0 5 )/n . sims
}
r e s u l t .mat ← as .matrix (expand . grid ( l o c i 1 , l o c i 2 , rho1 , rho2 ,
s lope1 , s lope2 , i n t e r c ep t1 , i n t e r c ep t2 , npcs
,
methy . change , n . cpgs , s p l i c e . change , n . exons
) )
colnames ( r e s u l t .mat) ← c ( ’ l o c i 1 ’ , ’ l o c i 2 ’ , ’ rho1 ’ , ’ rho2 ’ , ’ s l ope1 ’ , ’ s l ope2 ’ ,
’ i n t e r c e p t 1 ’ , ’ i n t e r c e p t 2 ’ , ’ npcs ’ , ’ methy . change ’ ,
’ n . cpgs ’ , ’ s p l i c e . change ’ , ’ n . exons ’ )
typeI . e r r o r ← apply ( r e s u l t .mat , 1 , compute . typeI , n = n . i i , n . sim = n . sims )
r e s u l t .mat ← cbind ( r e s u l t .mat , typeI . e r r o r )
cat ( ’ f i n i s h e d ’ , n . i i , ’ \n ’ )
r e s u l t .mat
}
names( r e s u l t s ) ← n
r e s u l t s . df ← NULL
for ( i i in 1 : length (n) ) {
r e s u l t s . df ← rbind ( r e s u l t s . df ,
cbind ( rep (n [ i i ] , nrow( r e s u l t s [ [ i i ] ] ) )
, r e s u l t s [ [ i i ] ] ) )
}
r e s u l t s . df [ , c (1 , 10 , 11 :14 , 15 ) ]
( r e s u l t s . df [ , c (1 , 10 , 12 , 14 , 15) ] )
setwd ( ’/home/manserpt/gdi ch3/data ’ )
save ( r e s u l t s . df , f i l e=’ cca−t e s t−power−r e s u l t s−r e a l i s t i c −a l t−prom . rda ’ )
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